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ABSTRACT 
Novartis Vaccines (NV) in Liverpool operates an egg-based, semi-automated, influenza 
vaccine manufacturing facility with the capability to process a batch per day. This thesis focuses 
on the Agrippal base product, an inactivated subunit trivalent vaccine. The objectives of this 
multidisciplinary project included optimisation of assays and introduction of analytical 
technologies that could potentially facilitate characterisation of viral concentration, particle size 
and aggregation interactions with a view to promote understanding of product stability and 
identify opportunities for process optimisation and yield improvements in the Agrippal 
platform.  
The first phase of this project focused on methods of nanoparticle analysis that could enable 
efficient monitoring of viral content from the early stages of product development and 
throughout the downstream operations. A comparative evaluation between commonly used 
particle analysers showed that differential centrifugal sedimentation (DCS) is the most suitable 
method for the analysis of in-process influenza vaccine samples. Novel applications of DCS 
throughout the manufacturing of egg-based inactivated influenza vaccines were examined and 
are reported herein. DCS was proven to be a valuable analytical tool by demonstrating high 
potential for process investigation and monitoring. Key applications include direct 
determination of viral content in allantoic fluid, viral quantification at whole virus process 
stages, characterisation of unit operations on a particle based approach and detection and 
monitoring of the kinetics of aggregation. Furthermore, DCS was specifically employed in a 
novel study entailing direct determination of influenza virus growth in allantoic fluid upon 
addition of glucocorticoids and other compounds (hydrocortisone, dexamethasone, 
corticosterone, AFZ077 and BYF589) into the viral seed inoculum. 
Additionally, the intricate, multi-step, multi-variable and poorly characterised solubilisation 
process of the membrane glycoproteins Haemagglutinin (HA) and Neuraminidase (NA) from 
the surface of influenza virus by the detergent CTAB, as applied in the Agrippal manufacture 
platform, was comprehensively examined with the aim of enhancing process understanding by 
identifying the key parameters potentially affecting solubilisation efficiency and product 
quality.  
Finally, the development and optimisation of a novel GNA-binding enzyme-linked 
immunosorbent assay (ELISA) as an alternative replacement to the Single Radial 
Immunodiffusion (SRID) potency assay for quantification of HA in vaccine samples is 
described.  
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1. INTRODUCTION 
 
1.1 OVERVIEW AND CLASSIFICATION OF INFLUENZA VIRUSES 
Influenza has been a common cause of illness and death for several centuries and still continues 
to pose a considerable threat to public health. The pandemic that occurred in the early part of 
the 20th century is estimated to have caused between 20 and 50 million deaths [1]. During the 
2009 influenza pandemic, the estimated mortality burden ranged between 151,700 and 575,400 
deaths worldwide [2]. 
Influenza viruses are negative single-stranded RNA viruses belonging to the family 
Orthomyxoviridae family and comprise three distinct types (genera): influenza A, B and C. 
Influenza A, B and C viruses differ with respect to internal Matrix proteins and Nucleoprotein 
(M and NP), host range, surface glycoproteins, pathogenicity, genome organization and 
morphology [3, 4]. Type A influenza viruses are further divided into subtypes based on 18 
different Haemagglutinin (HA) and 11 different Neuraminidase (NA) groups of proteins [5, 6]. 
The formal descriptive nomenclature for human influenza viruses indicates type, geographic 
site of first isolation, isolate number, year of isolation and in parentheses the HA and NA 
subtypes [4, 7]. For example, A/Brisbane/59/2007 (H1N1) describes an influenza A strain, 
number 59, isolated in Brisbane in 2007 which contains HA and NA of subtypes H1 and N1 
respectively.  
Influenza A is a zoonotic infection, infecting a range of mammals (e.g. swine, horses, seals, 
whales etc.), avian species (ducks, chickens, shore birds) and humans [8, 9]. At present, the 
most dominant human influenza A strains are H1N1 and H3N2 [8]. Type A strains are clinically 
the most significant pathogens as they can cause both epidemics and pandemics and therefore 
are included in annual vaccine formulations [4]. An important feature of influenza A is the 
transmission between animals and humans directly or through an intermediate host which can 
lead to viral reassortment and generation of new subtypes [4]. Possible routes of transmission 
are illustrated in Figure 1.1.  
Conversely, influenza B viruses circulate only among humans whereas influenza C viruses have 
been isolated from both humans and swine [8]. Type B viruses are responsible for epidemics 
with less severe symptoms compared to influenza A and are also included in seasonal influenza 
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vaccines [4]. Influenza B viruses are currently divided into two antigenically distinct lineages 
called B/Yamagata and B/Victoria which are named after the original isolates of the strains 
B/Victoria/2/1987 and B/Yamagata/16/1988 respectively [10].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Species infected with influenza A. Continuous arrows: established directions of transmission. 
Broken arrows: probable routes of transmission. Adapted from [7]. 
 
 
Influenza C viruses do not exhibit seasonality and are generally of limited public health concern 
causing only mild respiratory tract infections. These viruses are excluded from annual influenza 
vaccines [7]. 
 
1.2 VIRION STRUCTURE AND GENOME ORGANISATION  
Influenza viral particles are roughly spherical, although somewhat pleomorphic in nature, 
ranging from 80 to 120 nm in diameter whilst filamentous forms may be up to 300 nm in length 
[3, 11]. In influenza A and B viruses, there are approximately 500 surface spike-like 
glycoproteins per particle usually at a ratio of roughly four HA (rod-like shape) to one NA 
(mushroom-shaped), embedded in a host-derived lipid bilayer membrane [12, 13]. Conversely, 
influenza C viruses have only one spike composed of the multifunctional Haemagglutinin-
Esterase-Fusion (HEF) glycoprotein [5, 14].  
A typical schematic view of influenza A virion structure is presented in Figure 1.2. The viral 
envelope also contains the ion channel protein (M2) while the structural protein (M1) underlies 
the bilayer. The three transcriptases PB1, PB2, and PA, the nucleoprotein (NP) and the viral 
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RNA compose the ribonucleoprotein (RNP) complex. The core of virions also includes the 
nuclear export and non-structural protein (NEP/NS2) [4, 14, 15].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Left: Structure of influenza A virus. Right: Image of influenza B virus under  
an electron microscope. Bar=100 nm. [16]. 
 
Influenza A and B viruses contain genomes composed of eight separate RNA segments whereas 
influenza C viruses have seven such segments (vRNA) [5, 14]. Table 1.1 describes genome 
segments, viral proteins and their respective functions. 
Influenza virions are relatively unstable in the environment and can be inactivated by heat, 
dryness, high or low pH, detergents, organic solvents or organic substances such as 
formaldehyde and beta-Propiolactone (BPL) [5, 13, 17].   
 
Table 1.1: Influenza A genome and main functions of viral proteins (A/Puerto Rico/8/1934) [4, 18]. 
 
 
 
 
Segment vRNA Encoded 
Protein 
Number of 
Amino Acids 
Functions 
1 2341 PB2 759 Polymerase subunit, mRNA cap recognition  
2 2341 
 
PB1 
 
PB1-F2 
757 
 
87-91 
Polymerase subunit, endonuclease activity 
RNA elongation 
Pro-apoptotic activity 
3 2233 PA 716 
Polymerase subunit, protease activity, 
assembly of polymerase complex 
4 1778 HA 566 
Surface glycoprotein, receptor binding, 
membrane fusion, major viral antigen 
5 1565 NP 498 
Nucleoprotein, RNA binding activity 
required for replication 
6 1413 NA 454 
Surface glycoprotein, virus release, 
neuraminidase activity 
7 1027 M1 
 
M2 
252 
 
97 
Matrix protein, regulates RNA nuclear  
export, viral budding 
Ion channel activity, uncoating  
8 890 NS1 230 
Interferon antagonist, 
regulates host gene expression 
  NEP/NS2 121 Nuclear export of RNA 
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1.3 ENVELOPE GLYCOPROTEINS: HAEMAGGLUTININ AND 
NEURAMINIDASE 
HA is the major envelope glycoprotein accounting for approximately 25% of the viral protein 
mass and is distributed evenly on the virion surface. It is responsible for the virus’s binding to 
sialic acid containing receptors on host cells, internalisation of the virus (endocytosis), and 
subsequent fusion of the viral and endosomal membranes in the infected cell [9, 12, 19, 20].  
Structurally, HA is a rod-shaped trimer formed by the non-covalent association of three 
monomers (approximately 70-75 kDa) anchored in the virion’s envelope [8, 20, 21]. Each 
subunit consists of two disulphide-linked peptide chains (Figure 1.3), HA1 (approximately 50 
kDa or 328 residues) and HA2 (approximately 25 kDa or 221 residues) which are derived by 
proteolysis or cleavage of a common biosynthetic precursor HA0 [12, 22, 23]. The monomer of 
the HA molecule is alternatively subdivided into two distinct domains: a globular head domain 
that consists entirely of HA1 and includes the receptor binding site and five antigenic sites 
(highly variable domain) and a stalk (stem) domain formed by the rest of HA1 and the entire of 
HA2 (well-conserved domain) [4, 24].  
 
 
 
 
 
 
 
Figure 1.3: Up: Ribbon diagram of the 1918 influenza HA monomer. Structure generated from [25] using UCSF Chimera 
[26]. Down: schematic representation of HA. HA1 residues are shown in blue while HA2 residues are shown in red. 
Globular head: 
Highly variable 
Stalk: 
Conserved 
S-S 
HA1 HA2 
HA0 
Fusion 
Peptide 
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The HA1 region contains the sialic acid binding site and has the same N-terminal sequence as 
HA0 and a novel C-terminus [12, 21, 27] whereas HA2 has a novel N-terminus and shares the 
same C-terminus sequence as HA0 (Figures 1.3, 1.4) [12]. The N-terminal part of HA2 is also 
known as the fusion peptide [12, 28]. The proteolytic cleavage into HA1 and HA2 is essential 
for activation of membrane fusion [29-31] and consequently for virus infectivity [23, 32, 33]. 
Specifically, acidification of the endosomes at pH 5-6, triggers an irreversible conformational 
change in HA which subsequently activates fusion of the viral and endosomal membranes in 
order to release viral RNPs into the cytoplasm and further into the nucleus where viral genome 
transcription and replication occurs [21, 27, 34, 35].  
 
 
  
 
 
 
 
 
 
Figure 1.4: Three conformations of the HA: a) HA0, uncleaved [25], b) HA at neutral pH, cleaved [36] and c) fusion pH, 
cleaved HA-composite diagram of HA fragments from [37-39]. HA1 residues are shown in blue while HA2 residues are 
shown in red. Structures generated using UCSF Chimera [26]. 
 
 
NA glycoprotein is a tetramer (Figure 1.5) consisting of four identical non-covalently bound 
single polypeptide chains forming a homotetramer of approximately 240 kDa [12, 40, 41]. Each 
monomeric subunit is composed of about 470 amino acids and contains four domains [41, 42]. 
The main function of NA involves enzymatic cleavage of the terminal sialic acid residues from 
cellular receptors of the HA protein and therefore release of the virions and further spread of 
infection [4, 12]. An optimal functional balance between the HA and NA activities is critical 
for efficient replication and transmission [43, 44].  
 
 
a b c 
C-terminus 
N-terminus 
Fusion 
peptide 
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Figure 1.5: Crystal structure of NA of H5N1 [45].  
Structure generated using UCSF Chimera [26]. 
 
1.4 EVOLUTION OF INFLUENZA VIRUSES 
Influenza viruses in humans exist in the epidemiologic forms of sporadic seasonal epidemics 
(A and B influenza) and less frequently as more severe pandemics (A viruses) [14, 46]. 
Epidemics are caused by antigenic drifts which are defined as minor antigenic changes due to 
amino acid substitution in the antigenic sites of HA (primarily in the HA1 domain) and/or NA 
(Figure 1.6a) [14, 46, 47]. As genetic drifts occur annually, the resulting antigenic diversity of 
HA and NA leads to annual modification of vaccine composition [4]. At present, mutants of 
H1N1, H3N2 as well as influenza B viruses are responsible for epidemics [46]. Pandemics are 
the outcome of antigenic shift (Figure 1.6b). Antigenic shifts occur by genetic reassortment 
where exchange of one or more gene segments between two different strains may lead to 
emergence of a completely novel influenza A strain with new HA and NA antigens against 
which the human population has no immunity whilst potentially varying the host range of the 
virus [4, 47, 48].  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: a) Antigenic drift and b) Antigenic shift. Adapted from [49]. 
 
a b 
Accumulated 
point mutations 
Reassortment 
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In the past century, at least four major pandemics have been recorded: the “Spanish” influenza 
pandemic in 1918 (H1N1 subtype), the “Asian” pandemic in 1957 (H2N2 subtype) the “Hong 
Kong” pandemic in 1968 (H3N2 subtype) and the “Russian” pandemic in 1977 (H1N1 subtype) 
(Figure 1.7) [4, 9, 47-49]. Furthermore, in 2009, a swine-origin influenza virus H1N1 pandemic 
occurred and spread rapidly globally, whilst the descendants of the 1977 H1N1 virus were still 
in circulation [47]. 
 
 
Figure 1.7: Pandemics of influenza A viruses in the past century. Adapted from [48]. 
 
1.5 INFLUENZA VACCINES 
1.5.1 Overview of Commercial Vaccines  
Annually, seasonal influenza infections result in approximately three to five million 
hospitalisations and 250,000 to 500,000 deaths worldwide [51]. Vaccination against influenza 
remains the primary strategy for the effective prevention and control of both seasonal epidemic 
and pandemic influenza. As discussed earlier, due to the antigenic diversity of HA and NA, 
vaccine compositions require annual reformulation. Current licensed vaccines target the HA of 
two influenza A subtypes (H1N1 and H3N2) and the HA of one or two B strains (B/Victoria 
and B/Yamagata lineage) that are predicted by the World Health Organization (WHO) to 
circulate in humans the upcoming influenza season [52-54]. In the event of an inaccurate 
prediction, the antigenic mismatch between the vaccine and the circulating strains might lead 
to limited protection and vaccine effectiveness [52, 55].  
Mainly, two methods are used for the production of influenza vaccines, egg-based and cell-
culture-based manufacturing, with different types of vaccines (e.g. inactivated, live attenuated, 
recombinant) available [56, 57].  
Most of the traditional licensed vaccines (Table 1.2) are in the form of whole virus, split or 
subunit inactivated formulations (Figure 1.8). Generally, subunit vaccines have demonstrated a 
higher safety profile compared to other vaccine types [58, 59]. Currently, the most commonly 
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used seasonal influenza vaccine is the trivalent inactivated vaccine (TIV) consisting of two 
circulating H3N2 and H1N1 subtypes and one B type [60]. Adjuvants (e.g. MF59, AS03) are 
also used to enhance vaccine immunogenicity [53].  
 
 
 
 
 
 
 
 
Figure 1.8: Common influenza vaccine formulations: a) whole virus, b) split virion and c) subunit.  
Images from [61]. 
 
Table 1.2: Summary of licensed seasonal influenza vaccines in US [62]. 
Vaccine Manufacturer Vaccine Type 
Route of 
Administration 
Production Substrate 
Afluria  CSL Limited TIV, split virion Intramuscular Eggs 
Agriflu  
Novartis Vaccines 
and Diagnostics Inc. 
TIV, subunit Intramuscular Eggs 
FluLaval 
ID Biomedical 
Corporation of 
Quebec 
TIV, split virion Intramuscular Eggs 
Fluarix  
GlaxoSmithKline 
Biologicals 
TIV or 
quadrivalent, split 
virion 
Intramuscular Eggs 
Flublok  
Protein Sciences 
Corporation 
TIV Intramuscular 
Insect virus (baculovirus) 
expression system and 
recombinant DNA 
technology 
 
Flucelvax 
Novartis Vaccines 
and Diagnostics Inc. 
TIV, subunit Intramuscular Cell Culture 
Fluvirin  
Novartis Vaccines 
and Diagnostics Inc. 
TIV, subunit Intramuscular Eggs 
Fluzone  
(1980) 
Sanofi Pasteur, Inc. TIV, split virion Intramuscular Eggs 
Fluzone 
High-Dose  
Sanofi Pasteur, Inc. TIV, split virion Intramuscular Eggs 
Fluzone 
Intradermal 
Sanofi Pasteur, Inc. TIV, split virion Intradermal Eggs 
FluMist  MedImmune, LLC 
Live attenuated, 
TIV or 
quadrivalent 
Intranasal Eggs 
 
 
Despite significant advancements in the vaccine field, the egg-based production of inactivated 
virus has remained the most widely used technology for over 60 years [56, 63, 64]. 
 
 
a b c 
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1.5.2 Manufacturing of Egg-Based, Inactivated Influenza Vaccines 
All conventional licensed egg-derived, inactivated influenza vaccines are produced through a 
relatively similar manufacturing process involving the same major unit operations though the 
sequence of execution of process steps might differ between manufacturers. A typical flow 
diagram is shown in Figure 1.9. Virus seed culture of each viral subtype is inoculated into 10 
to 11-day-old fertilised eggs which are incubated for up to 72 hours at 35°C (influenza A) or 
33°C (influenza B) to allow viral multiplication [65]. Allantoic fluid (AF) is subsequently 
harvested and is commonly clarified by low speed centrifugation and/or concentrated by 
ultrafiltration. After harvest, whole-virus particles are chemically inactivated by formaldehyde 
or BPL for a validated time period and at a temperature proven to inactivate the virus. 
Purification from unwanted non-viral egg proteins is achieved through sucrose density gradient 
zonal ultracentrifugation [60, 64, 65].  The collected virus containing fractions exhibit a typical 
purity of 85–95% and after diafiltration and sterilising filtration procedures serve as whole virus 
vaccines [65]. Inactivated whole virus vaccines are not widely used. At present only Fluval AB 
by Omninvest is commercially available in EU/EEA. 
Split virion vaccines are generated after treatment with solvents (e.g., diethyl ether, Tween-
ether) or detergents (e.g. deoxycholate, TritonX100 etc.) that disrupt the viral particle thus 
releasing all viral proteins [60, 65, 66]. Detergents or solvents are subsequently removed with 
diafiltration or HA and NA are further purified though an additional sucrose gradient 
centrifugation [65]. Subunit vaccines contain predominantly surface antigens and are produced 
by addition of specific detergents, namely cetyl trimethylammonium bromide (CTAB) [67-68] 
or nonoxynol-9 (NP9 or Triton N101) [69, 70], that act by selectively stripping the HA and NA 
through solubilisation of the lipid membrane. CTAB is removed through adsorption to 
hydrophobic resins whereas NP9 is removed by phase-separation at the cloud point in the 
presence of phosphate [65, 69]. 
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Seed Virus Preparation
(Master & Working seed)
Virus Inoculation
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Clarifying Centrifugation/
Diafiltration
Virus Inactivation
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Ultracentrifugation
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Purifying Ultracentrifugation 
Whole Virus 
Vaccine
Split Vaccine
Subunit Vaccine
Sterilising Filtration
Monovalent Pool
Detergent Removal
 
Figure 1.9: General scheme for production of egg-derived inactivated influenza vaccines. Adapted from [63]. 
 
 
1.5.3 The Agrippal Platform 
The Novartis Vaccines (NV) manufacturing facility in Liverpool operates an egg based, semi-
automated, influenza vaccine manufacturing site with the capability to process a batch per day.  
The facility can process several hundred thousand eggs each day, with half batch processing 
capabilities within the downstream area. The Agrippal manufacturing process was transferred 
in 2010 from Novartis Vaccines in Siena to Liverpool, where it is intended to eventually replace 
the Fluvirin vaccine manufacturing process (TIV, BPL inactivated, NP9 solubilised). This was 
done as the Agrippal manufacturing process (and product) were deemed to be more cost 
effective with more doses of vaccine produced per number of eggs processed. The Agrippal 
manufacturing process is also the base for the manufacture of several other vaccine products 
namely Fluad, Aflunov and Foclivia which cover adjuvanted (MF59), pre-pandemic and 
pandemic versions of the Agrippal influenza vaccine. 
This thesis focuses on the Agrippal base product, an inactivated subunit TIV vaccine that 
contains purified HA and NA antigens recovered from the surface of three influenza virus 
strains, type A (H1N1, H3N2) and type B as recommended annually for immunisation by the 
WHO. A simplified overview of the process is given in Figure 1.10. Briefly, the modified egg-
adapted influenza virus strains are individually grown in embryonated chicken eggs which are 
Upstream Downstream 
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then harvested and inactivated using formaldehyde treatment. Purification consists of an initial 
ultracentrifugation step in a sucrose gradient which allows selective recovery and concentration 
of virus from AF. The last stage of the process consists of a solubilisation treatment with CTAB 
which solubilises the surface antigenic proteins from the virus membrane. Detailed descriptions 
of each unit operation with the respective critical control parameters and all Quality Control 
(QC) analytical tests are provided in Appendix 1.1. 
 
 
 
Figure 1.10: Simplified process flow diagram of Agrippal production.     : Haemaglutination Assay,    : total protein by 
Kjeldhal,   : total protein by Bio-Rad (non-PQS),    : total protein by BCA (non-PQS),      : SDS-PAGE,         : SRID. The 
term non-PQS refers to non-routine, “information only” testing. 
 
The major antigenic determinant is HA and is quantified towards the end of the process for 
individual monovalent bulks by the method of Single Radial Immunodiffusion (SRID or SRD). 
Although SRID is highly specific and has been used for influenza vaccine release for several 
decades [71-72] it suffers from several limitations as it is labour-intensive and time consuming 
(2-day process), it has a poor dynamic range, low sensitivity, and poor tolerance to high levels 
of contaminating proteins [72-74]. These features make the assay unsuitable for in process yield 
monitoring and high-throughput automation.  Additionally, the method requires strain specific 
virus reagents, including an HA reference standard and anti-HA sheep serum, which may delay 
the release of the early vaccine batches. The SRID assay is discussed at length in Chapter 6 
(6.1.1). 
Other off line analytical methods employed for characterisation of viral/yield titres are the 
haemagglutination assay (HA assay), total protein measurements by the Kjeldhal, bicinchoninic 
Upstream Downstream 
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acid (BCA) and Bio-rad (Bradford) assays and protein composition by sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) at the process stages noted in Figure 
1.10.  The HA assay was the first technique used for quantification of influenza virus [75] and 
it is based on the agglutination property or binding of red blood cells by HA. It is an inexpensive 
and simple assay to perform and it is utilised as a relatively fast (<1 hour) determination of viral 
presence or absence. Nonetheless, this method presents significant disadvantages such as lack 
of specificity, laborious preparation, low reproducibility due to the different origin and quality 
of erythrocytes as well as high influence of temperature and analytical expertise on the 
interpretation of the results [76]. The HA assay has been found to be inaccurate for analysis of 
post–split (subunit) samples [64] which led to its replacement by SRID [71, 77]. Total protein 
analysis via protein assays or SDS-PAGE provides an estimation of total protein content which 
in the upstream “crude” phases includes all the non-viral host-derived egg proteins. 
Consequently, these methods can only be directly correlated with viral and antigen yields for 
purified downstream samples.  
 
1.6 PROCESS ANALYTICAL TECHNOLOGY (PAT) AND CHALLENGES IN 
INFLUENZA MANUFACTURE 
Process analytical technology (PAT) is a key element of the “Pharmaceutical Current Good 
Manufacturing Practices (GMPs) for the 21st Century a Risk Based Approach” initiative 
launched by the Food and Drug Administration (FDA) in 2002 to improve and modernise the 
pharmaceutical industry by creating more flexible regulatory approaches. The essence of PAT 
involves designing, analysing and controlling manufacturing processes through real-time 
measurements of critical process parameters or quality attributes of raw or in-process materials 
and processes with the goal of ensuring final product quality [78].  
From an implementation point of view PAT is often illustrated as a three-step process (Figure 
1.11) [79-81]. In the initial design phase, the critical quality attributes (CQAs) that are being 
affected by a particular unit operation are identified along with the critical process parameters 
(CPPs) that affect the CQAs (process understanding). In the analyse phase, the CQAs and CPPs 
are monitored at-line, on-line, in-line, or off-line. Finally, in the control phase, a control system 
is designed that allows the data from the analysis to be used for real-time process decisions and 
consistent product quality and improved process performance can be achieved [79]. 
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Figure 1.11: Steps for PAT implementation. (Redrawn from [79]).  
 
Implementation of PAT in biopharmaceuticals has been characterised as challenging [79-83], 
as such biological processes are typically less controllable and more susceptible to variation 
than processes for small-molecule drugs due to the inherent complexity of live organisms, raw 
materials variability and incomplete process understanding [84]. A general indicator of ease of 
PAT application for a specific unit operation is the ratio of the average process time available 
for decision making before proceeding to the next process step to the time required for analysis 
of CQA(s) [79, 82]. If that ratio is significantly higher than 1, then PAT implementation is 
relatively easy. Typically, upstream operations involved in the production of most 
biotechnology products, i.e. microbial and mammalian cell cultures, are suitable for PAT 
implementation as the decision-making time is long comparatively to the sample analysis time. 
Conversely, downstream operations are less convenient due to much shorter decision times.  
Application of PAT in manufacturing of egg-derived influenza vaccines presents additional 
bottlenecks. Unique considerations include:  
 
 Lack of real time viral growth/infectivity monitoring during the critical stage of virus 
propagation in embryonated hen eggs.  In contrast to cell cultures, CQAs cannot be 
readily measured when eggs are utilised as bioreactors.  
 Use of non-specific offline analytical methods for product characterisation for upstream 
operations after harvest of AF. 
 
ANALYSE 
for pertinent 
CQA and 
monitor CPP 
 
CONTROL 
Using process 
understanding 
to control CPP 
so as to achieve 
consistent CQA 
 
 
 
DESIGN 
Define CQA 
pertinent for the 
process step and 
the CPP that 
impact them 
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 Limitations of offline assays and long analysis times for determination of main quality 
attributes throughout the downstream processing.  
 Egg variability and annual changes of influenza strains included in the TIV preparation. 
 Extreme product complexity and sample matrix modifications. Vaccine manufacture 
comprises of whole virus process phases containing host related and in-process 
impurities as well as post-split or solubilised purified antigen steps. 
 Limited process understanding. Unit operations are not entirely understood and 
therefore the impact on protein functionality and/or product quality cannot easily be 
defined. 
 
1.7 THESIS AIMS AND OBJECTIVES 
The objectives of this multidisciplinary project include optimisation of assays and introduction 
of analytical technologies that could potentially facilitate characterisation of viral 
concentration, particle size and aggregation interactions with a view to promote understanding 
of product stability and identify opportunities for process optimisation and yield improvements 
in the Agrippal platform.  
The first phase of this project focuses on methods of nanoparticle analysis that could enable 
efficient monitoring of viral content from the early stages of product development and 
throughout the downstream operations. An evaluation between commonly used particle 
analysers, discussed in Chapter 2, indicated that differential centrifugal sedimentation (DCS) is 
the most suitable method for the analysis of vaccine samples. Chapter 3 describes the technical 
potential of DCS in influenza vaccine production. Main objectives include characterisation of 
unit operations, viral quantification at whole virus process phases and determination and 
monitoring of the kinetics of aggregation. A particular novel application of DCS entailing direct 
determination of viral growth in allantoic fluid upon addition of glucocorticoids and other 
compounds into the seed inoculum is presented in Chapter 4. 
Additionally, the intricate multi-variable unit operation of antigen solubilisation, which is 
critical for recovery of biologically active HA, is comprehensively examined with the aim of 
enhancing process understanding by identifying the key parameters potentially affecting 
solubilisation efficiency and product quality (Chapter 5).   
Finally, the development and optimisation of a lectin-based enzyme-linked immunosorbent 
assay (ELISA) as an alternative replacement to the SRID potency assay for quantification of 
HA in vaccine samples is detailed in Chapter 6.   
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2. A COMPARATIVE STUDY OF METHODS OF 
VIRAL PARTICLE ANALYSIS 
 
2.1 INTRODUCTION  
2.1.1 Classification of Virus Quantification Techniques  
Accurate determination of viral yield and characterisation of viral replication rates are critical 
for vaccine development and manufacturing. Several traditional and modern methods are used 
for this purpose which can be broadly distinguished into four categories [1]: those that measure 
viral infectivity (plaque assays [2, 3], the FFA assay [4, 5] and the TCID50 or EID50 assay 
[6,7]), those that quantify viral proteins (e.g. the haemagglutination assay [8], protein assays 
etc.) those that assess total viral particle counts (e.g. TEM [9], AFM [10] etc.) and those that 
are based on detection of nucleic acid in the viral genome (qPCR [11, 12]). Table 2.1 
summarises some techniques commonly employed for virus quantification.  
 
Table 2.1: Analytical methods commonly used for determination of viral content [1, 13-15]. 
Detection Principle Method (s) Analysis time 
Infectivity 
Plaque Assay Days/Week(s) 
EID50/TCID50 Days/Week(s) 
FFA Days 
Protein/Antigen 
SRID Days/Week(s) 
ELISA Hours/Day(s) 
Haemagglutination  Hours/Day(s) 
Neuraminidase Hours/Day(s) 
Viral Particles 
TEM Hours/Day(s) 
AFM Hours/Day(s) 
DLS Minutes/Hour(s) 
Virus Counter  
(Virocyt) 
Minutes/Hour(s) 
SIOS (TRPS) Minutes/Hour(s) 
NTA Minutes/Hour(s) 
FFF-MALLS Minutes/Hour(s) 
Nucleic Acid qPCR or RT-qPCR Hours 
 
Conventional infectivity assays (plaque assay, EID50/TCID50) though well-established in 
quantifying infectious viral particles, are generally regarded as both time and labour intensive 
and relatively low throughput. The FFA assay is higher throughput than EID50/TCID50 
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methods and can generate results faster. However, it is complex and high-cost due to the use of 
specific antibodies. Similarly, PCR-based techniques are expensive, laborious, and sensitive to 
high levels of contaminants whilst high technical expertise is essential. 
More recent, cost-effective analytical technologies that biophysically count total number of 
virions have been able to provide results within minutes thus allowing real time monitoring of 
viral concentrations. Moreover, these methods allow simultaneous determination of particle 
size as well as detection of viral or protein aggregates. 
 
2.1.2 Overview of Particle Characterisation Methods 
There is a wide spectrum of particle size measurement techniques as illustrated in Figure 2.1. 
These are typically categorised as follows [16]:  
 
 Ensemble Methods: the particle size distribution (PSD) is obtained from a combined 
signal from an ensemble of particles: 
- Dynamic Light Scattering (DLS) 
- Laser Diffraction (LD) 
- Ultrasonic Attenuation Spectroscopy (UAS) 
- Electro-acoustics 
 Separation Methods: an outside force physically separates particles according to size. 
The separated different sizes are quantified: 
- Differential Centrifugal Sedimentation (DCS) 
- Size Exclusion Chromatography (SEC) 
- Field Flow Fractionation (FFF) 
- Analytical Ultracentrifugation (AUC) 
 Counting or “Fingerprint” Methods: each individual particle generates a size-related 
signal. The number of signals are categorised in size classes to develop a PSD: 
- Microscopy (TEM, SEM, AFM) 
- Flow Cytometry, Virus Counter (Virocyt) 
- Optical particle counters 
- Electrical Sensing Zone (Coulter Counter) 
- Scanning Ion Occlusion Sensing (SIOS)  
- Nanoparticle Tracking Analysis (NTA) 
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Figure 2.1: Schematic representation of typical size detection ranges for various techniques.  
Dashed lines denote influenza virus average size. 
 
The significance of adequate characterisation of particles in the 0.1–1 μm range for therapeutic 
proteins has been widely highlighted [17-20]. Nonetheless, analysis of submicron particulates 
is still regarded as challenging as very few methods cover this size range and/or only limited 
information can be obtained [21-22]. Traditional methodologies most commonly used for the 
analysis of nanoscale particles and protein aggregates are DLS, AUC, FFF, SEC and SDS-
PAGE [21, 23-28].  
 
2.1.3 Aims and Objectives 
Initial phases of this project (March-August 2012) investigated potential techniques that could 
facilitate real-time analysis of viral concentration, particle size and aggregation interactions in 
the early stages of influenza vaccine production and throughout downstream processing. The 
particle analysis capabilities between commercially available methods such as DLS, LD, SIOS, 
NTA and DCS were reviewed and compared in order to determine the most suitable viral 
particle analyser.  
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2.2 METHODS 
2.2.1 Assessment Criteria  
A number of commercially available analytical sizing techniques can potentially be used to 
monitor and characterise whole influenza virus particles. Taking into account the size of the 
virus (≈80-120 nm), a literature based comparison was performed mainly between five 
technologies, SIOS, NTA, DCS, DLS and LD. The evaluation criteria and the respective 
weighting factors utilised are summarised in Table 2.2.  
 
Table 2.2: Desired qualities for size determination and characterisation of viral particles. 
Parameter Requirement 
Weighting 
factor* 
Comments 
Total measurement 
range 
0.050-5 μm 5 
Range from the largest to the smallest particle size 
that is practically detected and measured. 
Resolution <5% 5 
Ability to clearly visualize a size distribution. 
Minimum difference in size between two perfectly 
narrow populations of particles that allows 
complete separation. 
Sample pre-treatment 
requirements 
Preferably 
None 
4 
Avoidance of chemical/biological modification of 
the sample. Minimisation of dilution error. 
Dilution may cause formation or/and disruption of 
aggregates. 
Accuracy <2% 4 
Agreement between the experimental value and 
what is regarded as the true value. 
Reproducibility <2% variation 4 
Variation between results when different people 
conduct the same measurement using the same 
method. 
Cost <£100,000 3 
Important if purchase of a new technology is 
required. 
Ease of operation Good 2 - 
Analysis Time <30 min 2 - 
In-/on-line capability Yes 1 - 
* Significance of weighting factors, 5: Very high importance, 4: High importance, 3: Medium importance, 2: Low importance, 
1: Very low importance, 0: Not important 
 
Additionally, the particle analysis capabilities of each method were subsequently investigated 
using mixtures of particle size standards and viral samples isolated from different production 
stages. DLS and NTA instruments were installed in Novartis Vaccines & Diagnostics (2011-
2012). The evaluation of SIOS and DCS was achieved through demonstrations by the respective 
manufacturing companies.  
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2.2.2 Scanning Ion Occlusion Sensing (SIOS) 
2.2.2.1 Operating Principle 
Scanning Ion Occlusion Sensing (SIOS) is a new technology for nanoparticle analysis 
developed by IZON (Izon Science Ltd, Christchurch, NZ) that uses a size-tunable elastomeric 
pore sensor to detect the passage of individual nanoscale objects in real-time. SIOS operates on 
the same principle as the traditional Coulter Counter (Electrical Sensing Zone) with the main 
difference being the use of resizable elastomeric pores instead of a fixed size pore. Although, 
fixed size pore sensors enable sensitive particle detection, they limit the measurable particle 
size range thus posing restrictions on analysis of particularly polydisperse samples. Adjustment 
of the stretch of the pore allows optimisation of pore size to particle size and can theoretically 
lead to more accurate measurements and increased sensitivity [29]. 
The device, characteristics and manufacturing of the pores have been described in various 
publications [30-33]. In brief, the pore is formed by mechanically puncturing a 250 μm thick 
TPU (polyethylene) membrane with a chemically-etched tungsten needle. The resulting pores 
are approximately conical in shape whereas their size depends on the puncturing processes. The 
membrane which contains this pore is a thin septum placed in a fluid cell in the device and is 
stretched onto four jaws forming a cross-shaped stretching platform (cruciform). Macroscopic 
stretching of the jaws is achieved using pegs, which generates changes in the size of the 
nanopore [33]. The main characteristics of the method are displayed in Table 2.3. 
 
Table 2.3: Features of SIOS [34]. 
Type of diameter Volume equivalent diameter 
Type of distribution Number based size distribution 
Measurement range 0.05–10 μm 
Calibration Standard polysterene beads 
Concentration range 105–1012 particles/ml 
Sample size 40 μl 
Measurement time 10-15 min 
Resolution about 3% relative 
Ease of operation Medium to low 
Cost £18-23,000  
 
The membrane which contains only a single pore divides two chambers containing an 
electrolyte solution. If an appropriate potential is applied across the membrane, an ionic current 
is driven through the pore [35]. Each time a particle passes through the pore, a blockade signal 
is recorded (Figure 2.2a), the magnitude of which is proportional to the particle size (Figure 
2.2b).  
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Figure 2.2: (a) Principle of detection. A blockade event is denoted each time a particle passes through the pore. Adapted from 
[36]. (b) Current pulses associated with the presence of particles within the channel. The magnitude of the pulse, ΔIm is 
proportional to particle size and the width, Δt, relates to translocation time [35]. 
 
Since particle blockade frequency or particle flow rate is proportional to sample concentration, 
titre determination can also be achieved by recording the particle flow rate at different applied 
pressures using the same pore size and electric field [37]. Concentrations are estimated by 
calibration to a reference particle solution. The PSD of an unknown sample is obtained by 
comparing the distributions of a blockade event of the calibration and the unknown sample [29]. 
Pressure is applied to the sample by an external manometer, which has an operating range of 
−1.8 kPa to 1.8 kPa. In case of low concentration samples, higher pressure is applied to increase 
the particle count rate [37]. 
Demonstration of the technology was conducted by IZON in Novartis Vaccines and Diagnostics 
using the qNano particle characterisation system. 
 
2.2.2.2 Particle Solutions 
PBS, pH 7.7 was used in all experiments as an electrolyte buffer. The same buffer was used for 
the cleansing of the pore and the fluid cell. A nanopore with nominal diameter of 200 nm was 
used (linear analysis range 100-400 nm). Calibration was performed with NIST traceable 
carboxylated polystyrene particles with nominal average diameter of 100 nm and concentration 
of 1×1013 particles/ml purchased from Thermo Scientific. The reference samples were 
suspended in buffered electrolyte PBS and had been subjected to ultrasonication prior to use. 
40 μl of suspended particles were introduced into the top of the fluid cell and a minimum of 
100 blockade events were recorded at a 47 mm pore stretch. The experiments were conducted 
using an applied voltage of 0.6 V at 8 cm H2O or 0.78 kPa. 
Eight samples from the production line of the vaccine against the seasonal viral strain 
A/California/7/2009 (X-181, H1N1) were analysed (Figure 2.3). Seven samples from whole 
virus process phases were examined, namely post-inactivation, peak and shoulder sucrose 
fractions, pre-diafiltration, post-diafiltration and post clarifying filtration, and one sample 
Stretch Stretch 
Current 
Stretch 
Blockades 
a  b 
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containing only purified surface antigens (final filtration). Finally, a mixture of polyvinyl 
chloride (PVC) standards with bead sizes 1.1 μm, 0.47 μm, 0.37 μm and 0.25 μm that had been 
previously used for the evaluation of the currently installed particle analysers in NV was 
examined.   
 
  
Figure 2.3: Sample collection points represented by arrows. 
 
2.2.3 Differential Centrifugal Sedimentation (DCS) 
2.2.3.1 Operating Principle 
Differential Centrifugal Sedimentation (DCS) is an analytical technique that has been widely 
used in the characterisation of size distributions of microscopic to sub-microscopic particles.  
The disc centrifuge designed by CPS (CPS Instruments, Inc., Florida, USA) is a hollow, 
optically clear disc with a distinct opening on one side (Figure 2.4) and a motor rotating at a 
known speed (600-24000 rpm) attached to the opposite side of the disc. As a detector beam, 
monochromatic light (400–500 nm) is employed [38]. Main characteristics of the method are 
presented in Table 2.4. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Left: Schematic representation of hollow disc centrifuge [38]. Right: Function diagram [39]. 
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To start the analysis, a fluid, containing a slight density gradient for stabilisation of 
sedimentation, is introduced into the rotating disc. The liquid at the outer edge of the disc is 
slightly denser than the liquid at the inside edge. A gradient that is compatible with the liquid 
in which the particles under investigation are suspended is selected. A sucrose solution is most 
commonly used. Calibration standards (e.g. PVC standard particles) with known density and 
size (hydrodynamic diameter) are then injected to calculate the rheological properties of the 
fluid (density, viscosity) [38, 40]. The sample, normally around 100 μl, is injected into the 
middle of the rotating disc, settles through the fluid and is detected optically by light absorption. 
In more detail, upon injection, particles hit the back edge of the rotating disc thus forming a 
thin band which rapidly spreads towards the fluid surface due to centripetal acceleration. When 
the sample solution reaches the surface, sedimentation of each particle occurs individually. If 
particles are of the same size and density, they sediment at the same settling velocity and reach 
the detector at the same time as a thin film. Larger, denser particles settle faster than smaller, 
less dense particles and consequetly arrive at the detector beam earlier. The sedimentation 
velocity of the particles can be calculated based on the time between particle injection and 
detection [38, 40]. The time the particles need to reach the light source versus the intensity of 
the beam is transformed to give the PSD using a variation of Stokes’ Law so that it accounts 
for the variation in gravitational force with the distance from the centre of rotation, and Mie 
Theory of Diffraction of Light [38, 41].  
The modified version of Stokes Law for centrifuge sedimentation is:  
t
RR
d
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if
2)(
)/ln(18




  
where d is the diameter of the particle, η is the viscosity of the media, Ri is the starting radii and 
Rf is the ending radii of rotation, ρP, ρF are particle and fluid densities respectively, ω is 
rotational speed and t is arrival time for particle from Ri to RF. 
 
Table 2.4: Features of DCS [38]. 
Type of diameter Stokes diameter 
Type of distribution Weight or intensity-based 
Measurement range 0.005-80 μm 
Calibration PVC particles 
Accuracy 0.25% 
Sample size 100 μl 
Measurement time 3-40 min 
Resolution >5% relative 
Ease of operation Good 
Cost £54,160  
 
Eq.1 
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Approximately 40 samples can be measured before the centrifuge disc fills and a new gradient 
needs to be formed. Generally, density gradients, depending on the molecular weight and 
viscosity of the forming materials, remain stable for up to 72 hours [38, 40]. 
Demonstration of the technique took place in Liverpool University (Department of Chemistry, 
Crown Street, Liverpool L69 7ZD, UK) by Analytik (Analytik Ltd. Swavesey, Cambridge, 
CB24 4AA, UK) using the CPS Disc Centrifuge DC24000. Disc rotation was set to 24000 rpm. 
Sucrose was used as the density gradient. After reaching the final rotation speed, the density 
gradient of a volume of 14.4 ml was established by injecting 1.6 ml of 9 sucrose solutions (with 
2, 2.75, 3.5, 4.25, 5, 5.75, 6.5, 7.25, 8 % (w/v) sucrose), beginning with the highest concentrated 
solution.  
 
2.2.3.2 Particle Solutions 
After equilibration (20 min), 100 μl of 522 or 337 nm PVC standard particles (CPS Instruments, 
Inc., Florida, USA) were injected for instrument (external) calibration before sample 
characterisation. Only four viral particle solutions of the strain A/California/7/2009 (X-181, 
H1N1) were analysed due to time limitations.  These were isolated from the product stream 
post-diafiltration, during the clarification filtration (after a 5 μm filter and after a 1.2 μm filter) 
and after final filtration (Figure 2.3). No dilutions were performed.  A solution consisting of a 
mixture of ten polystyrene standards covering the size range 0.1-2000 μm (Whitehouse 
Scientific, provided by CPS) was also measured.  
 
2.2.4 Nanoparticle Tracking Analysis (NTA) 
2.2.4.1 Operating Principle 
Nanoparticle Tracking Analysis (NTA), initially commercialised in 2006 by Nanosight 
(Nanosight Ltd., Salisbury, UK), is a recently developed laser illuminated microscopical 
method that allows nanoparticles in solution to be detected and sized by a charge-coupled 
device (CCD) camera in real time [42].  The Brownian motion of each particle is individually 
tracked by particle tracking image analysis software.  
A 640 nm, finely focused laser beam passes through a prism optical substrate that refracts the 
beam at the interface between the substrate and a liquid film above it. The refraction causes 
compression of the beam to a low level thus allowing visualisation of an intensely illuminated 
region in which particles are present in the liquid layer through a ×20 magnification microscope 
objective which is built-in a common microscope. A CCD camera which operates at 30 frames 
per second, records a video with a field of vision approximately 100 μm × 80 μm [44]. 
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Nanoparticles under Brownian motion are detected, sized, and counted through the NTA 
tracking software which identifies and tracks the centre of each particle individually throughout 
the captured video (typically 900 frames or 30 seconds) [44, 45]. A scheme of the NTA system 
is presented in Figure 2.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Left: NTA apparatus [42] and right: image particle tracks generated by NTA [43]. 
 
The average distance each particle moves in the x and y location is estimated and based on this 
value the particle diffusion coefficient, D, is subsequently deduced. Provided that the sample 
temperature, T, and the medium viscosity η are known, the hydrodynamic radius, rh, of each 
particle can be calculated by the following modification of the Stokes-Einstein equation [46]: 
 
πηr
Tk
Dty)(x
h
B
3
2
, 2   
 
where kB is the Boltzmann constant and         is the mean squared speed of a particle. 
Concentration of the sample should be between 107 and 109 particles/ml to allow the analysis 
of a sufficient number of particles and thus the generation of a statistically important and 
reproducible PSD. Dilutions are usually necessary in order to achieve this concentration. The 
lower detection size limit of NTA depends on the refractive index of the particles [45]. 
Specifications of the technique are summarised in Table 2.5. Applications of NTA have been 
reported in several areas including nanoparticle synthesis [47, 48] and virus counting [49]. 
 
 
 
 
 
 
 
 
 
 
2, y)(x
Eq.2 
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Table 2.5: Features of NTA [44]. 
Type of diameter 
Intensity-based,  
hydrodynamic diameter 
Type of distribution Number of particles-based distribution 
Measurement range 0.01-1μm 
Calibration No 
Sample size 300 μl 
Measurement time about 10 min 
Resolution Relative 2% 
Ease of operation Medium 
Cost £22,000  
 
In this study, measurements were performed with a NanoSight LM10, currently installed in 
NV. Injection of the samples in the sampling chamber was done with sterile syringes until the 
liquid appeared at the tip of the nozzle. The analysis was carried out at room temperature. The 
NTA 2.3 software was used for video capturing and data analysis. The samples were measured 
for 90 s.  
 
2.2.4.2 Particle Solutions 
The same mixture of particles of standard size and viral particle samples that were analysed 
with the CPS centrifuge were used. Dilutions were performed with PBS to achieve 
approximately a particle concentration of 5x108 particles/ml. 
 
2.2.5 Dynamic Light Scattering (DLS) 
2.2.5.1 Operating Principle 
In DLS, sometimes referred to as Photon Correlation Spectroscopy (PCS) or Quasi-Elastic 
Light Scattering (QELS), fluctuations in scattered light intensity due to the Brownian motion 
of an ensemble of nanoparticles, are recorded at a specific angle as a function of time (Figure 
2.6). These changes in intensity are converted to a mean translational diffusion coefficient 
which is subsequently converted into particle diameter through the Stokes–Einstein equation 
(Eq.2). The conversion is considered valid only under the assumption that the particles are 
spherical and not interacting [16]. Quality parameters of the method are given in Table 2.6. 
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Figure 2.6: Schematic representation of the dynamic light scattering technique. Image from [50]. 
 
DLS is generally regarded as user-friendly and currently is the method of choice for routine 
size determination of nanoparticles in solution. However, DLS is also known to suffer from 
several inherent limitations. The method is extremely sensitive to large particles as the intensity 
of light (Rayleigh approximation) is proportional to the sixth power of the particle diameter 
[46, 51, 52]. Hence, presence of even a few big particles could result in poorer resolution, 
inaccurate PSDs and size overestimation [53, 54]. Furthermore, DLS is limited to monodisperse 
samples and scatter-free environments. At high concentrations (> 0.01% v/v), interactions 
between particles and multiple scattering are observed and this can therefore lead to erroneous 
results. Only mean diameter values of an ensemble of particles are calculated [42]. 
 
 
Table 2.6: Features of DLS [16]. 
Type of diameter 
Intensity-based, 
hydrodynamic diameter 
Type of distribution 
Intensity-based size 
distribution 
Measurement range 0.3 nm–10 μm 
Calibration No 
Sample size μg to mg quantities 
Measurement time about 10 min 
Resolution 30% relative 
Ease of operation Very Good 
Cost £30-60,000  
 
DLS experiments were carried out with a Zetasizer ZS (Malvern, Herrenberg, Germany) 
equipped with a 633 nm laser at a 90o degree scattering angle in NV. Data were collected using 
the Dispersion Technology Software version 5.1 from Malvern. 700 μl of each sample was 
analysed in disposable polystyrene micro cuvettes with a pathlength of 10 mm. Temperature 
was maintained at 25°C. For every sample, 15 runs of 10 scans were performed with three 
repetitions.  
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2.2.5.2 Particle Solutions 
The same solutions described in 2.2.2.2 and 2.2.3.2 were analysed. 
 
2.2.6 Laser Diffraction (LD) or Low Angle Laser Light Scattering (LALLS) 
In this method, the light scattering pattern of an ensemble of particles which are dispersed in 
liquid or air is measured with a series of detectors placed at a wide range of different low 
scattering angles (Figure 2.7). The collected intensity data from all the detectors is then 
converted to a PSD by application of a theoretical optical model for light scattering of 
particulates. Mie theory is typically used for small particles. This model requires information 
on the real and imaginary components of the refractive indexes of both the particles and the 
solvent [16, 55]. Conversely, the Fraunhofer diffraction model is commonly applied for the 
determination of size of larger particles and does not require knowledge of the refractive index 
[16, 56]. Some characteristics of the method are displayed in Table 2.7. 
 
 
Figure 2.7: Principle of laser diffraction. Image from [57].  
 
At relatively high particle concentrations multiple scattering becomes an issue for operation of 
LD as particles have higher probability to re-scatter again at one or more other particles [16]. 
Similarly to DLS, this phenomenon can result in inaccurate PSDs. Only a limited number of 
instruments account for multiple scattering and through the application of multiple-scattering 
algorithms on the measured data (correction) can achieve relatively improved accuracy [58]. 
On the other hand, at too low concentrations, the scattering signals from the detectors are not 
strong enough hence leading to a low signal-to-noise ratio and subsequently decreased 
repeatability [16]. 
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Table 2.7: Features of LD [16]. 
Type of diameter 
Equivalent light scatter 
diameter(s) 
Type of distribution 
Volume based size 
distribution 
Measurement range     0.01 – 3,500 μm 
Calibration No 
Sample size mg to gram quantities 
Measurement time 0.01–30 s 
Resolution 15% relative 
Ease of operation Medium, skill required 
Cost 100-200,000 £ 
 
Evaluation of a laser diffraction particle analyser was not attempted due to readily identified 
unsuitability for characterisation of sub-visible particulates as well as cost limitations. The 
method is described only for theoretical comparison purposes.  
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2.3 RESULTS AND DISCUSSION 
2.3.1 Comparison between SIOS, DLS and DCS  
Eight samples from various stages of the vaccine manufacturing process were analysed using 
SIOS as described in the experimental procedure (2.2.2.2). Monomodal non-normal PSDs in 
the form of size histograms were obtained (Figure 2.8). 
 
Figure 2.8: Size histograms of examined viral samples, presented in increasing order of purity.  
Histograms were reproduced in Minitab 16 for presentation purposes.   
 
Relatively low particle count (concentration) was observed in shoulder fraction II which 
contains high levels of sucrose and in the final (monobulk) sample. In the latter, low particle 
count is expected as only viral subunits exist after the splitting stage. From the SIOS equipment 
manufacturer, a minimum of 500 particle counts is recommended for a statistically significant 
result and high signal to noise ratio.  Only half the samples exceeded this specification.  
The sample from shoulder fraction II also exhibited the highest value of standard deviation 
(Table 2.8) and probably longer analysis time was required for a more accurate distribution. 
Overall, the resulting size histograms gave a constant mode virus size of approximately 114 nm 
although for the final filtration sample, it is considered a coincidence that the surface antigens 
formed oligomers comparable in size to the intact virus. The maximum observed particle 
diameter was 491.5, which is above the limit of the linear range of the pore used in the 
experiments. Hence, use of a pore of greater size is recommended for measuring the larger 
particles and obtaining a complete PSD. 
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Table 2.8: Sample statistics. 
Sample 
Mean 
Diameter 
(nm) 
Mode 
Diameter 
(nm) 
St. 
Dev. 
Min 
(nm) 
Max 
(nm) 
Raw 
Concentration 
(particles/ml) 
Particle 
Count 
Post- 
Inactivation 
126.6 112.0 38.1 81.8 326.4 4.3E+011 397 
Peak Fraction 125.2 112.4 35.7 82.1 484.0 5.2E+012 1128 
Shoulder I 
Fraction 
133.1 119.5 38.5 88.6 404.2 3.6E+011 312 
Shoulder II 
Fraction 
165.0 124.6 64.3 92.9 528.7 2.5E+011 230 
Pre-Diafiltration 128.4 113.7 35.1 88.9 482.4 2.8E+012 1018 
Post-
Diafiltration 
125.2 112.4 34 82.9 434.5 5.2E+012 1128 
Post-Clarifying 
Filtration 
129.6 114.3 41.4 82.9 491.5 2.5E+012 967 
Final Filtration 134.9 120.1 43.9 86.4 336.1 4.1E+008 143 
 
Blockade magnitude plots against time show single peaks for the purer samples, pre-
diafiltration and thereafter, while multiple peaks and unstable current patterns are observed for 
the earlier production samples (Appendix 2.1). Single peaks in the blockade magnitude plot 
over time typically indicate detection of single particles exclusively whereas presence of 
additional peaks at multiples of the single particle size suggests passing of aggregates. Pre-
treatment by simple dilution with PBS by a factor of 400 or 500 was necessary for all samples 
to reduce the probability of pore blockade by aggregated particles. Detection of the passage of 
aggregates as single blockade events often leads to underestimation of particle concentration 
whereas blockage of the pore disrupts particle flow. Filtering was recommended for a more 
accurate size determination of the sucrose containing samples (peak and shoulder fractions).  
The same samples were analysed with DLS. The mean size values obtained by the two 
techniques are compared in Figure 2.9. Good agreement between the methods is noted for the 
three purer samples, i.e post-diafiltration, post-clarifying filtration and after final filtration. In 
the samples containing sucrose, the strong bias of DLS towards the largest particles, which were 
not detected with SIOS due to the use of a small pore, becomes apparent (inset in Figure 2.9). 
Specifically, DLS analysis of the sample from shoulder fraction I yielded only a monomodal 
broad intensity distribution with a main peak around 1.8 μm. This distribution corresponds 
possibly to viral aggregates, the formation of which might have been induced by the presence 
of sucrose or alternatively by modification of the optical parameters of the suspension medium 
not accurately defined for the conduction of the measurement. Detection of the four PVC 
standards (1.1 μm, 0.47 μm, 0.37 μm and 0.25 μm), that were previously used for determination 
of the sizing abilities of Zetasizer (Appendix 2.2a) and the CPS centrifuge installed in Novartis 
Vaccines in Marburg (Appendix 2.2b) was not possible by SIOS. Specifically, less than 100 
particle counts were recorded which suggests a particularly low particle concentration. DCS 
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identified all four particle populations at 0.26, 0.38, 0.48 and 1.36 μm (Appendix 2.2b). 
Conversely, DLS analysis generated a single broad peak at approximately 0.3 μm (Appendix 
2.2a). The same samples were not analysed with NTA as training could not be offered and the 
trained operator was not available around the time the demonstration took place. 
 
Figure 2.9: Comparison of mean particle diameters obtained by SIOS and DLS.  
Inset: PSD of sample from shoulder fraction I given by DLS. 
 
2.3.2 Comparison between DCS, DLS and NTA 
A mixture of ten narrow PVC standards and four viral samples derived from the manufacturing 
process, namely after diafiltration, clarifying filtration with filters of 5 and 1.2 μm and final 
filtration, were analysed with three particle analysers: DCS, DLS and NTA.  The previously 
described experimental procedures were applied. The size distributions of the PVC mixture 
obtained by all methods are shown in Figure 2.10.  
 
 
Figure 2.10: Intensity distributions of mixture of PVC standards generated by DCS, NTA and DLS. 
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DCS was the only technique able to detect and completely separate all populations, therefore 
demonstrating the highest resolving power. Detected peaks were noted at 1.4816, 1.0529, 
0.7227, 0.5328, 0.4081, 0.3162, 0.2544, 0.1866, 0.1518 and 0.1204 μm. Hence adjacent narrow 
peaks differing by less than 3% were resolved. A total number of 1398x106 particles were 
measured. NTA identified the presence of more than one particle population. However, 
separation was not possible. A main peak was observed at 0.166 μm whereas 3 more peaks 
were also visible at 0.128, 0.221 and 0.294 μm. As NTA requires particle concentrations of 
107–109 particles/ml, a 1:100 dilution was performed that resulted in a total concentration of 
6.51x108 particles/ml (734 particle tracks). Mean and mode diameters were found 0.182 and 
0.166 μm respectively. Finally, DLS only yielded a monomodal PSD with a mean diameter of 
0.220 μm. Dilution was not required as in DLS the concentration range is less critical than in 
NTA. It is readily deduced that the significant bias of the detection sensitivity of DLS to larger 
particles makes the method not particularly suitable i the analysis of polydisperse suspensions. 
Figure 2.11 displays distribution overlays from the analysis of the virus samples. The PSD 
obtained by DLS (Figure 2.11b) has roughly a bell shape and shows only one major peak. DCS 
detected at least three different particle populations (Figure 2.11a). NTA (Figure 2.11c) appears 
to recognise the presence of different particulates as deduced from the shoulders on the primary 
peak though peak resolution is substantially limited. Furthermore, disc centrifugation results 
show an increase in purity (reduction of particle weight) as the product passes through filters 
with decreasing pore size. Similar effect is not apparent with the other two examined methods. 
It is worth noting that for NTA analysis, dilutions up to 1:10000 were required.  
No particles were detected in the final filtration sample with the CPS or the Nanosight 
instrument due to low particle concentration. A peak of low intensity was recorded only by DLS 
(not presented here). 
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Figure 2.11: PSDs from (a) disc centrifugation, (b) DLS and (c) NTA measurements of viral samples after diafiltration (       ),  
clarification filtration with 5 um filter (       )  and clarification filtration with 1.2 µm filter (        ). Average mean diameters: 
disc centrifuge, 0.15 µm, DLS, 2.1 µm and NTA 0.17 µm.  
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2.4  OVERALL EVALUATION AND CONCLUSION 
It is generally accepted that all particle sizing methods have both strengths and weaknesses and 
usually more than one technique might be required for complete sample characterisation. Table 
2.9 briefly summarises the main strengths and limitations of the methods under investigation 
derived from the experimental comparability study as well as assessment of relevant literature.  
 
Table 2.9: Evaluation summary. 
Sizing 
Method 
Strengths Limitations 
SIOS 
- Easy calibration with known size 
standards 
- Particle by particle analysis  
- Suspension in conductive fluid 
- Dilutions required 
- Limited dynamic size  
- Potential blockage of orifice from oversized particles  
- Knowledge of particle shape 
DCS 
- High resolution 
- No sample pretreatment 
- Verification of accuracy using 
calibration standards 
- Long analysis times for particles <50 nm, with 
density close to the liquid density. 
 - No sample recovery 
 - Potential interference with sucrose  
 - Knowledge of optical parameters and shape 
DLS 
- Widely used  
 - Fast, simple, non-destructive  
-  Quick analysis time  
- Low resolution (30%) 
- Polydisperse samples cannot normally be measured  
- Bias towards larger particles  
- Knowledge of optical parameters and shape 
NTA 
- Visualisation of sample 
 - Particle-by-particle analysis 
-  Detection of polydisperse 
particles  
- Low reproducibility  
- Experienced operator required  
- Sample dilutions  
- Slow, and labour intensive 
- Knowledge of optical parameters and shape  
LD 
- Non-destructive 
- Easy sample recovery 
- Widely used on-line 
- Low resolution (15-20%) 
- Knowledge of optical parameters and shape 
- Polydisperse samples cannot be analysed 
- High Cost 
 
SIOS, as the most recently developed technology of particle determination, with the first bench-
top instruments being released only in 2009, is still in a research and development stage. The 
method can be easily calibrated with standards of known size and it enables measurements of 
particle size, concentration and potentially surface charge.  Nevertheless, it requires suspension 
of the biological samples in conductive fluid which might lead to undesired biological 
modifications. Moreover, as relatively low particulate concentration is required, dilutions have 
to be performed which is undesirable as this could induce aggregation state changes. As 
demonstrated earlier (2.3.1), the size range of the available elastomeric membranes is currently 
limited, and more than one membrane is required for complete characterisation of particle size. 
Additionally, though the pore is resizable there is a potential of blockage of the orifice from 
oversized particles. 
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DCS presents several advantages the most important of which appear to be its extremely high 
resolution, its broad dynamic range and its ability to analyse samples in their native form (no 
pretreatment). Furthermore, the method allows correction of the resulting size distribution when 
it is known that particles are not-spherical and low density particles can also be measured.  
Finally, the accuracy of the technique can be readily verified with calibration standards. The 
main disadvantages of disc centrifugation are that the sample cannot be recovered and relatively 
long measurement times are needed for particles smaller than 50 nm with density close to the 
liquid gradient’s density. There is also the possibility of interference with the sucrose gradient 
if the solution to be analysed already contains significant amounts of sucrose, which can be the 
case for the viral samples collected after the sucrose gradient centrifugation stage of the 
manufacturing process. Additionally, if the software does not account for particle shape, non-
spherical particles might be reported smaller than their actual size. This does not apply 
particularly to influenza virus samples as viral particles are approximately spherical.  
Currently, the most widely used method for particle analysis is DLS. This is probably due to its 
simplicity and the broad concentration range of the samples, i.e. usually no dilutions are needed. 
DLS is also non-destructive, fast and ideal for analysis of monodisperse systems. However, the 
resolution of the technique is particularly low as particles should differ in size by 30% or more 
to be detected. Polydisperse mixtures, consisting of particles of different sizes, usually cannot 
be detected as shown in 2.3.2 via the measurement of the mixture of particle standards. Lastly, 
analysis of the viral samples verified the well-known detection sensitivity bias of the method 
toward larger particles. 
NTA has several advantages particularly in comparison with DLS. Though the sizing accuracy 
of the method with regard to analysis of monodisperse populations is comparable to that of 
DLS, NTA is capable of detecting and separating polydisperse particles much more efficiently 
than DLS while it also provides an approximation of particle concentration. Unlike DLS, NTA 
is a particle-by-particle analysis as it allows visualisation of the sample and subsequent tracking 
of individual particles.  Hence it avoids DLS’s bias towards large particles whilst it does not 
involve knowledge of refractive indexes. On the other hand, NTA presents distinct limitations 
including a generally low reproducibility as the software sometimes detects and tracks more or 
less particles in repeated measurements of the same sample. This observed variation in the 
estimated number of particles may subsequently lead to possibly imprecise particle 
concentration measurements. The technique also requires an experienced/skilled operator as 
optimisation of sample pre-treatment is necessary. Overall, NTA measurements can be 
laborious and time-consuming (e.g. adjustment of camera settings, cleaning of the sample 
chamber after each analysis etc.) and several dilution steps might be needed due to the limited 
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concentration range of the method. If the concentration is too low, only a few particles are 
measured and the obtained results may not be statistically reliable. Conversely, if the 
concentration is high, particles cannot be distinguished effectively.  
LD allows rapid data collection, is non-destructive and the sample can be easily recovered while 
it can also be used for on-line monitoring. LD like DLS, has particularly low resolution as 
narrow peaks must differ in size at least 15-20% to be resolved. Accuracy of the measurements 
is determined by the accuracy of information on the optical properties and shape of the particles 
while polydisperse samples are difficult to be analysed. Non-homogeneity or presence of non-
spherical particles can also lead to erroneous results. 
Finally, to determine the most suitable analyser, the analytical methods under evaluation were 
scored (1-10) against the desired quality parameters that were described earlier (Table 2.2). 
From the results presented in Table 2.10, it can be deduced that DCS is the most appropriate 
particle sizer for the analysis of in-process influenza vaccine samples. DCS can be utilised for 
real-time measurements of total influenza physical titres (infectious and non-infectious) in the 
crude upstream phases as well as detection of aggregates that could cause manufacturability 
issues in subsequent downstream operations. In downstream whole virus phases (post-
inactivation), DCS can provide quantitative information of virus content and virus recoveries 
between steps. After virus solubilisation, DCS can be used for detection of viral aggregates 
(detection of antigens is not possible due to small size<50 nm) that could cause filter blockages. 
Novel applications of DCS in influenza samples are presented in subsequent chapters (Chapters 
3-5). 
 
Table 2.10: Scoring of sizing methods against desired specifications.    
Parameter (weighting factor) SIOS DCS DLS NTA LD 
Total measurement range (5) 8 10 10 8 10 
Resolution (5) 6 9 4 6 5 
Sample pre-treatment 
requirements (4) 
7 10 9 7 8 
Accuracy (4) 7 8 6 7 6 
Reproducibility (4) 7 9 5 4 5 
Cost (3) 7 5 10* 10* 2 
Ease of operation (2) 5 8 10 5 9 
Analysis Time (2) 8 8 8 3 8 
In-/on-line capability (1) 3 4 5 3 10 
Total Score (300) 204 252 221 191 201 
                              * Instruments already available on site. 
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3. APPLICATIONS OF DIFFERENTIAL 
CENTRIFUGAL SEDIMENTATION IN VIRUS 
QUANTIFICATION AND CHARACTERISATION 
OF INFLUENZA VACCINE MANUFACTURE 
 
 
3.1 INTRODUCTION  
3.1.1 Sedimentation Techniques  
3.1.1.1 Basic Theory of Sedimentation  
Sedimentation of particles in a fluid has been widely used to describe particle size distributions. 
Sedimentation can occur due to gravitational or centrifugal settling. Gravitational sedimentation 
(1 g force) is the outcome of three forces acting on a particle in suspension (Figure 3.1a): gravity 
(Fg), buoyant force (Fb) and the force due to viscous drag (Fd) [1]. Settling due to gravity is 
mainly applicable to large particles (0.3–200 μm) as small particles demonstrate such low 
sedimentation rates that result in impractically long analysis times [1, 2]. Moreover, Brownian 
motion or pedesis, i.e. the random diffusion of particles (Figure 3.1b), becomes considerably 
high for particles <1 μm thus preventing effective sedimentation [1, 2].  
Conducting of sedimentation in a centrifuge (multiple g force) enables analysis of much smaller 
particles. At high g force, the sedimentation velocities of small particles become much more 
significant than Brownian movements [2, 3].  
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Figure 3.1: a) Forces exerted on a solute particle in a gravitational field and  
b) Brownian movement of a submicron particle [4]. 
 
The sedimentation rate of spherical particles is expressed by Stoke’s law [1, 5, 6]  
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where v is the settling velocity of a particle, H is the settling height, d is the diameter of the 
particle, η is the viscosity of the media, ρP, ρF are particle and fluid densities respectively, g is 
the gravitational acceleration constant and t is the settling time for particle over height H. 
As described earlier (Chapter 2, 2.2.3.1), when a centrifuge is utilised, a modified version of 
Stoke’s law (Eq.1) is employed that takes into consideration the variation in centrifugal force 
with distance from the centre of rotation [2, 3, 5]. Two sedimentation methods are traditionally 
used, namely integral or homogeneous sedimentation and differential or two-layer 
sedimentation.  
 
3.1.1.2 Principles of Integral Sedimentation 
In integral sedimentation, a homogeneous suspension of particles is subjected to a centrifugal 
field. A light or X-ray detector positioned inside the centrifuge initially reads minimum 
intensity that correlates with maximum particle concentration [2, 7]. As the particles start to 
sediment through the liquid at a rate depending on particle size, density difference between the 
particles and the fluid and fluid viscosity, the light intensity reaching the detector increases 
proportionally to the reduction in concentration of particles remaining in suspension (Figure 
3.2) [2,7]. Particle size is determined by Stokes’ equation which estimates hydrodynamic 
diameter (the diameter of an equivalent hypothetical sphere diffusing in the same manner 
 
Fd Fb 
Fg 
a b 
Eq.4 
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as the molecule of interest) as a function of time. An integral (cumulative) representation 
of the particle size distribution (PSD) is produced by plotting particle diameter versus 
particle concentration. A differential PSD can be obtained through calculation of the first 
derivative of the integral distribution [2, 7]. 
 Integral sedimentation can also be used with particles less dense than the surrounding fluid. 
In this case, particles will float towards the fluid surface instead of sinking to the bottom.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Integral sedimentation. 
 
Integral centrifugal sedimentation presents significant shortcomings including [2, 7]:  
 Possible loss of resolution and inaccuracy in measurements due to thermal convection. 
Centrifuges operating at high speed typically generate large amounts of frictional heat 
that result in fluctuations of temperature during analysis.  
 The starting conditions are unstable and not accurately defined. Injection of a particle 
suspension in a centrifuge spinning at full speed will inevitably cause turbulent mixing 
of the sample during addition, thus impeding accurate calculation of sedimentation time. 
In contrast, injection of a sample in a centrifuge that is not spinning and is subsequently 
accelerated to full speed requires accurate measurement of speed modifications upon 
acceleration.  
 Limited throughput and labour intensive operation. The centrifuge needs to be stopped, 
emptied and cleaned after each sample.  
 
3.1.1.3 Principles of Differential Sedimentation 
In the differential sedimentation method (Figure 3.3), a small sample of particles is added on 
top of a clear fluid inside a spinning centrifuge.  Similarly to integral sedimentation, particles 
begin to settle through the liquid according to Stoke’s law, assuming stable sedimentation 
conditions. Initially, a light or an x-ray beam detector reads maximum intensity since the 
concentration of particles within the beam path is zero. The decrease in light intensity noted 
every time particles pass through the detecting beam relates to particle concentration. If an X-
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ray detector is used, the reduction in intensity is directly proportional to particle concentration 
whereas Mie scattering calculations on intensity data are performed in case of a monochromatic 
light beam.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Differential sedimentation. 
 
In differential sedimentation analysis, all particles start settling concurrently from the same 
known distance. Nonetheless, only particles of a certain hydrodynamic radii are detected at any 
time. Particle size is determined from the time needed for the particles to reach the detector. 
The resulting PSD is a differential plot (particle concentration versus particle diameter) while 
an integral PSD can be obtained by mathematical integration. Figure 3.4 displays an overlay of 
both distribution types [2, 3].  
 
 
Figure 3.4: Differential (blue) and integral (green) PSDs. 
 
Differential sedimentation can practically be applied only when a slight density gradient (e.g. 
sucrose, ethanol, glycerine etc.) is formed within the fluid inside the centrifuge to ensure that 
no instability occurs during sedimentation. This sedimentation instability, also known as 
“streaming” effect, is the settling of the entire sample suspension as a bulk liquid instead of 
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individual particles and it is frequently observed when the net density of the liquid containing 
the sample (average density of suspended particles and liquid) is higher than the density of the 
fluid layer directly below.  A number of methods have been reported to limit streaming [8-11]. 
Use of a density gradient (most commonly sucrose in aqueous systems) results in reduction of 
streaming as a continuous increase of the net density from the fluid surface to the bottom is 
accomplished throughout analysis [12]. Stable sedimentation is achieved when the following 
condition is fulfilled:  
0
R
pnet


 
where pnet is the net fluid density including particles and R is the distance from the centre of 
rotation.  
The gradient slope is based on the net density of the sample of interest, e.g. steeper gradients 
are needed for samples with higher net density compared to lower net density suspensions. 
Generally, density gradients below 0.01 g/ml per cm of fluid height can guarantee 
sedimentation stability for relatively low particle concentrations [2].  
In presence of a density gradient, friction-induced heat convection is also reduced and therefore 
small fluid temperature fluctuations do not affect sedimentation efficiency [2]. Additional 
advantages of differential against integral sedimentation include less labour-intensive and 
higher throughput operation as there is no need for emptying and cleaning the centrifuge after 
each run, i.e. multiple samples can be measured sequentially [2, 7]. The limiting factor with 
regards to continuous operation of the centrifuge is the gradual degradation of the density 
gradient due to molecular diffusion.  
 
3.1.2 Differential Centrifugal Sedimentation (DCS) 
3.1.2.1 Design of DCS Apparatus  
The most commonly used DCS design is currently commercialised by CPS Instruments Inc. 
and is detailed in Chapter 2 (2.2.3.1). 
 
3.1.2.2 Performance Features of DCS and Further Considerations  
3.1.2.2.1 Accuracy and Precision  
The accuracy of DCS relies primarily on accurate estimation of all the parameters involved in 
Stokes’ formula (Eq.1 or Eq.3, 4). An internal or external calibration standard of known size 
is typically used to ensure accuracy by specifically calculating a combinatorial constant value 
for all the factors of Eq.1.  Hence, Eq.1 is transformed into: 
Eq.5 
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where C is a combination of constants during analysis. 
Inaccuracy in PSD determination can also be caused by unstable sedimentation conditions. 
The CPS centrifuge assesses sedimentation stability automatically via the distribution of 
narrow calibration standards. In particular, the width and shape of the calibration peak is 
compared every time with the theoretical width and shape for that specific calibration standard. 
Notable changes in either characteristic suggest instability and therefore measurement 
inaccuracies can be avoided. Furthermore, loss of accuracy is probable when significant 
deviations from Stokes’ regime are observed.  
Generally most sedimentation processes are performed at Reynolds numbers (Re) <0.02, at 
which deviations from Stokes’ equation are negligible [2]. However, at too high Re which can 
be observed in presence of larger particles, extremely high sedimentation rates and low fluid 
viscosities [2], the deviations become significant and unless accounted for by the instrument, 
Stokes’ law is no longer valid [13]. Mathematical modifications are required in case of non-
spherical particles as well. Since Stokes’ equation is based on the assumption of spherical 
particles, particles with geometries greatly different from spheres, e.g. rods, will appear smaller 
than their “real” PSD [2, 14].  The accuracy of DCS has also been examined to a limited extent 
through comparisons with other orthogonal techniques. DCS results have shown to agree well 
with respective AUC [15] and TEM [16, 17] measurements. 
DCS has demonstrated high measurement precision or repeatability which is commonly defined 
by the relative standard deviation over replicate measurements of the PSD. Reported standard 
deviation values are 0.25-0.5% [2] and 1.4% [15].  
 
3.1.2.2.2 Resolution 
The results obtained by DCS typically show remarkably high, nearly chromatographic, 
resolution compared to other particle sizing technologies. The actual or experimental resolution 
of DCS, defined as the minimum difference in size between two perfectly narrow populations 
of particles that can be separated, is expressed as: 
21
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where Rp is the (%) resolution, d1 is the diameter of the bigger size population and d2 is the 
diameter of the smaller size population [2].  
Eq.6 
Eq.7 
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The theoretical resolution of DCS depends mainly on three parameters: the sedimentation 
distance, the initial width of the sample band and the width of the detector beam. Eq.8 is used 
for estimation of the theoretical resolution as a function of those three factors.  
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where RT is the (%) theoretical resolution, T is the sample thickness (mm), W is the beam 
width (mm) and D is the sedimentation depth (mm) [2].  
When analysis is performed at typical conditions (D=10 mm, W=0.5 mm and T=100µl≈ 0.066 
mm), a theoretical resolution of approximately 3% can be achieved according to Eq.8. Further 
enhancement of this value is possible by reduction of the sample volume (weight), increase of 
the sedimentation distance or decrease of the beam width [2].  
In practice, the actual resolution of DCS is slightly lower than the one predicted above. During 
analysis, the theoretical resolution of DCS can potentially be compromised by several factors 
such as Brownian diffusion of particles smaller than 0.3 μm, streaming, initial band broadening 
during the injection procedure and other deviations from Stokes’ law as a result of interaction 
of particles with the wall of the centrifuge chamber (e.g. particle adhesion) [2, 3, 18]. The 
impact of those elements on the resolution of the PSD can be mathematically estimated and if 
taken into consideration [2] for a particle of a diameter of 0.3 μm and at a sedimentation distance 
of 20 mm, the resolution is expected to be 1.9 -2.5%. 
 
3.1.2.2.3 Sensitivity and Analysis Time 
As described in Chapter 2, DCS is a highly sensitive particle analyser with only 1 µg of active 
weight required for acquisition of a satisfactory PSD [19]. The overall analysis time depends 
largely on the desired measurement range and the centrifugation speed. For samples containing 
small particles the total run time is reduced when DCS is set up at maximum centrifugation 
speeds. Analyses times for a typical size range of 25 (defined as the ratio of the maximum size 
to the minimum size to be measured) can vary between 10-45 min using a fixed centrifuge 
speed. As a general rule, analysis should not last for more than 45 minutes in order to obtain 
high quality PSDs [2, 3]. If examination of much broader dynamic ranges (above 60-70) is 
needed, then the disc design could be modified to allow speed ramping which expands the 
dynamic range up to 1000. Speed ramping applications were not investigated and are out of the 
scope of this thesis.  
 
Eq.8 
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3.1.2.3 Applications 
DCS has been extensively utilised for the characterisation of particle size distributions of a wide 
variety of colloids. Applications include measurement of SiO2 [20-23] and TiO2 particles [24-
26], BaTiO3 powders [27], pigments [28, 29], carbon nanotubes [30], gold nanoparticles [31-
34], various types of polymeric latexes [35-45], E.coli cells and inclusion bodies [46, 47], 
protein aggregates [48] and numerous forms of nanocomposite particles [49-64]. The use of 
DCS for virological applications has also been described [15, 65], where DCS was specifically 
employed as a tool for determination and identification of adenovirus aggregates (Figure 3.5). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Left: Adenovirus structure [66]. Right: Detection of adenovirus aggregates with DCS [15]. 
 
3.1.3 Aims and Objectives 
The work presented herein investigated the novel technical potential of the emerging DCS 
technology in egg-based influenza vaccine production. Main objectives included viral 
quantification in allantoic fluid, characterisation of whole virus process phases, and 
determination and monitoring of the kinetics of aggregation.  
Applications of DCS in virus seed optimisation studies involving direct analysis of virus-
containing allantoic fluid are described and compared with traditional quantification techniques. 
Furthermore, DCS was uniquely utilised for the estimation of yields of whole virus unit 
operations and for real time detection of aggregated virus and protein complexes.  
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3.2 MATERIALS AND METHODS 
3.2.1 Viral Stock Preparations  
Whole virus or post split vaccine formulations were obtained from three sources: production 
streams, pilot scale runs and laboratory scale experiments.  
For laboratory scale studies, virus was propagated in 11-day-old  embryonated hen eggs based 
on NV internal procedures. In brief, influenza virus seed stock of each subtype was diluted with 
PBS, pH 8 containing 0.2% v/v antibiotic (Polymyxin B or Neomycin) at an optimum 
infectivity concentration as determined by the NV seed laboratories. All eggs were candled 
prior to inoculation in order to detect and mark the air sac (Figure 3.6) as well as to confirm 
successful fertilisation and embryo viability. An egg driller was used to create a hole in the egg 
shell underneath the marked air sac. Approximately 0.2 ml of influenza virus dilution was 
inoculated aseptically with 1cc tuberculin syringes at a 45o angle as illustrated in Figure 3.7. 
The inoculation sites were subsequently sealed with wax to limit contamination and eggs were 
incubated for up to 72 hours at 35°C (influenza A) or 33°C (influenza B). Before harvesting, 
eggs were chilled for 8 to 24 hours at 4◦C to kill the embryo and reduce haemorrhage into AF. 
Harvest was performed aseptically by collecting 2 ml of AF per egg. Typically, fluids from 30 
eggs (1 tray) were pooled together. This composition of fluids is regarded as a sample. Cell 
debris was then removed by clarifying centrifugation at 2,000 rpm with a Thermo Heraeus 
Multifuge 1S-R centrifuge (Thermo Fisher Scientific, Inc, Massachusetts) for 10 minutes. The 
supernatants were collected and processed further through sucrose gradient purification (section 
3.2.3). DCS analysis was performed on freshly harvested or on clarified harvest supernatant 
(section 3.2.2).  
 
   
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Left: healthy living chicken embryo. Right: deceased embryo. 
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Figure 3.7: Left: inoculation of the allantoic cavity. Image adapted from [67]. Right: Manual harvest. 
 
3.2.2 DCS Measurements  
DCS analysis was performed with a disc centrifuge (model DC 24000UHR) from CPS 
Instruments Inc. in Novartis Vaccines. A beam of a 405 nm light source at the edge of the disc 
was employed for particle detection. Sucrose was used as the density gradient to stabilise the 
sedimentation process and prevent streaming. The disc was loaded with a sucrose gradient 
consisting of 4-12% w/w sucrose in PBS, pH 7.7. The sucrose gradient was established by 
injecting successively 1.6 ml of buffer with sucrose concentrations of 12, 11, 10, 9, 8, 7, 6, 5, 
4 % w/w into the disc, rotating at the maximum speed of 24,000 rpm. A small volume of 
dodecane (approximately 0.5 ml) was added to extend the lifetime of the gradient by inhibiting 
surface evaporation. The average density, refractive index and viscosity of the sucrose gradient 
were estimated as 1.026 g/ml, 1.347 and 1.189 centipoise (cps) respectively. The instrument 
was left to reach thermal equilibrium for 20 min before the conduction of any measurement.  
For each analysis a volume of 100 μl of influenza vaccine preparation was injected into the 
spinning disc. The sample parameters chosen were: 1.126 (g/ml) for particle density, 1.48 for 
refractive index [68-70], 0.001 for particle absorption [71], and 1.3 as a non-sphericity factor 
[71]. The non-sphericity factor was applied to account for the pleomorphism of influenza 
virions and accordingly Mie light scattering calculations for shape correction.  For a spherical 
particle the non-sphericity factor is 1. Rods have an aspect ratio of 2 and a corresponding non-
sphericity factor of about 1.5 [71, 72] while for extremely non-spherical particles a maximum 
non-sphericity value of 3 is assigned [71]. Recorded density values of influenza viruses based 
on sedimentation velocity data range from 1.10-1.19 g/ml [68, 73, 74]. The average density of 
the influenza virus samples used (1.126 g/ml) was estimated by iteration taking into 
consideration TEM images of an H1N1 virus (A/California/07/2009, NYMC X-181) vaccine 
Amniotic  
fluid 
Yolk 
Air sac Allantoic 
fluid 
Albumen 
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strain that suggested an average size of 100 nm (Figure 3.8a). In more detail, initial analysis of 
harvested influenza virus in AF under the aforementioned experimental conditions but whilst 
assuming a particle density of 1.19 g/ml returned a diameter of 78.8 μm (data not shown). That 
enabled expression and approximation of a set of factors (K) in Stokes’ equation (Eq.1) not 
influenced by errors in particle density during analysis of the sample and subsequently 
formation of a relationship between particle size and density, i.e.:  
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The theoretical density corresponding to a diameter of 100 nm, as estimated from Eq.10 (1.128 
g/ml), was used to recalculate the PSD and was readjusted accordingly at 1.126 g/ml in order 
to achieve the expected size. Two more measurements were conducted using these parameters 
(Figure 3.8b) which indicated an average virus size of 101.4±2.6 nm. This value was considered 
to be in acceptable agreement with the size-related information provided by the TEM images. 
 
 
 
 
 
 
 
 
Figure 3.8: a) TEM image of A/California/07/2009 showing an average virion size ~100 nm and b) PSDs obtained by DCS 
assuming a particle density of 1.126 g/ml. 
 
Prior to each run, a calibration measurement was performed with narrow PVC particle standards 
(476 or 359 or 239 nm) suspended in deionised water with a density of 1.385 g/ml and a half 
height peak width of 0.1 µm, according to the specifications given by the manufacturer. The 
purpose of the calibration was to verify the accuracy of measurements in the size range 0.05-2 
µm as well as to assess density gradient stability.  
The analysis time was typically 15-20 minutes for whole virus containing samples and 20-30 
min for post-split (subunit) vaccine formulations. All data were recorded using the proprietary 
100 nm 
Eq.10 
a b 
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CPS Disk Centrifuge software (version 9.5c). Data export and further analysis including area 
integrations was performed via Microsoft Excel and OriginPro 8.0.  
 
3.2.3 Virus Purification (Mini-gradient)  
Egg-grown influenza viruses in allantoic fluid were concentrated and purified through a 
simplified sucrose density gradient technique according to NV internal procedures. In this 
method, 25 ml of freshly harvested allantoic fluid is typically loaded onto a mini-gradient 
system composed of 60% (3 ml) and 30% (7 ml) w/w sucrose concentrations and is subjected 
to ultracentrifugation at 25,000 rpm with a SW 28 swinging bucket rotor (Beckman Coulter 
Inc., California) for 90 minutes. The whole virus forms a band at the interface between the 30% 
and 60% w/w sucrose concentrations (~45% w/w) whereas the egg-derived non-virus 
associated proteins remain on the top of the gradient. The viral band is collected and 
characterised by means of protein content, purity and/or HA activity. This small scale 
purification procedure is a prerequisite for evaluation and comparison of seeds, determination 
of growth kinetics and optimisation of viral inputs. Results obtained from analysis of mini-
gradient purified virus with standard methods were compared with respective DCS 
measurements of virus containing allantoic fluid (Figure 3.9). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Direct analysis of harvested AF via DCS compared to current virus quantification methodology. 
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3.2.4 Protein Concentration (Bio-Rad) 
3.2.4.1 Principle 
The Bio-Rad protein assay is based on formation of complexes between Coomassie Brilliant 
Blue G250 (Figure 3.10) and proteins [75]. Coomassie Brilliant Blue G250 exists in three 
forms, namely anionic (blue), neutral (green), and cationic (red) [76].  In acidic conditions, the 
dye in the red cationic form binds to basic and aromatic amino acid residues, predominantly 
arginine, tryptophan, tyrosine, histidine, and phenylalanine [76, 77]. Upon protein binding a 
shift of the absorbance maximum from 465 nm (red) to 595 nm (blue) is observed [78-79]. The 
protein concentration is proportional to the amount of dye in the blue anionic form and is 
determined by measurement of the absorption at 595 nm with a spectrophotometer or 
microplate reader [80]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Structure of Coomassie Brilliant Blue G250. 
 
3.2.4.2 Procedure 
Determination of protein concentration in the viral fractions collected post mini-gradient 
purification was performed with the Bio-rad (Bradford) method following NV internal 
procedures. The dye reagent concentrate (Biorad #500-0006) was prepared by 1/5 dilution with 
deionised (Milli-Q) water followed by filtration through grade 1 Whatman filter paper (Sigma 
#Z274852) in order to remove particulates. A solution of 1 mg/ml bovine serum albumin (BSA) 
in 0.15 M NaCl was used as a protein standard (Sigma # P0914). Dilutions of that solution were 
made with PBS, pH 7.7 to cover a range of concentrations (50-400 μg/ml). All standard aliquots 
were assayed in duplicate while influenza virus samples were tested in duplicate at two 
dilutions. 10 µl of each standard and sample solution were aliquoted into separate wells of a 96 
well flat-bottomed microplate. PBS, pH7.7 was used as a blank (10 µl/well). Diluted dye was 
dispensed with a multichannel pipette to every well containing a blank, standard or sample (200 
µl/well). The plates were incubated 15-60 min at room temperature and the absorbance was 
measured at 595 nm in a microplate reader (Molecular Devices VersaMax).  
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3.2.5 Specific Purity (PAGE) 
SDS-PAGE was used to visualize the types of proteins (viral or non-viral) present in the virus 
containing fractions following mini-gradient purification. Analysis was performed under 
reducing conditions according to NV internal procedures. Briefly, three parts of whole virus 
samples were incubated with one part of pre-warmed (4x) LDS sample buffer (Life 
Technologies #NP0008) at room temperature for 30-120 minutes. Reduction of disulphide 
linkages was achieved by addition of DTT (GE Healthcare #17-1318-02) to each sample to a 
final concentration of 0.2 M and incubation at 95°C for 5-10 minutes. Equivalent volumes of 
the samples (8-10 μl) were loaded in lanes of precast gels which varied depending on strain 
subtype along with 5 μl unstained molecular-weight size markers (Life Technologies 
#LC5801). Specifically, 12% Bis-Tris gels were used for H1N1 and B/Yamagata lineages (Life 
Technologies), 4-12% gradient gels were used for B/Victoria lineages (Life technologies) and 
10% Tris-Glycine TGX gels were used for H3N2 subtypes (Bio-Rad). Electrophoresis was 
performed at 200 V for approximately 45-55 min with (1x) MOPS-SDS running buffer (Life 
Technologies #NP0001). The gels were stained with (1x) Krypton protein stain (Pierce 
Biotechnology #46630) for 2-24 hours on a shaker followed by destaining with 5% v/v acetic 
acid for 5-15 min at room temperature. The Bio-Rad ChemiDoc imaging system was used for 
scanning of the gels. Protein bands were quantified by densitometry analysis via Image Lab 4.1.  
 
3.2.6 Haemagglutination Assay (HA Assay)   
3.2.6.1 Principle 
Influenza viruses are able to agglutinate red blood cells (RBCs) through binding of the surface 
HA to proteins containing N-acetylneuraminic acid on the surface of avian or mammalian 
erythrocytes (Figure 3.11a) [81]. This agglutination appears as a lattice structure in U-shaped 
microtitre plate wells (Figure 3.11c). In the absence of virus or at insufficient virus 
concentrations, the RBCs that are not bound by influenza particles will settle to form a sharply 
defined button at the bottom of the microtitre well (Figure 3.11b). This method provides an 
approximation of whole virus concentration of a sample expressed as the dilution titre required 
for agglutination. The HA titre assay can detect both viable and non-viable virus as well as 
inactivated or non-infectious viral particles [82].  
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Figure 3.11: a) The haemagglutination process: viral particles bind to red blood cells and form a lattice structure.  
b) Negative control well. c) Positive control well. 
 
Further antigenic characterisation of influenza viruses can be achieved with the 
haemagglutination inhibition assay (HAI) which is a variant of the HA assay (Chapter 6, section 
6.2.2.2). 
 
3.2.6.2 Procedure 
HA titre was measured in suspensions of influenza virus in allantoic fluid or sucrose containing 
solutions based on NV internal procedures. The test samples were pre-diluted with PBS, pH 7.3 
(1/10 or 1/100 or 1/1000) prior to execution of the assay. 50 μl/well of PBS was dispensed to 
wells (2-12) of a U-bottom microtitre plate whereupon 50 μl/well of PBS was added to all wells 
in a row assigned as a negative control. 100 μl/well of the pre-diluted samples were 
subsequently inoculated to the first well of each row and a series of 11 double dilutions were 
performed across the plate by transferring 50 μl of solution across to the next column. Finally, 
50 μl/well of 0.5% turkey RBC suspension was dispensed to all wells. The plates were 
incubated at room temperature for 60 minutes and read after tilting.  
The endpoint of the virus titration was determined by identification of the first well where no 
haemagglutination of RBCs is observed and subsequent assessment of the degree of 
haemagglutination in the following well. Table 3.1 displays the five possible grades of 
haemagglutination activity. Conversion of the endpoint result into haemagglutination units 
(HAUs) was facilitated by the calculation table available in Appendix 3.1. 
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Haemagglutination 
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Table 3.1: Assigned levels of haemagglutination.  
RBC  
Condition 
 
 
   
% 
Haemagglutination 
100 75 50 25 0 
Haemagglutination 
Assessment 
++++ +++ ++ + - 
 
3.2.7 Infectivity Assay (EID50)   
Viral infectivity was estimated through the 50% egg infectious dose (EID50) assay according 
to NV internal procedures. In this method, the virus sample or test inoculum is serially diluted 
(3-5 ten-fold dilutions) and each dilution is then inoculated into an identical number (commonly 
5) of 11-day-old embryonated chicken eggs (0.2 ml/egg). Dilutions are performed with PBS, 
pH 8 containing 0.2% v/v antibiotic (Polymyxin B or Neomycin) and the eggs are incubated 
for 72 hours at 35°C (influenza A) or 33°C (influenza B). A haemagglutination assay is 
subsequently performed on harvested AF (undiluted) from individual eggs to determine the 
presence of virus in the eggs. The infectivity titre is calculated based on the amount of virus 
required to infect 50% of the eggs, viz. the ratio of HA positive to HA negative tested eggs, 
using the Reed and Muench method [83].  
 
 
 
 
 
 
 
 
 
 
65 
 
3.3 SUMMARY OF STUDIES   
3.3.1 Monitoring and Quantification of Whole Virus 
3.3.1.1 Typical Influenza PSD Profile & Assessment of Dilution Linearity 
A representative PSD of an inactivated and purified influenza virus strain 
(A/California/07/2009, NYMC X-181) is presented in Figure 3.12. A main peak corresponding 
to the dominant virus population is observed at 105 nm. Furthermore, a secondary “shoulder” 
around 130 nm is detected. Taking into account the pleomorphic nature of influenza virions, 
this less abundant species is indicative of the presence of a different morphological possibly 
more filamentous-like class [84, 85]. Similarly to the chromatographic techniques, 
quantification at whole virus process steps (free, non-aggregated particles) is theoretically 
possible through integration of the peak area and/or measurement of the viral peak height in the 
obtained weight-based PSD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Left: PSD of purified A/California/07/2009 (NYMC X-181) virus. Relative quantification is possible by 
integration under the curve or measurement of peak height. Right: Examples of influenza morphology. Spherical particles (up) 
are considered the predominant class. Bar= 50 nm [88].  
 
The linearity of the method was determined by 2-fold dilutions with PBS of viral samples in 
concentrated (clarified) (Figure 3.13a) and freshly harvested AF (Figure 3.13b). According to 
the dilution profiles in Figure 3.13a, both peak area and height are linearly correlated to the 
quantity of virus present in the sample with a correlation coefficient R2≥0.99. The correlation 
becomes slightly weaker (R2<0.99) when viral particles in harvested unclarified AF are serially 
diluted (Figure 3.13a).  This could be attributed to the low amount of virus at the highest 
dilutions examined, e.g. active weight at 25% dilution=0.8 µg<1 µg, which were at the detection 
limit of the instrument. Additionally, the potentially reduced degree of homogeneity due to the 
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presence of cellular debris as well as dissociation of loosely associated large aggregates (<2 µm) 
of viruses/egg derived material upon dilution could contribute to the decrease of linearity.  
 
  
 
  
 
 
 
 
 
 
 
 
Figure 3.13: Dilution series and evaluation of dilution linearity of a) B/Massachusetts/02/2012 in clarified and concentrated 
AF (average size=107 nm) and b) A/California/07/2009, NYMC-X181in harvested AF (average size=100 nm). Samples were 
generated in the pilot plant facility.  
 
3.3.1.2 Size Differences between Strains 
Determination of the “true” size of various influenza viral subtypes has been attempted since 
the early 1940s primarily through sedimentation velocity experiments and electron microscopy 
[73, 86-90]. Analysis of electron micrographs has indicated that B strains (B/Lee/1940) are 
larger than A strains (A/Puerto Rico/8/1934 (H1N1)) by roughly 20 nm [92-94]. A wider range 
of size differences (8-20 nm) has also been reported based on sedimentation studies [73, 87]. 
Although the derived particle densities were found to be the same for both strains, B viruses 
exerted higher sedimentation constant [73]. 
Characterisation of a number of influenza viruses via DCS also demonstrated a noticeable 
difference in size between A and B strains whilst assuming similar particle densities. Figure 
3.14 displays an overlay of PSDs of selected strains analysed throughout 2013-2015, namely 
A/Christchurch/16/2010 (NIB-74) (H1N1), the swine A/California/07/2009 (NYMC X-181) 
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(H1N1), A/Texas/50/2012 (NYMC X-223) (H3N2), B/Massachusetts/2/2012 (B/Yamagata 
lineage) and B/Brisbane/60/2008 (B/Victoria lineage). The average size of all influenza A 
viruses shown was 103 nm whereas B virions were 109 nm in diameter regardless of antigenic 
lineage type.  
 
 
Figure 3.14: Size comparison of different influenza subtypes. PSDs were derived from analysis of purified whole virus 
samples (post-clarifying filtration) from pilot plant runs except for NIB-74 (harvested AF). 
 
Moreover, a comparison between DCS and AUC was conducted. AUC is a traditional method 
for characterisation of sedimentation behaviour of macromolecules in dilute solutions [91]. 
AUC analysis was performed by Dr. Alexander Bepperling (HEXAL AG, Germany). Three 
whole virus concentrate samples (post-clarifying filtration) were tested by both techniques: 
A/California/07/2009 (NYMC X-181), A/Texas/50/2012 (NYMC X-223) and 
B/Massachusetts/02/2012. The average sizes obtained by DCS were 104.9, 105.6 and 113.6 nm 
respectively (Figure 3.15a). AUC analysis was performed in sedimentation velocity mode 
which entails determination of size, shape and macromolecular interactions through real time 
observation of the different migration rates of solutes in high centrifugal fields [91, 92]. The 
resulting sedimentation coefficient distributions c(s) are presented in Figure 3.15b.  
Sedimentation coefficients or Svedberg (S) values were estimated as 778 S for 
A/California/07/2009, 735 S for A/Texas/50/2012 and 856 S for B/Massachusetts/02/2012. 
Direct conversion of the coefficient distribution into a particle size distribution was not 
performed as it required complex mathematical computations through specific software (e.g. 
SEDFIT [93]) that was not available, high expertise in AUC data interpretation and additional 
analysis. However, as the sedimentation coefficient is directly proportional to the second power 
of Stokes-equivalent spherical diameter when the same experimentation conditions are applied 
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[94, 95], the ratio of diameters of two different particle populations would equal the ratio of 
their respective coefficients. Taking into account the above, B/Massachusetts/02/2012 was 
estimated to be larger in size than the A strains analysed (average values) by 7% based on DCS 
and 6% based on AUC.  This good correlation observed between DCS and the classical first-
principle method of AUC demonstrates the satisfactory accuracy of DCS for detection of 
various influenza virus types.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: a) PSDs of purified whole virus Influenza preparations (production samples) by DCS and b) Sedimentation 
coefficient distributions by AUC. 
 
3.3.1.3 Monitoring of Virus Growth in Eggs   
Currently, viral growth in NV is determined by virus infectivity assays and application of 
pooled allantoic fluid harvested from eggs at various time points during incubation to small 
scale sucrose gradient centrifugations as described in 3.2.3. The level of virus purified using 
each sucrose gradient is then quantified by measurement of protein concentration.  
DCS was investigated as a potential technique to monitor viral growth inside the egg by direct 
analysis of the allantoic fluid pooled from 30 eggs. It was demonstrated that the peak height 
from the PSDs is indicative of the viral growth for different strains following the typical "one-
step" sigmoidal curve [96]. Boltzmann sigmoidal models (Appendix 3.2) were shown to 
adequately describe the system (Figure 3.16).  
Additionally, good correlation (R2>0.9) between the peak height and protein content was 
observed for all the strains that were analysed. Characteristic examples for two strains are 
shown in Figure 3.17. Data were collected at three different temperatures: 32, 33 and 34 oC for 
B/Massachusetts/2/2012 and 34, 35, 36 oC for the A/Texas/50/2012 reassortant. Based on the 
above, it can be deduced that DCS can provide a substantially faster, less laborious alternative 
to the virus purification (mini-gradient) and protein determination procedure for indirect 
b a 
0
300
600
900
1200
0.00 0.05 0.10 0.15 0.20
W
ei
g
h
t 
(µ
g
)
Diameter (μm)
A/California (H1N1)
A/Texas (H3N2)
B/Massachusetts
69 
 
monitoring of viral replication. Excluding preparation times, DCS enables sample analysis in 
10-15 minutes whereas current methodologies require at least 3 hours. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: Indicative viral growth curves constructed from DCS data for 
a) B/Massachusetts/2/2012 at 32 oC and b) A/Texas/50/2012 at 34 oC. 
 
 
 
 
 
 
 
 
 
 
Figure 3.17: Linear correlation of viral peak height with protein titres for  
a) B/Massachusetts/2/2012 and b) A/Texas/50/2012. 
 
Relationships between the PSD features and infectivity were also examined (Figure 3.18). 
Specifically, infectivity titres expressed as EID50/ml were compared with the total number of 
particles determined after mathematical conversion of weight PSDs into particle PSDs. As 
shown in Figure 3.18a, a rise in infectivity is noted approximately up to 36 hours of incubation, 
followed by a plateau between 36-60 hours and a decrease at the last two time points.  
Conversely, the total number of influenza particles as measured by DCS (Figure 3.18b) 
remained constant 36 hours post-inoculation.  
This discrepancy between the two methodologies is anticipated since DCS detects all particle 
populations and cannot therefore distinguish between active and inactive viruses.  
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Figure 3.18: Comparison of a) infectivity titre and b) total particle counts at different incubation temperatures for 
A/Texas/50/2012. 
 
 
3.3.1.4 Input Studies: Effect of Dose on Viral Growth  
It has long been acknowledged that variations in the amount and infectivity of the virus 
inoculum could potentially have an immense effect on quantity and quality of the resulting virus 
for some influenza subtypes [97-101]. In particular, inoculation with high concentrations of 
seed virus in the inoculum can lead to generation of large amounts of inactive or incomplete 
viruses (von Magnus particles) and therefore reduced multiplication [100-101].  Consequently, 
in NV assessment and optimisation of virus input is routinely performed through laboratory 
scale studies. For this purpose, pooled allantoic fluids harvested from eggs inoculated with 
varied concentrations of inoculum with regard to EID/egg are subjected to mini-gradient 
purification (3.2.3). Total protein of the purified viruses is then used as the main figure for 
evaluation of yields.  
DCS was employed in input optimisation studies for quantification of influenza virus in freshly 
harvested AF. Characteristic examples for two strains are displayed in Figure 3.19. Infectious 
dose was shown to have a limited impact on the final yield of both A and B strains based on 
both protein and DCS measurements. Overall, a limited data range was attained from input 
optimisation studies throughout 2013-2015 and therefore further correlations between 
measurement systems could not be made. It is worth noting that NV historical studies have 
suggested that lower infectious titres in the inoculum can benefit viral replication of some B 
strains thus leading to considerably increased yields.  
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Figure 3.19: Impact of infectious dose on viral growth. Comparison of protein concentration (Bio-Rad) and viral peak height 
(DCS) for a) A/Switzerland/9715293/2013(NIB-88) and b) B/Massachusetts/2/2012.  
 
 
3.3.1.5 Seed Evaluation 
Following the announcement of WHO recommendations on influenza vaccine composition, 
specific reassortant laboratories (e.g. NYMC, NIBSC, CSL) are responsible to supply vaccine 
manufacturers with wild-type (influenza B) or high growth reassortant candidates (influenza A) 
to allow for appropriate preparation of seed viruses [102]. Influenza B virus reassortants are 
less commonly used but have been available since 2010 [103]. The seed virus preparation 
selected for virus propagation is critical for final strain yields as well as product quality. At 
present, seeds are screened in NV by purification and concentration of the virus post-harvest 
followed by determination of protein content.  
DCS was used as an alternative method for faster evaluation of multiple seeds. In the example 
given in Figure 3.20, two seed batches of B/Massachusetts/02/2012 and batches of the H1N1 
strains A/California/07/2009 (NYMC X-181) and A/Christchurch/16/2010 (NIB74) were 
compared. It was demonstrated that the viral peak height from the PSDs as derived from 
analysis of pooled harvested material (2 replicates) correlates reasonably with respective viral 
protein values. It is highlighted that at this early stage of seed optimisation quick identification 
of the most promising seed with regards to viral yields is essential.      
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Figure 3.20: Multiple evaluation of seed batches by protein concentration (Bio-Rad) and viral peak height (DCS). 
 
3.3.1.6 Growth Variability in Individual Eggs  
Estimation of variation in multiplication rate of influenza virus in individual chicken eggs has 
not been attempted in the past due to lack of sensitive, virus-specific analytical methods.  In 
this study, AF harvested from 15 and 23 eggs infected with A/Texas/50/2012 (H3N2) and 
A/Christchurch/16/2010 (NIB74) (H1N1) respectively were analysed via DCS and the peak 
heights corresponding to free, non-associated virus populations were recorded (Appendix 3.3). 
Growth variability between eggs was assessed through individuals (Shewhart) control charts 
(Figure 3.21). The control limits are set at a distance of three standard deviations (s) above 
(UCL: Upper Control Limit) and below (LCL: Low Control Limit) the central line which is the 
average (X̄) of all the measurements. As illustrated in Figure 3.21a, data variation was found to 
be in control or consistent for A/Texas/50/2012 with two successive points outside the 2s level 
(circled in blue). Special causes relevant to the operation of DCS could not be identified and 
thus those elevated values are presumed to relate to visually obvious size differences between 
eggs (larger allantoic cavity volumes). The total coefficient of variation (CV) was 25.3%. The 
viral growth of A/Christchurch/16/2010 (NIB74) was deemed to be out of control with one 
unusual observation exceeding the UCL (Figure 3.21b). Although the PSD of AF extracted 
from this egg (4) was distinctly different (Appendix 3.3b), adequate justification to exclude the 
measurement cannot be provided and therefore any inconsistencies observed are considered 
indicative of variability in egg characteristics. Each egg functions as a single reaction vessel 
with individual properties.  A CV of 20% was calculated.  
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Figure 3.21: Individuals Control Charts of viral growth (peak height) of a) A/Texas/50/2012 and b) A/Christchurch/16/2010 
(NIB74). Data point outside the 2s level are circled in blue. Red points signify eight consecutive measurements on the same 
side of the central line. 
 
Furthermore, the viral content in pooled AF from an egg tray (30 eggs) was compared with the 
viral content in AF harvested from individual eggs composing the tray through a 1-Sample t-
Test or hypothesis testing procedure (Figure 3.22). Analysis indicated that the amount of virus 
measured in AF pools (H0) does not differ significantly from the mean value estimated from 
analysis of fluids from different eggs (P-value>0.05=significance level). Specifically, for 
A/Texas/50/2012 and A/Christchurch/16/2010 (NIB74) the P-values were 0.121 and 0.584 
respectively. As shown in Figure 3.22a, lack of symmetry and data skewing to the left is noted.  
 
Figure 3.22: Comparison of virus (peak height) in pooled AF with mean virus quantity from analysis of AF collected from 
different eggs for a) A/Texas/50/2012 and b) A/Christchurch/16/2010 (NIB74). The average estimated value (X) is likely to be 
equal to the specified H0 value since this value is within the confidence interval. Outliers are annotated as *.  
 
 
3.3.1.7 Effect of Freezing and Thawing on Whole Virus Samples 
Repeated freezing and thawing is known to severely reduce the haemagglutination ability, 
infectivity and enzymatic activity of influenza virus preparations and can result in degradation 
and complete disruption of the virions [104]. Infected allantoic fluid pooled from four 
individual chicken eggs was frozen at -20 oC and thawed four times during 15 days. 
Measurement by DCS demonstrated a rapid decline of the total viral content for all samples 
(Figure 3.23). Exponential decay curves could adequately describe the system (R2>0.91). A 
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shift of the viral peak in the PSDs was observed after the first freeze/thaw which could possibly 
suggest shrinking of the viral particles.  
 
 
 
 
 
 
 
 
 
Figure 3.23: Impact of freezing and thawing on viral particle size of B/Massachusetts/02/2012. 
 
3.3.1.8 Characterisation of Process Steps 
3.3.1.8.1 Upstream Operations: Harvest, Clarifying Centrifugation, Ultrafiltration 
(Concentration) and Viral Inactivation 
Currently, viral yields in the upstream process are characterised solely through measurement of 
total protein content by Bio-Rad, protein composition by SDS-PAGE and HA titre. The Bio-
Rad and SDS-PAGE assays are inherently non-specific at these early process phases due to 
abundance of non-viral related proteins, e.g. yolk protein, ovalbumin etc., whereas the HA assay 
offers a very rough approximation of virus concentration due to well-known limitations 
including low precision and reproducibility. DCS can be applied directly for specific 
quantification of influenza virus in allantoic fluid and therefore enables estimation of yields at 
whole virus production operations.  
Pilot plant batches of various strains were monitored and analysed with DCS throughout 2013-
2015. Representative PSD profiles of the upstream processing of the strains 
A/California/7/2009 (X-181) (reassortant, H1N1), A/Texas/50/2012 (X-223) (reassortant, 
H3N2), B/Brisbane/60/2008 (wild type, B/Victoria lineage) and B/Massachusetts/2/2012 (wild 
type, B/Yamagata lineage), are displayed in Figures 3.24, 3.25. Only small peak shifts (<1.5%) 
were recorded throughout the processing of the A strains (Figure 3.24) and the 
B/Brisbane/60/2008 subtype (Figure 3.25a).  
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Figure 3.24: PSD profiles during upstream processing of a) A/California/7/2009 (X-181)  
and b) A/Texas/50/2012. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.25: PSD profiles during upstream processing of a) B/Brisbane/60/2008 and b) B/Massachusetts/2/2012.  
 
Conversely, a significant peak shift towards smaller sizes and peak broadening was detected 
after the formaldehyde inactivation of B/Massachusetts/2/2012 (Figure 3.25b). This 
phenomenon occurred recurrently during the analysis of this strain as DCS analysis of multiple 
batches revealed (Appendix 3.4). Since inactivation is typically performed at the same 
conditions (duration, temperature, and formaldehyde concentration) for all viral types it can be 
presumed that the modified PSD of B/Massachusetts/2/2012 is associated with unique 
biophysical characteristics of this strain. A plausible explanation for the observed reduction in 
particle size is the chemical cross-linking of surface antigens induced by formaldehyde. It is 
widely known that formaldehyde rapidly reacts with the primary amines in proteins and forms 
strong, covalent bonds or cross-links between two or more protein molecules [105, 106]. This 
cross-linking of proteins creates a meshwork which is characterised by increased stability of 
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protein–protein interactions. Hence, it is possible that extensive cross-linking of the membrane 
glycoproteins intra-virion could result in minor shrinkage of virions.  
Taking into account the process volumes, mass balance and yields could be calculated based 
on viral peak height or integration of peak area. According to the bar chart in Figure 3.26, which 
displays viral recovery (free non-aggregated particles) estimated for four 
B/Massachusetts/2/2012 pilot plant batches, significant losses (~40%) were noted during 
clarification of AF. Consequently, optimisation of the clarifying centrifugation procedure is 
recommended.  
 
 
Figure 3.26: Approximation of yield for three (pilot) upstream operations from DCS analysis for 
B/Massachusetts/2/2012. 
 
3.3.1.8.2 Barium Sulphate Absorption-Elution  
Selective recovery and concentration of virus from inactivated AF is accomplished through 
sucrose density gradient zonal ultracentrifugation. The contents are collected in five main 
fractions (I-V) based on volume and/or sucrose content: fractions I and V contain only egg-
derived material and are discarded, fraction III constitutes the virus peak fraction and fractions 
II, IV which are the shoulder fractions are pooled together. An example of a typical sucrose 
density profile as determined by total protein and electrophoresis analysis is provided in 
Appendix 3.5a. 
The shoulder fractions are further subjected to barium sulphate absorption-elution treatment 
which aims to separate the virus from co-purifying egg proteins and endotoxins. Absorption of 
influenza virus onto barium sulphate followed by elution has long been used as a purification 
technique in vaccine manufacturing [107-110]. Due to high volumes the shoulder fraction pool 
is initially divided into three workstreams (A, B and C) which are treated identically. The first 
stage of the BaSO4 treatment process entails mixing of each workstream with 12.5% w/v BaSO4 
suspension to allow virus adsorption onto BaSO4 particles. After settling, the supernatant is 
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decanted while the BaSO4 containing virus particles that have settled to the bottom of the 
container are subjected to an initial centrifugation. The supernatant is again discarded and the 
BaSO4-virus pellet is subsequently processed through an extensive series of sodium citrate 
(0.45 M) elution and centrifugation steps. A schematic description of this unit operation is given 
in Figure 3.27.  
 
 
 
 
 
 
 
 
  
 
Figure 3.27: Summary of the barium sulphate treatment step shown for one workstream. The clarified eluates/supernatants 
from all three workstreams are pooled together (Pools 1, 2).  
 
The barium sulphate absorption-elution multistep procedure is complex, laborious, time-
consuming and currently not well characterised due to inefficient and/or insufficient product 
monitoring. Thus, a study that enabled collection of production samples (not routinely collected) 
from all eluate and waste phases from all workstreams was performed. Six batches (three from 
A/Texas/50/2012 and three from B/Massachusetts/2/2012) were sampled throughout the 
shoulder treatment step and the samples (19 per batch, Appendix 3.5b) were subsequently tested 
for influenza virus content by HA titre, SDS-PAGE (densitometric analysis) and DCS. It is 
noted that total protein measurements at this stage are not directly indicative of viral 
concentrations due to significant amounts of host-derived proteins (primarily ovalbumin) 
present. All samples required dilution with PBS prior to DCS analysis. Specifically, the sucrose 
containing peak, shoulder and waste samples were diluted by 20, 10 and 5-fold respectively to 
avoid potential interference with the sucrose density gradient employed for the measurement 
(4-12% w/w sucrose). Eluates were also diluted by 5 as analysis of virus in 0.45 M sodium 
citrate resulted in distorted PSDs characterised by excessive peak broadening and reduced 
resolution (data not shown). A discernible explanation for this effect cannot be readily provided 
considering sodium citrate buffers have well-known stabilising and anti-aggregation properties. 
It is possible that the estimated sample parameters (e.g. particle density, refractive index) used 
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for the calculation of the PSD of influenza virus in AF or PBS need to be modified for analysis 
in presence of sodium citrate.   
Determination of viral mass balance was achieved through both relative peak height and peak 
area values. The results for 3 batches of B/Massachusetts/2/2012 are summarised in Figure 
3.28. Viral yields are expressed in relation to the virus content detected in the whole gradient, 
i.e. in the peak and shoulder fractions prior to BaSO4 treatment. The two combined shoulder 
fractions were found to contain approximately 11% of virus. From this, 3.8% was effectively 
recovered through elutions at the end of the process step while 2.2% failed to absorb onto BaSO4 
particles and was decanted with the supernatant after mixing with BaSO4 and/or after the initial 
centrifugation (Figure 3.27). 5% of the virus could not be accounted for and it is therefore 
assumed that it remained absorbed to the discarded BaSO4 pellet. It is emphasised that as the 
samples analysed via DCS were diluted to different sucrose/sodium citrate levels some 
inaccuracies in the calculation of mass balance may be expected.  
 
 
Figure 3.28: Estimation of viral yields during BaSO4 adsorption-elution for B/Massachusetts/2/2012  
Based on DCS data (peak height). 
 
Following the establishment of a baseline for this unit operation, a number of lab scale 
experiments using material generated by the pilot plant were executed to potentially improve 
viral adsorption and elution from BaSO4. In Figure 3.29, viral recoveries at varying 
BaSO4/product volumes as determined by DCS measurements are shown. Currently, BaSO4 is 
added in production at a BaSO4/product volume ratio of 1:1. It was demonstrated that increasing 
this ratio above 3:1 could diminish viral losses in the waste streams (Figure 3.29a). Nonetheless, 
measurement of viral content after one elution with sodium citrate suggested that yields were 
not affected accordingly. No significant increase was observed at BaSO4/product volume ratios 
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above 1:1 (Figure 3.29b), i.e. viral particles could not be recovered as they remained bound to 
BaSO4.   
 
 
 
Figure 3.29: Estimation of virus content in a) waste and b) first eluate at increasing volume ratios of 
BaSO4/Product for B/Massachusetts/2/2012 based on DCS data. 
 
Overall, the barium sulphate treatment step is expensive, labour-intensive and of limited 
efficacy. Taking into consideration that less than 15% of total product is processed any 
optimisation attempts could only result in minor yield increase.  Instead, elimination of the 
whole unit operation and widening of the collection peak is recommended provided that this 
does not have a negative impact on product purity.  
Data collected as part of the BaSO4 investigations were also utilised for assay comparisons 
between DCS, HA titre and SDS-PAGE (relative intensity of HA2 band) through regression 
analysis. The relationship between free virus (peak height) measured by DCS with 
haemagglutination units (HAUs) and HA relative content was statistically significant 
(P=0.001<0.05) in the study described earlier (Figure 3.29). Sample volumes were taken into 
account in these correlations. The regression model of viral peak with HAUs and HA2 intensity 
captured 97.3% and 98.3% of the variation respectively (Figure 3.30). Perfect positive 
correlations of 0.99 were observed in both cases. It must be noted that all samples were tested 
for HA titre using the same batch of turkey blood which limited the low reproducibility and 
precision issues typically observed with this assay.  
Figure 3.30: Assessment of linear correlation of viral peak height (DCS) with HAUs (HA assay) (left) and HA2 relative 
intensity (SDS-PAGE) (right).  
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3.3.1.8.3 Assessment of Filter Efficiencies 
DCS was extensively employed in the optimisation of the clarifying filtration stage by 
determining product recoveries and characterising the filtration efficiency. In more detail, 
analysis of the process stream pre and post-clarifying filtration (1.2 μm filter cut off) showed 
an average approximate product loss of 20% which could not be attributed to the presence of 
aggregates. Representative data are displayed in Figure 3.31. Throughout a series of filtration 
studies, it was demonstrated that hydrophobic adsorption to the filter can potentially be 
eliminated if the filters are pre-treated with the non-ionic detergent Tween 80 (Figure 3.32).  
 
      
 
 
 
 
 
 
 
 
Figure 3.31: Determination of filtration losses based on peak height for A/Victoria/361/2011 (IVR-165). 
 
 
Figure 3.32: Filtration loses after pre-conditioning of the filters with Tween 80 for A/Victoria/361/2011 (IVR-165). 
 
 
3.3.1.8.4 Evaluation and Monitoring of Antigen Solubilisation 
Applications of DCS on antigen solubilisation are discussed in Chapter 5.  
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3.3.2 Detection and Monitoring of Aggregation 
3.3.2.1 Aggregation in Therapeutic Proteins 
The presence of aggregates in therapeutic proteins may have a serious impact on product quality, 
with regard to bioactivity and immunogenicity, as well as its manufacturability, e.g. filter and 
column blockages [111, 112]. Aggregates can range in size from small soluble dimers or 
oligomers to subvisible or even visible particles [113]. Protein aggregation can occur during 
production, storage, transport or delivery to the patient through a number of different 
mechanisms [114]. Changes in temperature, pH fluctuations, light, surfaces or agitation can 
cause protein aggregation at any of these stages [115, 116]. In particular, irreversible 
aggregation poses a serious problem for the storage stability of protein formulations [117]. If 
unwanted aggregates are not removed early and become part of the final product they may affect 
immunogenicity and lead to adverse reactions upon administration [118-122]. Hence, analytical 
tools capable of detecting and determining accurately the size of biopharmaceutical aggregates 
are required in order to increase the mechanistic understanding of aggregation and design 
formulations and processes that minimise or completely remove aggregates.  
 
3.3.2.2 Aggregation during Viral Inactivation 
Inactivation of the concentrated allantoic fluid containing influenza B viruses is achieved by 
incubation with a final concentration of 0.02% w/v formaldehyde at 24 ºC for 18 hours whilst 
stirring. As discussed in 3.3.1.8.1, PSDs are not significantly altered by formaldehyde treatment 
with the exception of the strain B/Massachusetts/2/2012. 
During DCS analysis of upstream samples of B/Brisbane/60/2008 generated by the pilot plant 
facility an atypical post-inactivation PSD was obtained (Figure 3.33). A prominent formation 
of a secondary shoulder is observed which is suggestive of aggregation interactions.  
 
 
Figure 3.33: Formation of aggregates during inactivation recorded by DCS for B/Brisbane/60/2008. 
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Further processing of this batch through sucrose gradient purification revealed the presence of 
two distinct populations as displayed in the protein profile in Figure 3.34. The first peak 
corresponds to normal virus species. The second most abundant less dense population was 
similar in composition to influenza virus based on protein electrophoresis results (not shown). 
Subsequent analysis of the sucrose gradient fractions 10 and 23 via DCS verified that the 
secondary viral species was essentially the aggregated shoulder initially detected after 
inactivation (Figure 3.35).  
 
 
 
Figure 3.34: Sucrose gradient purification profile based on protein concentration (Bio-Rad) of the B/Brisbane/60/2008 batch 
that exhibited aggregation after inactivation in comparison with a typical profile for this strain.  
 
 
Figure 3.35:  Overlay of PSD profiles obtained from analysis of sucrose fractions 10 and 23 with aggregate-containing post-
inactivation PSD of B/Brisbane/60/2008. 
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assumptions can be made. The cross-linking of proteins induced by formaldehyde could 
theoretically lead to formation of complexes between viral particles though no evidence exists.  
The case described above effectively demonstrates that DCS could potentially be used for at-
line monitoring of the inactivation process.  
 
3.3.2.3 Detection of Aggregation during Amberlite Mixing 
Polystyrene resin (Amberlite XAD-4) is added to the supernatant pool after the solubilisation 
procedure for removal of the detergent (CTAB) from the protein solution. The 
product/Amberlite suspension is kept under continuous stirring for 16-24 hours. The resins are 
subsequently removed through a clarifying filtration process utilising a 0.65 μm polypropylene 
filter and a 0.65 μm cellulose acetate filter. Due to frequent filter blockages, it was deemed 
essential to improve understanding of this unit operation by monitoring particle aggregation 
throughout the Amberlite mixing.   
Five pilot batches of B/Massachusetts/2/2012 were generated and measured by DCS at various 
time intervals over a 24 hours mixing period with Amberlite. At this stage, the majority of the 
viral cores should have been removed by a previous ultracentrifugation step. The product 
consists predominantly of surface antigen solubilised in detergent micelles (Chapter 5, Figure 
5.6). The batches differed with regard to CTAB reaction time: for batches A, B and C the 
contact time with CTAB was 7 h whereas for batches D and E a shorter contact time of 2.5 h 
was chosen. In batch C no Amberlite was added. In all batches particle aggregation with size 
between 0.6-1.3 μm occurred after approximately 16-18 h. In Figure 3.36, the PSDs recorded 
from the analysis of batch A are shown. Similar results were obtained from the analysis of the 
other batches, i.e. increased degree of aggregation with time. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.36: PSD during 24 h of mixing with Amberlite resins (Batch A). Selected time points are shown. 
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According to Figure 3.37, a rapid increase in the aggregation generation rate was observed at 
16-24 h of mixing time which is more intense in batch C in the absence of Amberlite, i.e. at 
higher/non-reduced CTAB concentration. 
 
 
Figure 3.37: Amount of aggregates estimated from DCS data during 24 h of mixing with Amberlite for batches A-E. 
 
From the comparison of the final sample that was analysed at 24 h of mixing between the 
different batches (Figure 3.38), the following observations are noted:   
o The contact time with CTAB influences the extent of aggregation despite the removal 
of the viral core material through an ultracentrifugation procedure. Relatively higher 
amounts of particles ≥0.65 μm were formed in batches A, B, C.  
o CTAB continues to solubilise non-split virus post centrifugation thus inducing further 
aggregation (batch C).  
 
 
Figure 3.38: Final PSDs of batches A-E after 24 h of Amberlite mixing. 
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Based on the above and also taking into account that the CTAB levels are typically depleted 
approximately after 4 hours of Amberlite treatment the following modifications could enhance 
process efficacy and product quality:  
 Mixing with CTAB for precisely 2 h to partly limit formation of particle complexes 
and/or protein degradation.  
 Conducting ultracentrifugation directly after the completion of the solubilisation 
process and addition of Amberlite beads immediately after ultracentrifugation. 
 Mixing with Amberlite for a maximum of 16 h (current specification: 16-24 h).  
 
3.3.2.4 Aggregate Formation during Antigen Solubilisation  
Applications of DCS on antigen solubilisation are included in Chapter 5.  
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3.4 CONCLUSIONS AND FUTURE PROSPECTS 
The technical applicability of DCS throughout the manufacturing of egg-based inactivated 
influenza vaccines was investigated. DCS was proven to be a valuable analytical tool by 
demonstrating high potential for process investigation and monitoring. Key applications include:  
 
o Direct quantification of virus in allantoic fluid in seed and viral growth optimisation 
studies. DCS was specifically employed for determination of viral growth in a novel 
study entailing addition of glucocorticoids and other compounds into the seed inoculum 
which is discussed in length in Chapter 4. 
o Virus quantification at whole virus process stages (upstream and downstream). 
o Characterisation of unit operations on a particle based approach (e.g. Amberlite mixing, 
determination of filtration losses, monitoring of inactivation etc.). 
o Detection and characterisation of aggregation/particle monitoring. Aggregation 
phenomena during the critical process stage of solubilisation of the membrane antigens 
are described in Chapter 5. 
 
Future work could potentially entail routine use of the DCS for seed optimisation studies (e.g. 
determination of optimum incubation conditions and input dose) as well as implementation of 
the technique for at-line analysis throughout whole influenza virus unit operations (virus 
quantification, particle size fingerprinting, aggregation detection).  
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4. THE INFLUENCE OF HYDROCORTISONE AND 
OTHER COMPOUNDS ON INFLUENZA VIRUS 
PRODUCTION  
 
4.1 INTRODUCTION 
The effects of cortisone and other structurally related steroid hormones on influenza viral titres 
in embryonated eggs have been known since the 1950s [1-7]. It has been demonstrated that 
under specific experimental conditions, administration of cortisone to chicken embryos through 
the yolk sac prior to viral inoculation may lead to remarkable yield increase of influenza B 
viruses (~200-280%) [1-3]. Initial studies exploring possible mechanisms by which cortisone 
affects influenza B virus multiplication suggested that cortisone enhances virus yields primarily 
by inhibiting or negating viral interference caused by large amounts of non-infectious viruses 
[5, 6]. This phenomenon of autointerference negation relates particularly to the presence of an 
oxygen atom at the carbon 11 position of the steroid structure (Figure 4.1) [6].   
 
Figure 4.1: Structure of cortisone.  
 
Contradictorily, it was also shown that cortisone inhibits initial viral synthesis temporarily [5, 
7]. Later investigations [8, 9] elucidated that cortisone limits viral interference by specifically 
inhibiting synthesis of interferon (IFN), an antiviral protein that can interfere with virus 
multiplication during the course of infection [10]. It was also indicated that cortisone has an 
inhibitory impact on the activity of preformed IFN [9]. It is noted that in studies [5-9] the terms 
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cortisone and hydrocortisone diethylaminoacetate - a water soluble hydrocortisone ester- are 
used interchangeably.  
The potential mechanism of action of cortisone when injected in influenza infected fertilised 
hen eggs is more readily comprehended upon review of the dynamics of influenza infection 
(Figure 4.2). Epithelial cells which are the target of influenza virus can be categorised into five 
types based on infection stage [11]: uninfected or susceptible cells (T), cells in eclipse phases 
(E1, E2), infected cells (I), pre-refractory cells (W) and refractory cells (R). T cells are assumed 
to get infected at a rate proportional to the virus amount (V) [11-13]. Those cells subsequently 
enter an eclipse phase (E1) before they are able to produce virions [11]. Infectious cells (I) 
secrete free virus and IFN (F) which decay at rates c and d respectively [11, 12]. IFN elicits an 
antiviral effect (φ) thus allowing susceptible T cells to become refractory to infection (R) [11, 
12]. Prior to the refractory phase, cells undergo a pre-refractory stage (W) during which they 
might become infectious [11, 14]. If W cells get infected, they go through a second eclipse 
phase (E2) and release further IFN due to previous exposure to IFN that originally induced the 
antiviral state [11]. Hydrocortisone is believed to prevent protein synthesis of IFN by infected 
cells (I) as well as IFN-induced effects that enable cells to become resistant to infection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Schematic diagram of influenza infection dynamics. Administration of hydrocortisone is assumed to inhibit IFN 
generation and its antiviral activity by blocking the paths marked “X”. Adapted from [11]. 
 
As part of this thesis, the impact of five substances (Table 4.1) on influenza virus recovery upon 
addition to the seed inoculum and subsequent inoculation through the allantoic cavity was 
investigated. Three glycocorticoids, i.e. steroids with anti-inflammatory and 
immunosuppressive properties that bind to the glucocorticoid receptor (GR) [15], were 
examined: hydrocortisone or cortisol (HC), dexamethasone (DEX) and corticosterone (CC).  
 
Clearance (c) 
Uninfected (T) Infected (I) 
Eclipse Phase (E1) 
Virus (V) 
Interferon  
IFN (F) 
Clearance (d) 
Refractory (R) Pre-refractory (W) 
IFN-induced  
effect (φ) 
Eclipse Phase (E2) 
IFN-reduced 
infectivity 
IFN-reduced 
production 
Death (δ) 
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Table 4.1: Substances evaluated for enhancement of influenza virus yields. Structural differences of selected glycocorticoids 
with cortisone are shown in green. 
Compound Structure Comments/Description 
Hydrocortisone 
or Cortisol 
(HC) 
 
 Dominant glucocorticoid in humans. 
 Anti-inflammatory and 
immunosuppressive activity. 
 Active metabolite of cortisone (hydroxyl 
group at C-11 instead of a ketone group). 
 Medical applications in humans. 
Dexamethasone 
(DEX) 
 
 Anti-inflammatory 9-fluoro-
glucocorticoid.  
 Enhanced anti-flammatory potency at 
lower dose levels and slower metabolism 
than HC. The extra double bond between 
C-1 and C-2, the fluorine at C-9 and the 
methyl group at C-16 result in increased 
glycocorticoid activity and stronger 
binding to GR.  
 Medical applications in humans. 
Corticosterone  
(CC) 
 
 Weak glucocorticoid potencies in humans. 
OH group at C-17 is essential for optimal 
activity. 
 The principal avian glucocorticoid  
 Expected to have similar impact as HC on 
immune responses. 
 No medical applications in humans. 
AFZ077 
 
 Modulator of the 5-HT7 receptor. 
 Potential off-target effects on apoptosis and 
cell survival. 
 
BYF589 or 
Pitavastatin 
 
 Inhibitor of HMG-CoA reductase which 
down-regulates cholesterol synthesis. 
 Evidence for decrease of interferon-beta 
expression. 
 Approved by the FDA since 2009 for 
hyper-cholesterolaemia and for the 
prevention of cardiovascular disease. 
 
HC which is the corresponding active form of cortisone was used to evaluate whether allantoic 
injection of HC and influenza virus could elicit similar effects to those published by Kilbourne 
et al. DEX, a 9-fluoro-glucocorticoid that is based on the HC structure, was investigated as a 
more potent alternative. Specifically, DEX binds more powerfully to GR and exerts 25-30 times 
more anti-inflammatory activity than HC [16, 17]. Finally, CC was chosen as it is the primary 
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glucocorticoid in birds [18] and due to structural similarities with HC it is expected to influence 
immune responses correspondingly. However, CC exerts lower glucocorticoid activity in 
humans than HC mainly because it lacks a hydroxyl group at C-17 [19]. Two Novartis research 
compounds that had demonstrated promising results when introduced to the viral seed inoculum 
for MDCK cells in the Flu Cell Culture (FCC) process were also evaluated: AFZ077, an 
antagonist of the 5-HT7 receptor that affects apoptosis and cell survival [20] and the statin 
BYF589 or Pivastatin which inhibits an enzyme involved in cholesterol synthesis [21] and 
potentially decreases production of interferon-beta [22].  
The main purpose of the work described here was the identification of a glycocorticoid or other 
compound that could lead to enhanced viral yields of influenza A and B viruses when added to 
the viral inoculum. DCS was utilised for the determination of viral growth in allantoic fluid 
along with conventional techniques of virus quantification.  
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4.2 MATERIALS AND METHODS 
4.2.1 Viral Stock Preparations  
Whole virus formulations were derived from  laboratory scale experiments through virus 
cultivation procedures detailed in 3.2.1. Viral inoculum was prepared at the concentration 
routinely utilised in production. Four influenza B strains and one influenza A strain were 
examined: B/Massachusetts/2/2012 (wild type, B/Yamagata lineage), B/Massachusetts/2/2012 
(BX-51B) (reassortant, B/Yamagata lineage), B/Hubei-Wujiagang/158/2009 (BX-39) 
(reassortant, B/Yamagata lineage),  A/California/7/2009 (X-181) (reassortant, H1N1) and 
B/Brisbane/60/2008 (wild type, B/Victoria lineage). 
 
4.2.2 Yield Enhancing Substances and Description of Runs   
The effects of the five compounds of interest of Table 4.1 on influenza virus growth of A and 
B strains were examined through 13 small scales studies summarised in Table 4.2.  
The following stock solutions were prepared/supplied and then added to the inoculum: 
 Hydrocortisone (high aqueous solubility 400 mg/ml): 1 mg/ml of highly water soluble 
cyclodextrin-encapsulated hydrocortisone (SIGMA #H0396) in deionised water. Runs 
1-9. 
 Hydrocortisone (powder, solubility 0.28 mg/ml): Pure hydrocortisone (≥98%) in 
deionised water at a concentration of 0.2 mg/ml sourced by SIGMA through their 
imMEDIAte ADVANTAGE™ service (#87292C-2BEVA). Runs 9-13. 
 Dexamethasone: 1 mg/ml of dexamethasone  (Cayman Chemical #11015) in DMSO. 
Runs 2-5. 
 Corticosterone: 1 mg/ml of corticosterone in methanol as supplied by SIGMA (#C-
117). Runs 5-6, 8. 
 AFZ077-NX-1: 32 mg/ml of AFZ077 in DMSO (Novartis #NVP-AFZ077-AA-4). 
Runs 3, 4. 
 BYF589-BA19 (Pitavastatin): 5 mg/ml of BYF589 in DMSO (Novartis #NVP-
BYF589-BA-1). Runs 3, 4. 
 
The concentrations of the candidate substances were selected based on literature values as well 
as results from preceding experimental runs. Replicates were performed on each study, (2 
replicates for runs 1 to 3 and 3 replicates for runs 4 to 12).  Each replicate consisted of 30 eggs, 
which were analysed independently by DCS and sucrose gradient purification. 
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Table 4.2: Summary of small scale experiments involving yield enhancing substances. 
Run Strain Compounds 
Concentration 
(μg/egg) 
Remarks 
1 B/Massachusetts/2/2012 HC 0, 1, 5, 10, 20 
Dose 
Optimisation 
2 B/Massachusetts/2/2012 HC, DEX HC, DEX: 0.02, 0.1, 0.5 
Dose 
Optimisation 
3 B/Massachusetts/2/2012 HC, DEX, AFZ, BYF 
HC: 1, DEX: 0.1, 
AFZ, BYF: 1.75, 3.5,  8.75 
Effect on 
Growth 
4 
B/Hubei Wujiagang/158/2009  
(BX-39) 
HC, DEX, AFZ, BYF 
HC: 1, DEX: 0.1, 
AFZ: 8.75, BYF: 0.22 
Effect on 
Growth 
5 A/California/7/2009 (X-181) HC, DEX, CC 
HC: 1, DEX: 0.1, 
CC: 0.01, 0.1, 1 
Effect on 
Growth  
6 A/California/7/2009 (X-181) HC, CC 
HC: 0.1, 10, 
CC: 0.001, 1, 10 
Effect on 
Growth 
7 
B/Massachusetts/2/2012  
(BX-51B) 
HC 1 
Different 
Infectious 
Doses and 
Incubation 
Times 
8 B/Massachusetts/2/2012 HC, CC HC: 1, CC: 10 
Impact of 
Modification 
of  HC 
Formulation 
(SIGMA) 
9 B/Massachusetts/2/2012 HC 1 
Comparison 
HC High vs 
Low 
Solubility  
10 B/Massachusetts/2/2012 HC 0.1, 0.5, 1, 5, 100 
Dose 
Optimisation 
11 B/Brisbane/60/2008 HC 0.1, 0.5, 1, 5, 100 
Dose 
Optimisation 
12 
B/Massachusetts/2/2012  
(BX-51B) 
HC 0.1, 0.5, 1, 5, 100 
Dose 
Optimisation 
13 B/Massachusetts/2/2012 HC 1 
Growth 
Kinetics at 
33, 34 and 
35 oC 
 
4.2.3 Analytical Methods  
4.2.3.1 DCS Measurements 
DCS analysis of freshly harvested AF was performed following the procedure detailed in 3.2.2.  
 
4.2.3.2 Virus Purification (Mini-gradient)  
Influenza viruses in AF were purified from egg-derived material through small scale sucrose 
density gradient centrifugation (3.2.3). The collected virus was subsequently characterised by 
means of protein content by Bio-Rad (3.2.4), purity and relative density of the well-defined 
HA2 band by reducing SDS-PAGE (3.2.5) and HA activity by SRID (4.2.3.3). 
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4.2.3.3 HA activity (SRID or SRD) 
HA content in different influenza virus preparations (viral fractions collected post mini-gradient 
purification) was determined by SRID according to NV internal SOP which is largely based on 
the method described by Wood et al. [23, 24]. The principle of the SRID assay is detailed in 
Chapter 6 (6.1.1). In brief, 1.5% (w/v) agarose gels were cast with a predetermined amount of 
strain-specific reference HA antiserum (NIBSC or CBER) The solidified gels were 
subsequently stamped with a 4 mm well puncher. Antigen reference standards and vaccine 
samples (pre-diluted at approximately 30 μg/ml HA) were first incubated with 1 % w/v 
Zwittergent 3-14 (Calbiochem #693017) for at least 30 minutes at room temperature, diluted 
with PBS, pH 7.3, loaded onto agarose gels (20 µl/well) and incubated for 20-24 hours at room 
temperature in a humidity chamber. Each sample was tested in triplicate at four dilutions. 
Following incubation, the gels were washed with deionised water for 1 hour, compressed with 
0.65 kg weights for 30 minutes, dried and then stained with 0.3% w/v Coomassie Brilliant Blue 
R-250 (AMRESCO #0472) for 5-15 minutes.  The gels were then washed (30% v/v MeOH, 10% 
v/v AcOH) until precipitin halos were visible and in good contrast with the background gel. 
The diameters of the precipitin rings were measured using the ProtoCOL 3 zone measuring 
reader system and HA concentration of the samples was calculated relatively to the HA 
concentration of the standard using the slope–ratio model [25].  
 
4.2.3.4 Infectivity Assay (EID50)   
Viral infectivity was determined with the EID50 method as part of the growth kinetics study 
(Run 13) as described in 3.2.7.  
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4.3 RESULTS AND DISCUSSION 
4.3.1 Runs 1-3: Dose Effect of HC, DEX, AFZ077 and BYF589 on Growth of 
B/Massachusetts/2/2012 
The purpose of the initial experimental work was to assess whether HC, DEX, AFZ077 or 
BYF589 could lead to improved viral yields upon addition to the inoculum of the wild type 
strain B/Massachusetts/2/2012 that belongs to the B/Yamagata lineage of viruses.  
In run 1, HC was injected at doses of 1, 5, 10 and 20 µg/egg. Virus concentrations were 
estimated by testing pooled AF from eggs of each tray (replicate) by DCS and determination of 
protein concentration (Bio-Rad), HA content (SRID) and densitometric analysis by SDS-PAGE 
after virus purification (mini-gradient). Results are graphically displayed in Figure 4.3 and 
analytical data are provided in Appendix 4.1.  
 
 
 
 
Figure 4.3: Influence of HC on final yields of B/Massachusetts/2/2012 as measured by a) viral peak height (DCS), b) protein 
titre (Bio-Rad), c) HA content (SRID) and d) relative intensity of the HA2 band (SDS-PAGE). 
 
It was found that viral yields attained from HC-injected eggs were 92 to 175% higher of those 
from control eggs as measured by all analytical techniques. As indicated by the error bars in 
Figure 4.3a, DCS showed the highest variability between replicates (CV>15%). This is well 
anticipated as DCS analysis of freshly harvested samples can provide a measurement of only 
free non-aggregated viral particles and no estimation/assumption of viral content in detected 
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aggregates or complexes that exceed 2 µm can be made. No significant yield increase or a dose-
response relationship was observed for HC doses>1 µg/egg. Furthermore, it was noted that 
administration of HC had no considerable impact on the mortality rate of the embryos or the 
quality of harvested fluid. 
Run 2 was designed to evaluate the effect of addition of lower doses of HC (0.02, 0.1 and 0.5 
µg/egg) on viral recoveries of B/Massachusetts/2/2012. The more potent glucocorticoid DEX 
was also examined at the same concentration range. Results are presented in Figure 4.4 
(analytical values are available in Appendix 4.2). 
 
 
 
 
 
 
Figure 4.4: Influence of HC and DEX on final yields of B/Massachusetts/2/2012 as measured by a) viral peak height (DCS), 
b) protein titre (Bio-Rad) and c) HA content (SRID). d) Dose-response curve of HC based on DCS data. 
 
Administration of both HC and DEX in the inoculum resulted in significant yield improvement 
compared to the control samples. According to the results by all analytical methods utilised, the 
optimum HC and DEX levels were 0.5 and 0.1 µg/egg respectively at the range examined. 
Specifically, at a dose of 0.5 µg/egg HC, the viral yield increased 50% based on protein and 
DCS measurements and 120% by SRID. DEX gave similar results at the lower dose of 0.1 
µg/egg. Additionally, a dose-response relationship was suggested as virus generation increased 
with increasing concentrations of HC and DEX. In Figure 3.26d, the dose-response (Gompertz) 
sigmoid fitting (R2≈1) for HC is shown using DCS data. Neither HC nor DEX affected specific 
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virus purity patterns or egg mortality rates. Nonetheless, DEX had a noticeable impact on the 
quality of harvested AF as demonstrated by an increase of turbidity and elevated blood diffusion 
into AF.  
In run 3, eggs were injected with 1 µg/egg HC and 0.1 µg/egg DEX that were identified as 
optimum in runs 1 and 2. Moreover, the compounds AFZ077 and BYF589 were evaluated at 
concentrations of 1.75, 3.5 and 8.75 µg/egg. Since DEX, AFZ077 and BYF589 all required 
dissolution in DMSO, it was deemed essential to include a DMSO control (0.87 % v/v) to ensure 
that the solvent did not exert any deleterious effects on viral growth or embryo development.  
As illustrated in Figure 4.5, addition of HC and DEX yielded a 40-50% increase in viral 
recovery based on DCS and protein measurements (complete data are available in Appendix 
4.3). Administration of DEX led to inferior harvest quality as observed previously. It is 
noteworthy that the control sample derived from simple viral inoculation was substantially 
higher in viral content compared to previous runs (Figure 4.3a, 4.4a). Both control samples 
could not be duplicated due to limited incubator capacity. Viral inoculation in presence of 
DMSO had no influence on viral yield or embryo health. The NV candidate substances that had 
shown potential in small scale cultures of MDCK cells had no equivalent effect in the chick 
embryo model. Although the mechanism of action of these compounds has been studied in 
tissue cultures it can be presumed that the effect is negligible or less obvious at these dose levels 
in the chicken embryonic system.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Influence of HC, DEX, AFZ077 and BYF589 on final yields of B/Massachusetts/2/2012 as measured by a) viral 
peak height (DCS) and b) protein titre (Bio-Rad). 
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4.3.2 Run 4: Effect of HC, DEX, AFZ077 and BYF589 on Growth of B/Hubei 
Wujiagang/158/2009 (BX-39)  
The aim of this study was to verify the effects of HC, DEX, AFZ077 and BYF589 observed in 
previous experiments on the reassortant influenza B strain B/Hubei Wujiagang/158/2009 (BX-
39) of the B/Yamagata lineage. Similarly to the wild B/Massachusetts subtype, HC and DEX 
succeeded in significantly increasing viral yields whereas the AFZ and BYF compounds had 
no influence on viral growth as shown by all analytical methods employed (data not shown).  
 
4.3.3 Runs 5-6: Effect of HC, DEX, CC on Growth of A/California/7/2009 (X-181) 
Experimental runs 5 and 6 focused on the impact of glucocorticosteroids on growth of the 
influenza A strain A/California/7/2009 (X-181). In run 5, HC and DEX were added in the 
inoculum at the concentrations determined as optimum for yield recoveries of 
B/Massachusetts/2/2012. The natural corticosteroid hormone CC was also injected at doses of 
0.01, 0.1 and 1 µg/egg. In contrast to B viruses, HC and DEX induced approximately a 20% 
reduction in virus multiplication of X-181 based on DCS data shown in Figure 4.6a (complete 
dataset available in Appendix 4.4-4.5). Administration of CC appeared to have limited influence 
on viral recoveries. Although a 10% virus increase was noted at 0.1 and 1 µg/egg based on 
mean measurements, the standard deviation between replicates renders this yield enhancement 
insignificant.  
 
 
 
 
Figure 4.6: Influence of HC, DEX and CC on final yields of A/California/7/2009 (X-181) as measured by viral peak height 
(DCS). a) Run 5 and b) run 6.  
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possibly relates to the low glucocorticoid potency of CC compared to HC due to lack of the 
hydroxyl group at the C-17 position of the molecule.  
Inhibition of production of various influenza A viruses in eggs by cortisone has also been 
reported by Kilbourne [5]. This study suggested that cortisone inhibits viral synthesis not only 
in the initial stages of infection –as observed with B strains- but also throughout the course of 
viral multiplication. Relatively increased yields in presence of cortisone were only manifested 
when inoculums with higher proportions of non-infectious viruses were utilised [5, 26]. 
Nonetheless, these observations are inconsistent with others published earlier [1] that had 
shown 123-155% increase in the viral concentration of A/Puerto Rico/8/1934 (H1N1) as 
measured by the HA assay in cortisone-injected eggs regardless of the population of inactive 
particles included in the inoculum. In subsequent studies, Kilbourne’s group indicated that 
suppression of interferon synthesis by cortisone has a considerably greater impact on yields of 
influenza B strains compared to A strains [27]. These findings are in agreement with results 
published by Reinicke’s laboratory [28] which demonstrated that hydrocortisone diminishes 
interferon formation without a corresponding increase in yields of influenza A viruses 
inoculated in cultures of chick embryo fibroblasts. It needs to be taken into account that 
determination of interferon activity at the time of these publications [27, 28] was performed 
indirectly through Wagner’s method [29] that expresses all interferon concentration as the 
decrease in viral production (hemagglutination) in vitro in cultures of chorioallantoic 
membranes [5, 8].  
The observed inhibitory impact of HC on multiplication of A viruses in eggs might also relate 
to the well-known differences in the function of the non-structural protein 1 (NS1) between A 
and B strains. In more detail, it has been shown that the NS1 protein of influenza B viruses 
binds only the human and non-human primate IFN-stimulated gene ISG15 -a protein that exerts 
potent antiviral activity- and blocks its conjugation to target proteins thereby promoting viral 
growth [30-32]. The inability of NS1 to bind to ISG15 of other species including canine cells 
like MDCK [31, 32] is believed to partially account for the restriction of influenza B infections 
mainly in humans [30, 32, 33]. In contrast, the NS1 protein of influenza A viruses acts as an 
IFN antagonist in a wide range of avian and mammalian species thus counteracting IFN-
mediated antiviral activity and allowing virus propagation [34].  
In addition to the above, there is some evidence that B viruses trigger IFN responses 
considerably faster compared to A strains in infected monocyte-derived dendritic cells [35]. 
Specifically, influenza A types have shown to induce IFN expression only after production of 
viral RNA while B viruses activate immune responses at early stages of the infection prior to 
viral synthesis.  
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Finally, the effects of HC on influenza A replication could be associated with the different types 
of epithelium cells typically targeted by these viruses compared to influenza B. The allantoic 
layer of 11 days fertilised chicken eggs is an epithelium composed of mainly two layers: a 
superficial that is in contact with AF and an underlying, deeper layer. Influenza A rapidly infects 
and eventually destroys the superficial layer whilst leaving the deep layer intact [36]. 
Conversely, influenza B viruses affect both layers and at late infection phases cause complete 
loss of the epithelium [37].  
Overall, the kinetics of interferon formation upon infection with A and B strains are not well-
established. Determination of production of the antiviral cytokines interferon alpha (IFN-α) and 
beta (IFN-β) in fertilised chicken eggs infected with A and B viruses with or without HC was 
attempted using the most sensitive commercially available ELISA kits (MyBioSource 
#MBS703812, #MBS703820). IFN-α was undetectable in AF throughout the infection course 
despite the high sensitivity of the assay (0.78 pg/ml) while IFN-β generation was variable across 
different experiments (data not shown). Further studies are required to clarify the potential 
differences in IFN response in A and B influenza infected chick embryos as well as the 
antagonistic function of HC in A strains. 
 
4.3.4 Runs 7-9: Effect of HC on Growth of B/Massachusetts/2/2012 (BX-51B) and 
Evaluation of Modified HC Formulations  
The results of experimental runs 7-9 are only briefly discussed here. Run 7 assessed the impact 
of treatment with 1 µg/egg HC on viral replication of the reassortant B strain 
B/Massachusetts/2/2012 (BX-51B) whilst varying infectivity titres and incubation times. Eggs 
were infected with 5 ID/egg for 72 hours and 50 ID/egg for 48 and 72 hours. According to DCS 
measurements (Figure 4.7), viral concentrations obtained from HC-injected eggs incubated for 
72 hours were greater than 40% for both 5 and 50 ID/egg, viz. HC increased yields regardless 
of input values.  
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Influence of HC at different infectious doses and/or incubation times on final yields of B/Massachusetts/2/2012 
(BX-51B) as measured by viral peak height (DCS). 
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Moreover, it was shown that viral titres from HC treated eggs incubated for only 48 hours (50 
ID/egg) remained practically unchanged compared to non-HC treated eggs. Conversely, greater 
yield enhancement was achieved in eggs incubated for 72 hours. Thus HC potentially exerts its 
effect on viral production between 48-72 hours of incubation. The influence of incubation time 
was further characterised through growth kinetics studies detailed in 4.3.6 (Run 13). 
Run 8 briefly explored the impact of CC addition on growth of the wild type B strain 
B/Massachusetts/2/2012. Analogously to A strains, CC did not affect viral multiplication (data 
not shown).  
Run 9 was designed to evaluate whether free (pure) HC of low aqueous solubility (0.28 mg/ml) 
could elicit the same effect on yields of B/Massachusetts/2/2012 as the previously used HC-
cyclodextrin inclusion complex that exhibits enhanced solubility (400 mg/ml). Despite its 
substantially decreased solubility, use of free HC was considered as the preferred choice since 
it avoids introduction of an additional element, i.e. cyclodextrin, in the manufacturing process 
and therefore the amount of characterisation studies required for regulatory submission. The 
results as derived by all analytical methods employed (data not shown) suggested that free HC 
affects influenza B virus growth similarly to encapsulated HC (yield increase > 60%).  
 
4.3.5 Runs 10-12: HC Dose Optimisation for Maximisation of Yields of B strains 
Three experiments involving administration of pure HC at various levels (0.1, 0.5, 1, 5 and 100 
µg/egg) on antigenically different strains of influenza B virus were executed sequentially in 
order to define an optimum HC concentration per viral type and simultaneously to assess 
whether optimisation studies are needed when strain changes in vaccine formulation occur. The 
viruses examined included: the wild types B/Massachusetts/2/2012 and B/Brisbane/60/2008 
from the B/Yamagata and B/Victoria lineages respectively and the genetic reassortant 
B/Massachusetts/2/2012 (BX-51B). Results are summarised in Figure 4.8. As also shown in 
earlier experiments (Figure 4.4d), a slight dose-response relationship is observed for HC 
concentrations < 0.5 µg/egg. Overall, no significant impact on viral recoveries are noted for HC 
doses 0.5-5 µg/egg whereas reduced yields were attained when excessive amounts of HC were 
injected. In the latter case, elevated embryo mortality rates and extensive blood diffusion into 
AF were recorded.  
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Figure 4.8: Influence of HC on final yields of B/Massachusetts/2/2012, B/Brisbane/60/2008 and BX-51B as measured by a) 
viral peak height (DCS), b) protein titre (Bio-Rad), c) HA content (SRID) and d) relative intensity of the HA2 band (SDS-
PAGE). 
 
Taking into account all the assays utilised to determine viral content; addition of HC at a dose 
range of 0.5-5 µg/egg is predicted to result in viral yields greater than 50% compared to typical 
control values regardless of the provenance of the B type virus. Hence, an HC concentration of 
1 µg/egg which was employed in most preliminary trials can be confirmed as suitable for future 
yield improvements of B strains as well as scale up.   
 
4.3.6 Run 13: Effect of HC on Growth Kinetics of B/Massachusetts/2/2012 
Finally, the potential influence of HC on the dynamics of viral growth of 
B/Massachusetts/2/2012 was explored. Fifteen trays (30 eggs/tray) of 11-days-old hen eggs 
were inoculated with viral inoculum containing 1 µg/egg HC, with a further fifteen trays being 
inoculated with viral inoculum without HC. Eggs were incubated at 33oC (typical temperature), 
34oC and 35oC. Replicate samples could not be generated due to limited incubator capacity. 
DCS, Bio-Rad protein assay, SRID, SDS-PAGE and infectivity analysis (EID50) were 
performed. Selected results are presented in Figure 4.9 while all data are provided in Appendix 
4.6.  
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Figure 4.9: Viral growth charts of B/Massachusetts/2/2012 at 33, 34 and 35 oC with and without HC created from a) viral 
peak height (DCS), b) protein titre (Bio-Rad) and c) infectivity (EID50) data. 
 
As three variables were involved in this experiment, viz. temperature, incubation time and 
hydrocortisone addition, all obtained measurements were fitted in a full factorial design and 
were subsequently evaluated through statistical significance testing (ANOVA) in Minitab. This 
facilitated interpretation of results as well as deduction of more confident conclusions.  
 
Table 4.3: ANOVA analyses for determination of critical parameters affecting viral growth with and without HC. 
Term 
P-value 
Viral Peak  
Height  
(DCS) 
Protein 
Concentration 
(Bio-Rad) 
HA  
Activity 
(SRD) 
HA2 
 Intensity 
(SDS-PAGE) 
EID50 
Incubation  
Time 
0.000 0.000 0.000 0.000 0.009 
HC 0.001 0.000 0.000 0.000 0.217 
Temperature 0.102 0.066 0.683 0.021 0.691 
Time X HC 0.006 0.000 0.000 0.000 0.332 
Time X  
Temperature 
0.133 0.014 0.231 0.004 0.824 
HC X  
Temperature 
0.278 0.634 0.526 0.897 0.658 
R2 0.976 0.999 0.987 0.998 0.815 
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ANOVA analyses for viral peak height (DCS), protein concentration (Bio-Rad), HA activity 
(SRID), relative HA2 intensity (SDS-PAGE) and infectivity titre (EID50) are summarised in 
Table 4.3. Factors with P-values less than the specified significance level of 0.05 are considered 
significant. Taking into consideration the above, the following tentative observations and 
postulations are expressed:  
 With the exception of SDS-PAGE analysis (P=0.021), incubation temperature had a 
limited impact on the growth rate of this particular strain irrespective of HC presence 
(Figure 4.9a, b).  
 Based on DCS and Bio-Rad data, addition of HC generally altered the form of the 
growth curve (Time X HC) by delaying the maximum release of virus from 48 to 60-72 
hours. This observation is in agreement with the results of Run 7 reported earlier (4.3.4) 
as well as published studies [5]. The viral peak height data point at 34 oC at 60 hours 
(Figure 4.9a) is considered unusual as it does not fit well with the typical sigmoidal 
profile. 
 Viable (infectious) titres depicted in Figure 4.9c, were not altered significantly by 
different incubation temperatures or HC presence. However, the latter is potentially 
associated with the low resolving power of the EID50 assay. This possibly justifies some 
of the initial conclusions made by Kilbourne regarding the initial inhibitory effect of 
cortisone on viral synthesis in early infection stages. A reliable method of higher 
resolution is required for identification of distinctive differences in infectivity titres 
upon administration of HC. 
 
4.3.7 Comparability between Assays  
All viral peak height (DCS), protein (Bio-Rad) and HA content (SRID) measurements recorded 
in experiments 1-13 were utilised for assay comparison studies through regression analysis. 
Correlations of peak height with the intensity of the HA2 band as derived from reduced SDS-
PAGE analysis were not attempted as the method was only used for relative comparisons within 
each experiment. The dataset included 131 points (sample size) with DCS, Bio-Rad and SRID 
ranges of 32.3, 251.6 and 141.9 respectively. Linear regression graphs are displayed in Figure 
4.10.  
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Figure 4.10: a) Assessment of linear correlation of viral peak height (DCS) with a) protein concentration (Bio-Rad) and b) HA 
content (SRID). Red: large residuals, green: unusual variation and purple: large residuals and unusual variation.   
 
The relationship between free virus in allantoic fluid measured by DCS and protein or HA 
concentration in purified virus samples was statistically significant with P=0.001< 0.05. The 
regression model of viral peak with protein (Figure 4.10a) captured 68.6% of the variation with 
a high positive correlation factor of 0.83 while the respective regression with HA activity 
(Figure 4.10b) explained 51.8% of the variation with a positive correlation of 0.72. As shown 
in Figure 4.10, a few points marked in red were not described adequately by the regression 
equations (large residuals). Additionally, a number of observations, shown in green, exhibited 
unusual variation especially in the DCS-SRID correlation. Those form a secondary cluster that 
includes all samples with HA content>115 µg/ml. Although these points have a strong influence 
on the results, special causes that would justify removal were not identified. Samples 
represented by these points belong to runs 2-4, involve different strains and contain HC or DEX.  
Taking into account that DCS analysis is performed on a different cruder sample matrix the 
correlations achieved are regarded as adequate. It is noted that the respective correlation 
between protein and HA activity measurements of the same samples was R2= 68.5. DCS allows 
fast estimation of viral content in harvest samples and has demonstrated that can be used as a 
predictor of total viral or HA protein in sucrose containing purified virus preparations.  
 
4.3.8 Influence of HC on Viral Composition and Morphology 
In experiments exploring the effect of HC dose on influenza virus yields (runs 1-3 and 10-12) 
in embryonated hen eggs, protein electrophoresis analysis revealed a notable modification of 
virion composition with increasing levels of HC. Specifically, band quantification in protein 
electrophoresis gels (Appendix 4.7) suggested that the higher the HC dose injected, the higher 
the percentage of NA in the produced viruses (Figure 4.11a). Interestingly, this phenomenon 
was also accompanied by a corresponding decline of the ratio of membrane glycoproteins 
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(HA/NA) as presented in Figure 4.11b. Administration of 1 µg/egg HC resulted in a consistent 
34% reduction of HA/NA in all three B strains examined.  
 
 
 
 
 
 
 
 
 
Figure 4.11: Impact of increasing concentrations of HC on a) NA% and b) ratio of surface antigens (HA/NA) based on SDS-
PAGE data from experiments 10-12. 
 
It is well established that an optimal functional balance between the opposing activities of HA 
and NA is critical for efficient replication and transmission [38]. HA binds to sialic acid 
containing receptors on host cells and initiates virus infection whereas NA acts as a receptor-
destroying enzyme by cleaving sialic acid residues from virion and cellular components thus 
facilitating release of progeny viruses and preventing aggregation of viral particles [38-40]. 
Impairment of the NA function by mutation, deletion, or inhibition, or any other disruption of 
the existing balance between HA and NA activities leads to viral aggregation and therefore 
affects propagation of the infection [41].  
In order to assess whether addition of HC disturbs the HA-NA functional match, NA enzymatic 
activity was determined via the colorimetric fetuin-based ELISA [42] in samples generated 
from runs 10-12. The results were subsequently expressed as NA activity (mIU) per μg of viral 
protein to ease correlations with SDS-PAGE data. In Figure 4.12 the relative increase of NA 
content with NA potency upon addition of different levels of HC is compared.  
It was demonstrated that administration of HC at doses greater than 0.1 μg/egg in runs 10-11 
(Figure 4.12 a, b) and 1 μg/egg in run 12 (Figure 4.12 c) resulted in generation of viral particles 
containing disproportionally high amounts of inactive or impaired NA protein. This finding, 
which has not been previously reported in any pertinent study, is of particular importance as it 
potentially elucidates why viral multiplication of B strains was not favoured at HC 
concentrations above 0.5 μg/egg.   
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Figure 4.12: Comparison of NA activity with total NA content recovered at increasing concentrations of HC for a) 
B/Massachusetts/2/2012 (run 10), b) B/Brisbane/60/2008 (run 11) and c) B/Massachusetts/2/2012 (BX-51B) (run 12). 
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4.4 CONCLUSIONS AND FUTURE PROSPECTS 
The effect of five substances (hydrocortisone, dexamethasone, corticosterone, AFZ077 and 
BYF589) on influenza virus recovery upon addition to the seed inoculum and subsequent 
inoculation through the allantoic cavity of fertilised chicken eggs was assessed.  
Co-administration of hydrocortisone with B type viruses at a dose range of 0.5-5 µg/egg 
resulted in viral yields greater than 50% compared to typical control values irrespective of virus 
provenance. The more potent synthetic glycocorticoid dexamethasone yielded comparable 
results at the lower dose of 0.1 µg/egg though it also had a noticeable impact on the quality of 
harvested allantoic fluid as demonstrated by increase of turbidity and elevated blood diffusion. 
The avian glycocorticoid corticosterone as well as the NV research compounds AFZ077 and 
BYF589 had no influence on viral growth of influenza B strains as shown by all analytical 
methods utilised (DCS, Bio-Rad protein assay, SRID).  
In contract to B viruses, addition of hydrocortisone at 1 and 10 µg/egg halted virus 
multiplication in A strains by approximately 20 and 40% respectively based on DCS data. The 
mechanism by which hydrocortisone inhibits growth of influenza A viruses is unknown as this 
phenomenon had not been established prior to conduction of the studies reported here. It is 
tentatively postulated that the observed inhibitory impact of HC on multiplication of A viruses 
in eggs is associated with differences in interferon expression, activity and infection dynamics 
compared to B strains. Administration of corticosterone appeared to have limited or 
insignificant influence on viral recoveries of A type viruses. 
In addition to the above, it was demonstrated that injection of hydrocortisone at increasing 
concentrations modified the composition of the generated virions of B virus types by increasing 
the relative mass percentage of NA on the viral surface, viz. the higher the hydrocortisone dose 
injected, the higher the percentage of NA. This effect was also accompanied by a decline of the 
ratio of membrane glycoproteins (HA/NA). Moreover, it was shown that administration of 
hydrocortisone at doses greater than 0.1-1 μg/egg induced production of viral particles 
containing disproportionally high amounts of inactive or impaired NA thus suggesting a 
mismatch between NA physical mass and activity. These findings are novel and potentially 
explain why viral multiplication of B strains was not favoured at high hydrocortisone 
concentrations. Although the impact of hydrocortisone on viral morphology needs to be fully 
investigated it needs to be emphasised that as Agrippal is a subunit vaccine -there is no 
requirement for in-process whole virus influenza protein purity profile and relative 
quantification of proteins- and only presence/detection of NA through the NA fetuin activity 
assay is required for vaccine release, the CQAs of the final product are expected to remain 
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unaffected. Depletion of the residual hydrocortisone throughout processing and no interference 
with assays should be proven nonetheless. 
The next phase of this project could involve further characterisation of the mechanism of action 
of hydrocortisone and other structurally related glycocorticoids on viral growth of B strains in 
terms of interferon responses, elucidation of the antagonistic function of hydrocortisone in A 
strains and identification of a non-steroidal compound that could promote replication of A type 
viruses. It is noted that although the NV candidates AFZ077 and BYF589 had no influence on 
the growth of B viruses, they could exert a different effect when used with A viruses. Finally, 
the hydrocortisone-induced modification of viral composition of influenza B virus types and/or 
morphology needs to be investigated further (e.g. TEM analysis, alternative methods of 
quantification of NA activity, NA sequencing etc.).     
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5. INSIGHT INTO SOLUBILISATION OF MEMBRANE 
GLYCOPROTEINS FOR PRODUCTION OF 
INFLUENZA SUBUNIT VACCINES 
 
5.1 INTRODUCTION  
5.1.1 Solubilisation of Membrane Proteins by Detergents 
Biological membranes are composed of a complex lipid bilayer in which proteins are 
embedded. The lipid bilayer contains a diverse variety of lipids (e.g phospholipids, cholesterol 
and glycolipids) that consist mainly of two hydrophobic tails linked to a hydrophilic polar head 
[1, 2]. This membrane architecture is known as the “fluid mosaic” model (Figure 5.1) and has 
been described by Singer and Nicholson [3]. Membrane proteins are categorised as integral 
(intrinsic) which are firmly anchored in the membrane by hydrophobic interactions between the 
hydrophobic domains of proteins and the lipid tails or peripheral (extrinsic) which are loosely 
bound to the membrane via interactions with integral proteins or the lipid heads [4, 5]. Unlike 
peripheral proteins, integral proteins are generally insoluble in water and consequently use of 
detergents or surfactants is required for their extraction or solubilisation from biomembranes.  
 
 
Figure 5.1: Simplified fluid mosaic model of a biological membrane and structure of a phospholipid. 
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Detergents are soluble amphipathic substances (Figure 5.2a) that contain both a hydrophilic 
(lipophobic, polar) head and a hydrophobic (lipophilic, non-polar) tail. According to their 
structural features, detergents are commonly classified into four main categories: ionic, bile 
acid salts, non-ionic and zwitterionic [6-8]. Characteristic examples of each detergent class are 
presented in Figure 5.3.  
 
Figure 5.2: A detergent a) monomer and b) micelle.  
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Structural formulas of commonly used detergents of various charge types.  
 
Ionic detergents consist of head groups with a net charge and can be either cationic (e.g. CTAB) 
or anionic (e.g. SDS). These detergents are efficient solubilisers of membrane proteins but are 
denaturing to some degree [7-9]. Bile salts (e.g. sodium deoxycholate) are a separate class of 
relatively mild anionic detergents that contain a steroidal backbone [6, 7]. Non-ionic detergents 
contain uncharged hydrophilic heads that are commonly composed of a polyoxyethylene 
SDS  
(anionic) CTAB  
(cationic) 
Sodium Deoxycholate 
(bile salt) 
Tween 80 
(non-ionic) 
CHAPS 
(zwitterionic) 
Zwittergent 3-14 
(zwitterionic) 
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moiety (e.g. Triton X-100, Tween 80) or the glycosides (e.g. octyl glucoside). Generally, 
detergents belonging to this class mainly act by disrupting lipid-lipid and/or lipid-protein 
interactions and are considered non-denaturing and therefore suitable for isolation of 
biologically active proteins [7, 9]. Finally, zwitterionic detergents (e.g. CHAPS, Zwittergent 3-
14) combine the properties of ionic and non-ionic detergents since they contain polar heads 
with both positive and negative charges. In general, they are more denaturing than non-ionic 
detergents but more efficient solubilisers as they also prevent protein-protein interactions [7, 
9].  
Detergents solubilise membrane proteins by imitating the lipid-bilayer environment [6]. In 
aqueous solutions, detergent molecules exist as monomers at low concentrations. Increase of 
detergent concentration above a specific value known as the critical micelle concentration 
(CMC) leads to spontaneous formation of spherical, thermodynamically stable, non-covalent 
clusters called micelles (Figure 5.2b) [10-12]. In micelles, the hydrophobic tails aggregate into 
the core of the sphere whereas the hydrophilic heads face outwards analogously to the lipid 
bilayers of the biological membranes [9, 12].  Membrane lipids and proteins incorporate into 
detergent micelles thus shielding their hydrophobic regions whilst their hydrophilic domains 
are exposed to the aqueous medium [9]. The CMC of a detergent is a crucial parameter that 
determines detergent behaviour and consequently solubilisation efficiency. It is dependent on 
numerous factors/experimental conditions including pH, temperature, ionic strength (salt 
concentration), length of the alkyl chain of the detergent and presence of additives (e.g urea) 
and impurities [6, 9, 12, 13]. Additionally, CMC may be affected by other elements of the 
biological system under study such as lipids, proteins or presence of other detergent molecules 
[7, 8]. 
 
Other properties commonly used to characterise detergent behaviour are:  
o Aggregation number (N): Average number of monomers contained in a micelle. It is 
affected by the molecular weight of the monomer and the ionic strength of the solution 
[14, 15]  
o Critical micelle temperature (CMT): The temperature at which the detergent transitions 
from a hydrated crystalline form to a micellar solution, i.e. the lowest temperature at 
which micelles are formed [6, 10, 13]. 
o Cloud point (CP): The temperature at which (non-ionic) detergent solutions become 
cloudy and separate into a detergent (micelle) rich and an aqueous (detergent depleted) 
phase [6, 9].  
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o Hydrophile-lipophile balance number (HLB): Relative measure of (non-ionic) detergent 
hydrophilicity/ hydrophobicity. Typical values are 12–15. Detergents with HLB<10 are 
insoluble in water whereas those with HLB>16 are normally utilised as protein 
stabilisers [12]. 
 
Specific properties of detergents commonly employed for solubilisation of membrane proteins 
are described elsewhere [6, 12, 13].  
Extraction of membrane proteins by detergents is a complex process that occurs in three stages 
based on the relative ratio of detergent to membrane protein or lipid content (Figure 5.4) [7, 10, 
16-18]. At low concentrations of the detergent (<CMC), monomers merely bind to the 
membrane and initiate partitioning of the lipid bilayer. As the amount of detergent reaches a 
concentration≥CMC (approximately at a detergent to protein molar ratio of 1:10), the 
membrane bilayer is disintegrated and detergent-lipid-protein complexes are formed. Further 
increase in detergent concentration (detergent to protein of 1:1) leads to formation of 
heterogeneous complexes of detergent, lipid, and protein.  Finally, delipidation of the 
complexes at a detergent to protein ratio≥10 individual detergent-protein and detergent-lipid 
micelles are generated. Practically, the optimal solubilisation conditions for any specific 
membrane system are determined empirically. If isolation of native integral membrane proteins 
that retain their functionality is intended, a non-denaturing detergent such as Triton X-100 or 
CHAPS would be preferred. Other factors that should be taken into account when choosing a 
detergent include pH, temperature, ionic strength and potential interference with assays.  
 
 
Figure 5.4: Schematic diagram of various stages of solubilisation of membrane proteins by detergents. 
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5.1.2 Solubilisation of Influenza Virus Membranes: Split Virion and Subunit Vaccines 
Currently, most commercially available inactivated influenza vaccines are split virus or subunit 
vaccines (see also 1.5.1 in Chapter 1). Split virion vaccines are prepared after treatment with 
detergents that disrupt the whole virus particle thus releasing all viral components in solution. 
Detergents are subsequently removed with diafiltration or the surface antigens are further 
purified though sucrose gradient centrifugation [19]. Detergents commonly used for production 
of split virus vaccines include the non-ionic detergent Triton-X100 [20, 21] and the anionic bile 
salt sodium deoxycholate [22, 23]. Subunit vaccines contain predominantly the purified viral 
surface proteins HA and NA and are generated by treatment with the cationic detergent CTAB 
[24, 25] or the non-ionic nonoxynol-9 (NP9 or Triton-N101) [26, 27]. These detergents 
selectively solubilise the HA and NA whilst leaving the residual virus core particles intact. 
CTAB is removed through adsorption to hydrophobic resins whereas NP9 is removed by phase-
separation at the cloud point in the presence of phosphate [19, 26]. Table 5.1 provides a 
summary of the detergents most commonly used for production of split virion and subunit 
formulations along with examples of currently licensed influenza vaccines. 
 
Table 5.1: Detergents utilised for manufacture of split virus and subunit vaccines. 
Detergent 
MW 
(Da) 
CMC 
at 25 oC 
(mM) 
Vaccine 
Type 
Manufacturer 
(Vaccine(s)) 
Inactivation 
Method 
Triton-X100 
630 
(average) 
[9] 
0.3 
[9, 13] 
Split 
virion 
Sanofi Pasteur: 
Fluzone/Vaxigrip/Intanza 
HCHO 
 
Sodium 
Deoxycholate 
(DOC) 
414.6 
[12, 18] 
2-8 [9, 12] 
Split 
virion 
 ID Biomedical 
Corporation of Quebec: 
Flulaval 
 GSK: Fluarix 
 HCHO 
 
 
 HCHO 
Sodium 
Taurodeoxycholate 
521.7 
[10] 
2-6 [10] 
Split 
virion 
        CSL: Afluria BPL 
NP9 
(Triton-N101) 
616.8 
[28] 
0.097 [28] Subunit 
Novartis Vaccines: 
Fluvirin 
BPL 
CTAB 
364.5 
[12] 
0.9-1 [12, 
18] 
Subunit 
 Novartis Vaccines: 
Agriflu/Agrippal, 
Flucelvax/Optaflu 
 Abbot Healthcare: 
Influvac, Imuvac (EU) 
 HCHO 
 
 
 HCHO 
  
NV manufactures exclusively influenza subunit preparations. This thesis focuses particularly 
on solubilisation of the membrane antigens with CTAB.  
 
5.1.3 Surface Antigen Solubilisation in Agrippal 
A critical step during the Agrippal downstream process is the splitting of the influenza whole 
virus resulting in solubilisation of the surface antigens from the virus cores. The goal of this step 
is to separate the viral surface antigens HA and NA and selectively recover them without 
128 
 
compromising their immunogenicity and their stability. Solubilisation is performed with the 
cationic detergent CTAB based on a procedure originally developed by Bachmayer et al. in the 
70s [24, 25, 29, 30]. Bachmayer et al. demonstrated that selective solubilisation and isolation 
of the membrane glycoproteins could be accomplished after treatment of the influenza virus 
with cationic detergents (preferably CTAB) for 30-60 minutes at room temperature or overnight 
at 4 oC at an optimum detergent:protein weight ratio of roughly 1:2 [25, 29, 30].  The remaining 
intact viral cores comprising of lipids, RNA and all other internal (non-glycoprotein) viral 
proteins (Figure 5.5) could be readily separated from the solubilised antigens via traditional 
separation techniques such as sucrose gradient centrifugation, sedimentation or 
ultracentrifugation due to differences in size and/or density [29, 30]. HA and NA recoveries 
over 80% [25] were achieved with this method as quantified by haemagglutination and a fetuin-
based ELISA (thiobarbituric acid assay) [31] respectively. It is emphasised that the WHO-
approved gold standard potency assay of SRID that measures only the antigenic (functional) 
forms of HA did not replace agglutination tests until 1978 [32], i.e. after the Bachmayer 
publication and patent filings. Addition of lower concentrations of CTAB 
(detergent:protein<1:5) led to incomplete solubilisation of HA and NA whereas disruption of 
the viral cores occurred when higher detergent concentrations were used 
(detergent:protein>1:1) [25, 29, 30].   
 
Figure 5.5: TEM images of left: untreated influenza virus and right: viral cores (subviral particles) 
 after CTAB treatment [25]. 
 
In the Agrippal process, the optimum concentration of CTAB required for the isolation of HA 
and NA from the whole virus is established for different strains through an analytical, small 
scale “Split Test”. The “Split Test” is performed for each new virus strain according to a step 
wise approach. In the case of manufacturing of a new strain, protein recovery, antigenic potency 
(HA and NA) and purity at a range of CTAB splitting concentrations are evaluated. Once the 
best conditions are selected they are confirmed in three consecutive production batches. In 
subsequent lots, CTAB concentration is calculated only on the basis of total protein content. A 
more detailed description of the “Split Test” is provided in Appendix 5.1. A second detergent, 
the non-ionic detergent Tween 80 (Polysorbate 80) is also added prior to CTAB addition at 
129 
 
standard concentrations for H1N1, H3N2 and B viruses primarily to prevent aggregation of the 
antigens of interest. In general, Tween 80 (CMC= 0.012 mM [12]) is widely used in 
biomanufacturing to protect proteins from surface-induced damage and as an inhibitor of 
aggregation both during production processes as well as in final product formulation [33, 34]. 
Protein stabilisation by Tween 80 is achieved through several possible mechanisms [35] 
including competition with protein molecules for adsorption sites on surfaces [36], binding to 
the hydrophobic regions of the protein surface and thus minimising intermolecular interactions 
[37, 38] and by facilitating protein refolding over aggregation through transient binding to 
partially folded protein [39]. In the Agrippal manufacturing process, CTAB treatment is 
typically conducted for 2 hours at 2-8oC. The soluble surface antigens are subsequently 
separated from the viral core proteins through continuous flow ultracentrifugation. The 
resulting supernatant containing the antigens is collected and CTAB is removed by adsorption 
to polystyrene resins leading to formation of rosettes (subunits) of HA and NA. Solubilisation 
efficiency is determined by HA activity (SRID), NA presence and specific purity (SDS-PAGE). 
A schematic diagram of the solubilisation with CTAB is given in Figure 5.6. Further details on 
the experimental conditions of the solubilisation procedure are provided in Materials and 
Methods. 
In engineering batches generated during the technical transfer of Agrippal in 2010, significant 
levels of HA were detected in re-suspended centrifugation pellet samples indicating that 
solubilisation conditions might be sub-optimal despite the determination of the optimal CTAB 
concentration by an analytical “Split Test”. 
 
Figure 5.6: Theoretical scheme of CTAB solubilisation in Agrippal. 
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5.1.4 Aims and Objectives 
The work presented herein investigated the complex multi-variable and inadequately 
characterised solubilisation process of the HA and NA glycoproteins from the influenza virus 
membrane via CTAB for generation of subunit vaccines.   
In the first stage of this project, factors and conditions (CTAB and Tween 80 concentration, 
ionic strength, solubilisation duration and temperature) considered key for achieving high HA 
recovery and specific purity were screened following a DoE approach using B/Hubei-
Wujiagang/158/2009 (BX-39) as a model virus. 
Based on the findings of the preliminary screening experiments, the next stage assessed the 
impact of various detergent-to-protein ratios on solubilisation efficiency and aggregation 
formation/composition. DCS was uniquely utilised for the at-line monitoring of solubilisation 
processes.   
Additionally, the solubilisation of HA and NA proteins from the surface of formalin inactivated 
influenza virus with various detergents (NP9, DOC, C12E8) was examined with the aim of 
improving HA yields and obtaining an understanding of the influence of formalin on the 
effectiveness of solubilisation procedures.  
The last phase of this project explored an apparent proteolysis phenomenon observed in post-
solubilised CTAB preparations.   
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5.2 MATERIALS AND METHODS  
5.2.1 Viral Stock Preparations  
Formaldehyde-inactivated whole virus concentrate post clarifying filtration was obtained from 
either the full scale Agrippal manufacturing line or pilot scale runs.   
 
5.2.2 Antigen Solubilisation with CTAB  
Small scale typical solubilisation experiments were conducted according to NV pilot plant run 
descriptions and/or internal manufacturing SOPs. The sequence of operations involves the 
following:   
 Initial Tween 80 addition: A strain specific volume of 0.6% v/v (6420 μg/ml) Tween 80 
solution (outsourced media) was added to the whole virus concentrate. Specifically, for 
H1N1, H3N2 and B viruses Tween 80 was added at a volume ratio of 75, 47 and 38 
ml/L respectively. The mixture was agitated with a magnetic stirrer at approximately 
125-150 rpm for 1 hour±5 minutes at 2-8°C.   
 PBS and secondary Tween 80 addition: The Tween 80 containing virus preparation was 
diluted with PBS, pH 7.3 to a protein concentration of 2000 μg/ml (concentration used 
in the “Split Test”) when necessary. A second addition of 0.6 % v/v Tween 80 was 
performed to a final volume ratio of 94 (H1N1 and B strains) or 75 (H3N2) ml per L of 
product. The solution was agitated with a magnetic stirrer at approximately 125-150 
rpm for 1 hour±5 minutes at 2-8°C.  
 CTAB solubilisation: Solubilisation was performed with addition of 1% w/v CTAB 
solution (outsourced media) to a final concentration determined by the “Split Test” for 
each strain examined. Table 5.2 summarises the final detergent concentrations and 
CTAB-to-protein ratios used for each viral stain. Solubilisation was performed at 
approximately 125-150 rpm for 2 hours±10 minutes at 2-8oC. 
 
Table 5.2: Current solubilisation parameters. 
Strain CTAB/Protein* CTAB** (μg/ml) Tween 80 (μg/ml) 
B/Massachusetts/02/2012 1:2.64 758 376 
B/Hubei Wujiagang/158/2009 
(NYMC BX-39) 
1:2.56 782 376 
B/Brisbane/60/2008 1:3.09 647 376 
A/California/07/2009 (H1N1) 1:2 1000 376 
A/Texas/50/2012 (H3N2) 1:1.17 1709 300 
* CTAB/Protein weight ratio as determined by the “Split Test”. 
**Concentration assuming a protein content of 2000 μg/ml. 
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 Ultracentrifugation: The residual subviral particles were removed via 
ultracentrifugation at 89,712 g for 13 minutes and the resulting subunit supernatant was 
collected.  
 Removal of CTAB: Polysterene resin Amberlite XAD-4 (Sigma #XAD4) suspended in 
PBS, pH 7.3 (20% w/v) was added at a volume equivalent to 25% of the supernatant 
volume to absorb residual CTAB molecules. The supernatant pool was then gently 
stirred overnight for 16-24 hours at room temperature. After the Amberlite was allowed 
to settle for 15-30 minutes, the supernatant suspension was collected.   
Supernatants were typically analysed for HA activity by SRID, total protein content by BCA 
and protein composition by SDS-PAGE. Real-time monitoring of solubilisation processes and 
characterisation of particle size distributions was performed via DCS. 
 
5.2.3 Screening Experiment for Identification of Critical Factors    
5.2.3.1 Study Design 
The objective of this preliminary study was to obtain an improved understanding of critical 
parameters and conditions affecting the efficiency of the solubilisation process. Factors 
considered key for achieving high HA recovery and specific purity were screened through a 
small scale DoE. These included:  
 CTAB concentration: As described previously optimum CTAB concentrations to be 
used in vaccine manufacturing are routinely determined through the “Split Test” for 
each viral strain (Appendix 5.1). A CTAB concentration that strikes an intricate balance 
between three aspects, i.e. maximum yet functional and selective solubilisation of 
membrane proteins, is regarded as optimum.  
 Tween 80 concentration: Tween 80 is added at specific concentrations for each viral 
subtype and is not typically altered and/or optimised. The effects of Tween 80 in a mixed 
detergent system with CTAB in presence of biological membranes have not been 
characterised. 
 NaCl concentration (ionic strength): Ionic strength or buffer composition modifications 
are not examined in the “Split Test”. Nonetheless, ionic strength has been found to be 
an important parameter in the FCC splitting process and is therefore regularly optimised 
for production. Moreover, increase of ionic strength achieved by addition of NaCI or 
KCl has shown to improve the solubilisation efficiency of ionic surfactants by 
drastically altering their properties [10, 12]. Specifically, the CMC of charged 
detergents generally decreases with increasing salt concentrations due to reduced 
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repulsions between charged headgroups induced by the higher amount of counter ions 
present [6, 8, 10]. This consequently leads to formation of micelles and solubilisation at 
lower detergent concentrations [8].  
 Contact time with CTAB or solubilisation duration: Mixing with CTAB is normally 
performed for 2 hours. Insufficient reaction time with CTAB would result in incomplete 
isolation of surface antigens whereas prolonged exposure to CTAB could cause protein 
denaturation. 
 Solubilisation temperature: Solubilisation is typically conducted at 5±3 oC to maintain 
product stability. Temperature changes can affect detergent CMC, solubility or micelle 
size [12]. The temperature impact on CMC is more pronounced in non-ionic detergents 
while the CMC of ionic detergents remains relatively unaffected. [6]. 
In this study, a half fraction 25 central composite design (CCD) with 26 runs and 7 replications 
of the centre points were used to determine the optimal CTAB, Tween 80 and NaCl 
concentrations, solubilisation time and temperature on HA yield and specific purity. CCD is one 
type of response surface methodology (RSM) statistical approaches [40] which allows 
estimation of polynomial regression between independent variables and dependent variables 
[41]. RSM is considered ideal when dealing with multifactor experiments as it enables 
determination of the influences of individual parameters as well as their interactive influences 
with a minimum number of experiments [42, 43].  
Figure 5.7 shows a graphical depiction of the design. The coded and respective actual values are 
given in Table 5.3. The corresponding central composite experimental design is shown in 
Appendix 5.2a.  
 
 
 
 
 
 
 
 
Figure 5.7: Illustration of the central composite design  
(only 3 out of the 5 dimensions are shown). 
 
X1 
X2 
X3 
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Experiments were repeated seven times at the central point to provide an estimate of pure error 
and run-to-run variation, whereas the remaining experiments were performed without replicates. 
Current solubilisation conditions are more closely represented by the central point shown in 
yellow in Table 5.3 with the exception of salt addition. Concentrations of NaCl to add were 
chosen based on previous NV reports by FCC manufacturing sites.  
 
Table 5.3: Coded and actual values of experimental variables used in the central composite experimental design. 
Factor Symbol 
Coded factor level 
-2 -1 0 1 2 
CTAB 
(µg/ml) 
X1 625.6 703.8 782 860.2 938.4 
Tween 80 
(ml/L or  
μg/ml**) 
X2 
56 or 
224 
 
75 or 
300 
 
94 or 
376 
 
113 or 
452 
 
131or 
524 
Contact Time  
(h) 
X3 0 1 2 3 4 
NaCl* 
(g/L) 
X4 1.461 2.922 4.383 5.844 7.305 
Temperature 
 (oC) 
X5 2 4 6 8 10 
* Additional NaCl: amount added over and above the standard PBS concentration 
**Tween 80 concentration after addition of all media 
 
A mathematical model with a second-order polynomial regression was developed to describe 
the relationships between the predicted response variables (HA or specific purity) and the 
independent variables (CTAB, Tween 80, NaCl, contact time, temperature). The generalised 
regression equation was described as follows: 
  
  
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5
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jiijiiiii xxxxy   
where y is the predicted response variables (HA or specific purity); β0 is a constant, βi is the 
linear coefficient, βii is the quadratic coefficients, βij is the interaction coefficients of the model, 
respectively; xi and xj (i = 1, 5; j=1, 5; i≠j) represent the non-coded independent variables (CTAB 
concentration, Tween 80 concentration, NaCl concentration, CTAB contact time, temperature).  
Whole virus concentrate of B/Hubei-Wujiagang/158/2009 (BX-39) from the production process 
was used for this investigation. Each splitting experiment contained a total volume of 15 ml. 
The protein concentration for all experiments was adjusted to 2000 μg/ml as per standard 
procedure (5.2.2). The required amounts of NaCl solution, Tween 80, and CTAB were added 
according to the study design (Appendix 5.2a). After addition of all the components volumes 
were made up with PBS to obtain a total volume of 15 ml. Solubilisation was performed at the 
Eq.11 
135 
 
defined temperature for the defined time. After the splitting, each 10 ml solution was subjected 
to centrifugation at 89,712 g for 13 minutes with a SW 60 Ti rotor. CTAB and Amberlite 
removal was conducted as detailed in 5.2.2. 
 
5.2.3.2 Analytical Methods 
The resulting supernatant samples following Amberlite removal were analysed for total protein 
concentration by the TN analyser and HA activity by SRID. Specific purity was determined by 
SDS-PAGE or it was expressed as the ratio of HA (SRID)/Total Protein (TN). 
 
5.2.3.3 Statistical Methods 
For all response variables, an analysis of variance (ANOVA) according to a quadratic 
polynomial with two factor interactions was performed. Within the full model, all model 
coefficients outside the 5% significance level were eliminated. This was achieved by following 
a step-wise or backward algorithm for including and excluding model terms one by one. A 
model parameter is not significant to the 5% level of significance if P-value>0.05 for this 
parameter. After model estimation the model residuals were graphically checked for normality 
and for the assumption of constant variance. All evaluations were performed with Minitab 
(version 16).  
 
5.2.4 Fluorescent Labelling of Influenza Virus  
The lipid membrane of influenza viruses was specifically labelled with the red fluorescent 
lipophilic carbocyanine dye DiD (Figure 5.8a). DiD, which has a maximum fluorescence 
absorption and emission at 644 nm and 665 nm respectively, is weakly fluorescent in aqueous 
solutions and highly fluorescent once incorporated into lipid bilayers [44].  
 
 
 
Figure 5.8: Structures of fluorescent labels a) DiD and b) Alexa Fluor® 546 carboxylic acid, succinimidyl (NHS) ester.  
 
a b 
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A/Texas/50/2012 (H3N2), B/Massachusetts/02/2012 and B/Brisbane/60/2008) viral particles 
after clarifying filtration were incubated with 5 µM DiD (1 mM solution in EtOH, Life 
Technologies #V-22887) at room temperature for 2 hours [45, 46]. Unbound DiD molecules 
were removed by a PD-10 desalting column (GE Healthcare #17-0851-01) following 
manufacturer’s instructions. 
The surface antigens of the DiD-labelled A/Texas/50/2012 viruses were subsequently labelled 
with the amine reactive dye Alexa Fluor® 546 (Life Technologies #A-10237). Alexa Fluor dyes 
generally lead to more bright, photostable dye-protein conjugates and are less pH-sensitive than 
commonly used dyes like fluorescein and rhodamine [47]. In non-enveloped viruses, e.g. 
adenoviruses [48], capsids can also be labelled with Alexa Fluor dyes whereas in enveloped 
viruses surface proteins are selectively labelled [49]. In particular, the Alexa Fluor® 546 dye 
(Figure 4.8b) contains a succinimidyl ester group that binds covalently mainly to the primary 
amines (R-NH2) of proteins or nucleic acids [50]. The resulting Alexa Fluor® 546-protein 
complexes have an approximate maximum excitation of 554 nm and emission of 570 nm. To 
label A/Texas/50/2012 influenza virus particles, 200 µl of 1 M sodium bicarbonate buffer, pH 
8.3, was added to 2 ml of purified virus concentration and mixed.  This buffer was used to raise 
the pH of the solution and consequently maximise labelling efficiency as binding of NHS esters 
is optimum at pH 7.5–8.5 [51]. The mixture was then incubated with the Alexa Fluor 546 dye 
in the dark for 1.5 hours at room temperature. Unbound dye was removed as mentioned 
previously through PD-10 desalting columns (GE Healthcare #17-0851-01).  
Fluorescence measurements were conducted on a Spectra max Gemini XS (Molecular Devices, 
California) plate reader. Determination of protein content on the collected fractions after 
removal of unbound dye(s) was performed via the BCA assay.    
 
5.2.5 Antigen Solubilisation at Various Detergent Ratios: Impact on Aggregation and 
Antigen Yields 
5.2.5.1 Variation of CTAB/Protein Ratio  
0.6 ml of the dually-labelled A/Texas/50/2012 viruses (5.2.4) with a protein concentration of 
1646 µg/ml (BCA assay) were disrupted at three different CTAB-to-protein weight ratios: 1/2 
(823 µg/ml CTAB) 1/1.17 (concentration of 1407 µg/ml CTAB routinely used in production) 
and 1/0.67 (2457 µg/ml CTAB). Tween 80 was added at the standard final concentration of 300 
µg/ml and all other solubilisation conditions were kept constant as in 5.2.2. Following 
solubilisation, 0.8 ml of each preparation was fractionated through a continuous sucrose 
gradient (5.2.7). 
 
137 
 
5.2.5.2 Variation of Tween 80/Protein Ratio  
The viral membrane of 0.8 ml of DiD-labelled B/Massachusetts/02/2012 (5.2.4) with a protein 
content of 2000 µg/ml (BCA assay) was disrupted at three different Tween 80-to-protein ratios 
as calculated after CTAB addition: 1/10.64, 1/5.32 (current) and 1/4.24. CTAB was added at 
the typical concentration of 760 µg/ml and all other solubilisation conditions were kept constant 
as in 5.2.2. Following solubilisation, 1 ml of each preparation was fractionated through a 
continuous sucrose gradient (5.2.7).  
Furthermore, the solubilisation rate of A/California/07/2009 (H1N1) was monitored over time 
with DCS at increasing levels of Tween 80. Specifically, stocks of 0.6, 1, 2, 3 and 6 % v/v 
Tween 80 in PBS, pH 7.3 were utilised and solubilisation was conducted at 376 (current), 627, 
1253, 1880 and 3760 µg/ml respectively. 
 
5.2.5.3 Variation of CTAB/Protein Ratio and Addition of Tween 80 Post-centrifugation  
Finally, in order to further characterise the effect of CTAB concentration on HA yield and to 
assess potential benefits of Tween 80 on product quality, five additional solubilisation 
experiments were executed using B/Brisbane/60/2008 whole virus concentrate (Figure 5.9).  
 
 
Figure 5.9: Study design.  
 
Whole virus suspension (30 ml) of a protein content of 2000 μg/ml (TN analyser) was 
solubilised at 3 different CTAB/Protein ratios, namely 1/4.46, 1/3.57 (current) and 1:2.98. 
Tween 80 was added at the typical concentration of 376 μg/ml and solubilisation, centrifugation 
and CTAB removal was normally performed (5.2.2). Two further conditions were examined in 
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which reaction with CTAB occurred at the standard CTAB/Protein ratio of 1/3.57 followed by 
addition of 500 and 2500 μg/ml of Tween 80 post-centrifugation. Supernatants of all five-
examined solubilisation were analysed for HA activity (SRID), total protein content (BCA) and 
protein composition by SDS-PAGE. 
 
5.2.6 Antigen Solubilisation with Alternative Detergents  
5.2.6.1 Nonoxynol 9 (NP9 or Triton-N101) 
Solubilisation of membrane antigens from the surface of formaldehyde inactivated virus with 
the non-ionic detergent NP9 (Figure 5.10) was explored. NP9 has been efficiently employed 
for decades in the manufacture of the NV BPL-inactivated subunit vaccine Fluvirin. Viral 
splitting with NP9 in Fluvirin is typically performed by centrifugation of influenza virus 
through a sucrose gradient that contains 0.2 % v/v NP9 for approximately 10 minutes. Three 
experiments involving NP9 are briefly described here:  
1) Solubilisation of low protein formaldehyde inactivated virus with NP9: 47.7 ml of 
B/Massachusetts/02/2012 whole virus concentrate of a protein content of 2284.7 µg/ml 
(TN analyser) were mixed with 0.2% v/v NP9 at room temperature for 4 hours. 
Separation of the solubilised antigens via ultracentrifugation and subsequent removal of 
NP9 from the supernatant was achieved similarly to standard CTAB solubilisation 
procedures (5.2.2), i.e. via adsorption to Amberlite beads.   
2) Solubilisation of high protein formaldehyde inactivated virus with NP9: 40 ml of 
A/Texas/50/2012 (H3N2) whole virus filtrate of a protein content of 5306.3 µg/ml (TN 
analyser) were initially mixed with 0.2% v/v NP9 for 2 hours at room temperature. 
Further processing was conducted as described above.   
3) Comparison of NP9 solubilisation efficiency in BPL and formalin inactivated viruses: 
6 ml of formalin inactivated B/Brisbane/60/2008 (protein content of 384 µg/ml) and 
BPL inactivated B/Brisbane/9/2014 (protein content of 504.1 µg/ml) were incubated 
with 0.2% v/v NP9 for 10 minutes at room temperature under gentle stirring. 5 ml of 
each splitting preparation was subsequently subjected to sucrose gradient centrifugation 
as detailed in 5.2.7.  
 
 
Figure 5.10: NP9 structure.  
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Reactions with NP9 were monitored at-line via DCS. The supernatants after NP9 removal of 
experiments 1 and 2 were further analysed for total protein concentration (BCA), DCS and 
protein composition (SDS-PAGE). 
 
5.2.6.2 Sodium Deoxycholate (DOC) 
Solubilisation of influenza antigens from the surface of formalin inactivated virus with the 
anionic bile salt DOC (Figure 5.3), that is commonly used for generation of split virus vaccines, 
was attempted. 3 ml of post clarifying diafiltered whole virus suspension of B/Brisbane/60/2008 
of a protein concentration of 2000 µg/ml was disrupted with 60 μl of 10% w/v DOC (Sigma 
#D6750) in PBS, pH 7.3 to the experimentally determined optimum concentration of 0.2% w/v 
DOC under gentle stirring conditions at room temperature. The reaction was allowed to take 
place for 15, 30 and 45 minutes. The mixture was then centrifuged at 90,220 g for 30 minutes 
to remove internal viral proteins and/or viral cores. Centrifugation speed was calculated and 
optimised (data not shown) based on sedimentation coefficients of viral components reported 
in [52]. The supernatant was dialysed to remove DOC against PBS, pH 7.3 for 24 hours at 2-
8°C through dialysis cassettes Slide-A-Lyzer (Thermo scientific #66381) with a molecular 
weight cut off of 10 kDa. The experimental procedure is schematically shown in a flow diagram 
in Figure 5.11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11: Solubilisation of B/Brisbane/60/2008 with DOC.  
 
DCS analysis of all three samples was performed prior to centrifugation. The supernatants after 
dialysis were further characterised for total protein content by BCA, HA activity by SRID and 
protein composition by SDS-PAGE. 
 
Whole Virus 
(2000 µg/ml) 
Addition of  
0.2% w/v DOC  
Mixing for 30 min at 
room temperature 
Mixing for 45 min at 
room temperature 
Mixing for 15 min at 
room temperature 
Centrifugation at 
90k g for 30 min  
Removal of DOC 
by dialysis 
Analysis of 
supernatant 
140 
 
5.2.6.3 Octaethylene Glycol Monododecyl Ether (C12E8) 
Reconstitution of the influenza virus envelope with the non-ionic detergent C12E8 (Figure 
5.12) was also examined. Solubilisation was carried out at a detergent-to-protein weight ratio 
of approximately 13:1 or detergent-to-lipid ratio of 46:1 [53, 54]. DiD-labelled Influenza 
viruses (5 ml) of B/Brisbane/60/2008 (5.2.4) diluted to a protein content of 2000 µg/ml were 
solubilised with 0.6 ml of 464 mM C12E8 (Sigma #74680) for 30 minutes at 2-8 oC whilst 
stirring. 5 ml of this mixture were then loaded onto a continuous sucrose gradient (5.2.7).   
 
 
Figure 5.12: C12E8 structure (CMC=0.08 mM). 
 
5.2.7 Sucrose Gradient Centrifugation  
Fractionation of virus preparations after detergent treatment was achieved through continuous-
step density gradient centrifugation (5-60% w/w). This allowed biophysical separation of 
components based on size and/or density, viz. denser/larger complexes (e.g. viral cores and 
aggregates) sedimented faster to denser layers of the gradient while less dense solubilised 
proteins, lipids and detergent micelles remained on the top of the gradient (Figure 5.13). 
Composition and physical features of the sucrose gradients utilised are provided in Appendix 
5.3. 
 
Figure 5.13: Fractionation of detergent treated viral solutions. 
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Ultracentrifugation, fraction collection and further analysis were performed as follows:  
 Variation of CTAB/Protein and Tween 80/Protein ratios (5.2.5.1, 5.2.5.2): 
Centrifugation was performed at 89,712 g for 13 minutes. Fractions of approximately 1 
g were collected. CTAB was removed from the upper fractions (<5% w/w) by 
adsorption to Amberlite resins. All fractions were subsequently tested for protein 
concentration (BCA), protein composition (SDS-PAGE) and fluorescence intensity. 
Selected fractions of protein content>100 μg/ml were analysed for HA activity (SRID) 
and particle size distribution (DCS).     
 Comparison of NP9 solubilisation efficiency in BPL and formalin inactivated viruses 
(5.2.6.1): Centrifugation occurred at 112,500g for 30 minutes. Fractions of 
approximately 1.5 g were collected. NP9 was removed from the upper fractions (<5% 
w/w) by adsorption to Amberlite resins. All fractions were then tested for protein 
concentration (BCA) and protein composition (SDS-PAGE). DCS analysis was 
performed on selected fractions of protein content>60 μg/ml. 
 Purification of C12E8 generated virosome preparation (5.2.6.3): Centrifugation was 
executed at 112,500 g for 30 minutes.  Fractions of approximately 1.5 g were collected. 
C12E8 was removed from the upper fractions (≤5% w/w) by adsorption to Amberlite 
resins. All fractions were subsequently analysed for protein concentration (BCA), 
protein composition (SDS-PAGE) and fluorescence intensity of the DiD bound lipids. 
Selected fractions of protein content>100 μg/ml were analysed via DCS. Determination 
of HA activity (SRID) was performed only on the less dense fractions (≤ 5% w/w). 
 
5.2.8 Impact of Protease Inhibitors and Characterisation of Protease Activity 
The purpose of this study was to investigate the apparent proteolysis phenomenon observed in 
preliminary solubilisation experiments in the presence of a mixture of six different protease 
inhibitors (Protease Arrest, GBiosciences #786-437). In order to establish the specific protease 
type, the six individual components of the inhibitors mixture along with the metalloprotease 
inhibitor EDTA were added to diafiltered whole virus material of B/Massachusetts/2/2012 (30 
ml, 3828 µg/ml protein) sampled from vaccine production lines. Table 5.4 outlines the 
inhibitors examined and the respective amounts used. All inhibitors were introduced prior to 
the addition of CTAB. Three controlled experiments were executed: typical solubilisation in 
absence of inhibitors (positive control), solubilisation with the cocktail of inhibitors (negative 
control) and solubilisation with MeOH/AcOH (9:1) to evaluate the possible effect of the 
pepstatin diluent (pepstatin control). As the experiments were performed in three days, three 
positive and negative controls were utilised. 
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Table 5.4: Protease inhibitor details. 
Inhibitor 
Protease 
Target 
Inhibition 
Type 
Stock 
Concentration 
(Diluent) 
Working 
Concentration 
 
Supplier 
(Product Code) 
AEBSF Serine  Irreversible 
100 mg/ml 
(PBS, pH 7.3) 
1 mg/ml 
AMRESCO 
(#30827-99-7) 
Aprotinin Serine  Reversible 
200 µg/ml 
(PBS, pH 7.3) 
2 µg/ml 
AMRESCO 
(#9087-70-1) 
Bestatin 
Amino-
peptidase 
Reversible 
5000 µg/ml 
(MeOH/) 
50 µg/ml 
AMRESCO 
(#58970-76-6) 
E-64 Cysteine  Irreversible 
100 µM 
(PBS, pH 7.3) 
1 µM 
AMRESCO 
(#66701-25-5) 
Leupeptin 
Serine and 
cysteine  
Reversible 
500 µg/ml 
(PBS, pH 7.3) 
5 µM 
AMRESCO 
(#103476-89-7) 
Pepstatin Aspartic acid  Reversible 
100 µM 
(MeOH/AcOH) 
1µM 
AMRESCO 
(#26305-03-3) 
EDTA Metalloprotease Irreversible 
500 µm  
(H2O) 
5 µM 
GBiosciences 
(#786-437) 
 
The resulting monobulk solutions were analysed for protein concentration (BCA), protein 
composition (SDS-PAGE), HA activity (SRID) and protease presence (zymography, H-RBBR 
proteinase assay). 
 
5.2.9 Analytical Methods 
5.2.9.1 Protein Concentration  
5.2.9.1.1 Bicinchoninic Acid (BCA) 
The bicinchoninic acid (BCA) protein method, developed by Smith et al. [55], is based on a 
two-step chemical reaction (Figure 5.14) involving reduction of Cu2+ to Cu1+ by protein in an 
alkaline medium (the Biuret reaction) followed by chelation of the monovalent cuprous ions 
with two molecules of BCA [55-57].  
 
Protein  +  Cu2+                                            Cu1+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14: BCA reaction. 
OH- 
2xBCA 
Cu1+ 
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The resulting purple BCA-copper complex has an absorbance maximum at 560-565 nm [55-
57]. The BCA assay is sensitive to amino acid composition, and thus a protein standard with 
similar protein composition to the protein of interest is recommended [56]. This method is 
compatible with non-ionic detergents including the Tween series which interfere with 
Coomassie dye assays like the Bio-Rad (Bradford) assay [17].  
Determination of protein concentration with the BCA assay was performed according to NV 
internal SOP using the Pierce BCA protein assay kit (Thermo Scientific #23225). A solution of 
1 mg/ml BSA in 0.15 M NaCl was used as a protein standard (Sigma # P0914). Dilutions of 
that solution were made with PBS, pH 7.7 to cover a range of concentrations (50-1000 μg/ml). 
All standard aliquots were assayed in duplicate while influenza vaccine samples were tested in 
duplicate at two dilutions. 25 µl of each standard and sample solution were aliquoted into 
separate wells of a 96 well flat-bottomed microplate. PBS, pH 7.7 was used as a blank (25 
µl/well). BCA dye was dispensed with a multichannel pipette to every well containing a blank, 
standard or sample (200 µl/well). The plates were incubated at room temperature for 1 hour or 
at 37oC for 30 minutes. The absorbance was measured at 562 nm in a microplate reader 
(Molecular Devices VersaMax).  
 
5.2.9.1.2 Total Nitrogen (TN) Analyser   
TN analysers employ catalytic oxidative pyrolysis and chemiluminescence for quantification 
of total nitrogen content of solid or liquid samples. Samples are combusted into a tube packed 
with an oxidative catalyst in an oxygen atmosphere. Oxidation at high temperature (800–900 
°C) results in conversion of chemically bound nitrogen into nitric oxide (R-N        CO2 + NO). 
The nitric oxide formed is led through a drier that removes the water generated during 
combustion and then passes to a chemiluminescence detector where it reacts with ozone thus 
forming excited nitrogen dioxide (NO + O3                  NO2
* + O2). NO2 rapidly decays whilst 
generating radiation in the 590-2900 nm range (NO2
*         O2 + hv) which is detected and 
amplified by a photomultiplier tube. The total nitrogen content is estimated by the produced 
signal and is expressed as µg/ml [58]. A conversion factor of 6.25 is applied for calculation of 
protein concentration assuming that proteins are the main N-containing constituents of the 
sample. 
TN analysis was performed using the automated system Mitsubishi TN-100 (Cosa Instrument 
Corporation, US) according to NV internal SOP (not detailed here) predominantly for 
determination of protein concentration of whole virus post clarifying filtration prior to 
solubilisation.  
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5.2.9.2 HA Activity (SRID) 
HA activity in all influenza vaccine formulations was measured via the SRID assay as described 
in Chapter 4 (4.2.5).  
 
5.2.9.3 Specific Purity (PAGE) 
SDS-PAGE was used to fractionate and visualize the different types of viral proteins present in 
whole virus and post-splitting material. Electrophoretic analysis was performed under reducing 
(Chapter 3, 3.2.5) and/or non-reducing conditions. For non-reducing SDS-PAGE, no boiling or 
addition of reducing agents (DTT) occurred.  
 
5.2.9.4 DCS Measurements 
DCS was utilised for monitoring of solubilisation reactions. Measurements were conducted as 
detailed previously for virus quantification (Chapter 3, 3.2.2) using a 4-12% w/w sucrose 
gradient. A new gradient was created each time a sample containing CTAB was analysed as 
accumulation of CTAB inside the gradient was led to ongoing solubilisation of whole virus 
particles during the measurement time (data not shown).  
 
5.2.9.5 Protease Activity 
5.2.9.5.1 Gelatin Zymography 
Substrate or in-gel zymography is a widely used electrophoretic technique, based on SDS-
PAGE that involves a proteolytic substrate (e.g. gelatin, casein, fibrin, hyaluronan etc.) co-
polymerized with acrylamide in the separating gel [59, 60]. Following separation of proteins 
by molecular weight by denaturing but non-reducing electrophoresis, i.e. without heating and 
reducing agent, the gel is renatured by replacement of the SDS by a non-ionic detergent like 
Triton X-100 which allows the proteolytic enzymes to return to their native enzymatically 
active conformation [59-61]. The gel is subsequently incubated in an appropriate developing 
buffer containing divalent metal cations thus allowing the enzymes to degrade the embedded 
substrate [59, 60, 62]. Areas of proteolytic activity are visualised as clear bands against a dark 
blue background following staining with Coomassie Blue [59, 60]. 
Zymography was performed using 10% Tris-Glycine zymogram gels (Life Technologies 
#EC61752BOX) containing 0.1% w/v gelatin as the proteolytic substrate according to the 
manufacturer’s instructions [63]. In brief, one part of each protein sample was denatured with 
one part of (2x) Tris-Glycine SDS sample buffer (Life Technologies #LC2676) and was then 
loaded onto the gel without heating (15-20 µl). 15 μl of a pre-stained protein standard (Life 
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Technologies # LC5625) were also loaded. Electrophoresis was performed at 125 V at room 
temperature for approximately 90 minutes with (1x) Tris-Glycine SDS running buffer (Life 
Technologies #LC2675-4). After electrophoresis, the gel was incubated in (1x) renaturing 
buffer (Life Technologies # LC2670) that contained 2.5% v/v Triton X-100 for 30 minutes at 
room temperature with gentle agitation. The gel was then equilibrated with (1x) developing 
buffer (50 mM Tris, 200 mM NaCl, 5 mM CaCl2, pH 7.5, Life Technologies #LC2671) for 30 
minutes at room temperature. The developing buffer was renewed and the gel was further 
incubated at 37 0C overnight.  Visualisation of the protease bands was achieved after staining 
with colloidal blue (Life Technologies #LC6025) and destaining with distilled water. 
5.2.9.5.2 Hide–Remazol Brilliant Blue R (H-RBBR) Test 
Rapid determination of proteinase presence was performed through the qualitative H-RBBR or 
hide powder azure (Sigma #H6268) method [64]. H-RBBR is an insoluble proteolytic substrate 
composed of insoluble hide powder covalently conjugated to Remazol Brilliant Blue R dye 
[64].  In presence of protease enzymes, hide powder is enzymatically cleaved thus releasing the 
dye into solution. Approximately 0.5-1 ml of vaccine samples were incubated with H-RBBR at 
37 oC overnight. H-RBBR was added in each sample using tweezers.  Trypsin and PBS, pH 7.3 
were used as positive and negative controls respectively. Following incubation, samples were 
centrifuged and the colour changes of the supernatant were assessed visually.  
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5.3 RESULTS AND DISCUSSION 
5.3.1 Screening Experiment for Identification of Critical Factors    
5.3.1.1 HA Yield (SRID) 
5.3.1.1.1 Construction of the Regression Model  
Firstly, the experimental results were fitted to a full quadratic second order polynomial 
regression model containing 5 linear, 5 quadratic and 10 interaction terms. Run 26 was excluded 
from the analysis as the relatively high HA concentration measured by SRID resulted in 
extremely high specific purity value (SRD/TN>95%) which was not compatible with the 
respective SDS-PAGE result (≈66%). Additionally, the observation was characterised as 
unusual during the initial model fitting. It is noted that the assay CV of the centre runs (2, 3, 4, 
9, 11, 19 and 27) was 8.8%. 
The final improved response surface model containing only the most significant variables was 
developed by excluding the terms with P-values greater than the a-level (0.05) in a stepwise 
manner is presented in Tables 5.5 and 5.6. According to the P-value (P= 0.000< 0.05) the model 
predicting HA yield by SRID is significant, viz. at least one of the terms in the equation affects 
the mean response. Specifically, there are significant linear (P=0.001), interaction (P=0.000) 
and quadratic (P=0.004) effects.  The lack of fit was not significant (P=0.366) whereas the 
coefficient of multiple determination R2, was found to be 86%, which suggests that 86% of the 
total variation is explained by the model. The regression model for HA content (Y1) is expressed 
by Eq.12.  
 
Table 5.5: ANOVA in the regression model selected through variable selection for HA. 
Source DF Seq SS Adj SS Adj MS F P 
Regression 12 72384.8 72384.8 6032.1    9.66 0.000 
Linear 5 21521.0   21521.0   4305.4 6.90 0.001 
Square 1 6715.6 6715.6 6715.6 2.91 0.004 
Interaction 6 44148.3 44148.3 7358.0 11.79 0.000 
Residual Error 19 11860.6 11860.6 624.2 - - 
Lack-of-Fit 13 8869.4    8869.4    682.3 1.37 0.366 
Pure Error 6 2991.2    2991.2    498.5 - - 
Total 31 84245.4 - - - - 
S = 24.9848    PRESS = 39657.6 
R2 = 85.92%, R2(pred) = 52.93%, R2(adj) = 77.03% 
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Table 5.6: Estimated regression coefficients for uncoded values. 
Term 
Coefficient 
Estimate 
F P 
Intercept 21.2408 - 0.000 
X1-CTAB - 709.432 0.02 0.901 
X2-Tween 80 -650.761 20.21 0.000 
X3-Contact 
Time 
-242.595 10.19 0.005 
X4-NaCl 84.945 1.16 0.295 
X5-
Temperature 
171.275 2.91 0.105 
 
-14.99 10.76 0.004 
X1X2 9805.17 5.48 0.030 
X1X3 284.590 12.79 0.002 
X1X5 -131.736 10.96 0.004 
X2X3 1022.8 9.68 0.006 
X2X4 -863.657 14.73 0.001 
X2X5 -679.194 17.07 0.001 
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The linear effect of X2 (P=0.000) and the interaction effects of X2X4 and X2X5 (P=0.001) have 
the most significant effect on Y1 followed by the interaction effect of X1X3 (P=0.002), the 
quadratic effect of        and the interaction X1X5 (P= 0.004), the linear effect X3 (P=0.005), 
the interaction X2X3 (P=0.006) and finally the interaction X1X2 (P=0.03).  
Analysis of the residual plots (Appendix 5.2b) reveals the following: there is no evidence of 
nonnormality, skewness or outliers in both the normal plot and the histogram and the residuals 
seem randomly scattered around zero.  
 
5.3.1.1.2 Assessing Factor Effects with the Main Effects Plot 
The effect of each factor on the response was assessed graphically through the main effects plot 
(Figure 5.15). The main effects plot is constructed by plotting the response mean for each factor 
level. An effect is considered main when different levels of a factor influence the response 
differently. Figure 5.15b shows that Tween 80 exhibited the greatest main effect on HA content 
as increased concentrations of Tween 80 generally led to increase of HA values. The high impact 
of Tween on the efficiency of the solubilisation process has also been reported in previous 
optimisation studies for the FCC process documented in internal NV reports. As Tween 80 is a 
mild weak non-ionic detergent, it is considered unlikely that it directly induces selective 
solubilisation of HA and/or delipidation of influenza membranes.  Tween 80, which has a 
2
3X
2
3X
Eq.12 
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relatively low CMC (0.012 mM) [12], has only been reported to slowly solubilise fatty 
molecules and bilayer membranes such as soybean phosphatidylcholine [65] as well as the 
susceptible to solubilisation membrane protein sarcoplasmic reticulum Ca2+-ATPase [66]. 
Nonetheless, taking into account data obtained in subsequent experiments discussed in 5.3.3.2, 
the mechanism by which Tween 80 enhances HA recovery is probably not related to its 
solubilising properties but its ability to suppress aggregation and stabilise proteins. Furthermore, 
the effect of increasing concentrations of Tween 80 on the SRID assay (not assessed by NV) 
needs to be taken into consideration as high Tween 80 concentrations can potentially lead to 
reduced HA aggregation and therefore higher SRID readings. This was assessed in succeeding 
studies and is briefly described in 5.3.3.3.  
 
 
Figure 5.15: Main effects plot of CTAB (a), Tween 80 (b), contact time (c), NaCl (d) 
and temperature (e) on HA (SRID). 
 
Figure 5.15c suggests that contact time with CTAB also influences the response. For contact 
times>2 hours a decrease in the solubilised HA is observed thus indicating possible antigen 
denaturation due to prolonged contact with the detergent. Finally, the splitting temperature at 
the range examined has an apparent yet not significant impact on the response only at very high 
(2) or very low factor levels (-2). The CTAB and NaCl concentrations exert the least important 
effects (Figure 5.15a, 5.15d) as the response line becomes horizontal (parallel to the x-axis).  
 
5.3.1.2 Specific Purity (SRID/TN)  
5.3.1.2.1 Construction of the Regression Model  
In addition to the HA yield (SRID), specific purity expressed as HA (SRID)/Total Protein (TN) 
was also analysed. The significance and adequacy of the regression model were tested using 
ANOVA, in a similar manner to HA per SRID.  The final model obtained, detailed in Tables 
5.7 and 5.8, is significant (P=0.000), it contains only 10 explanatory variables but captured only 
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74.72% of data variability. The lack of fit is insignificant (P=0.310) indicating that the model 
fitting was appropriate and not due to noise. The improved regression model for specific purity 
(Y2) is described by Eq.13:  
52423231
2
5543212
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XXXXXXXX
XXXXXXY


 
 
Table 5.7: ANOVA in the regression model selected through variable selection for specific purity (SRID/TN). 
Source DF Seq SS Adj SS Adj MS F P 
Regression 10 2909.91   2909.91   290.991 6.21   0.000 
Linear 5 566.75    571.16 114.232    2.44   0.068 
Square 1 245.54    245.54    245.543 5.24   0.033   
Interaction 4 2097.62   2097.62   524.404   11.19   0.000 
Residual Error 21 984.56    984.56    46.884 - - 
Lack-of-Fit 15 781.57    781.57    52.105    1.54   0.310 
Pure Error 6 203.00    203.00    33.833 - - 
Total 31 3894.48 - - - - 
S = 6.84719    PRESS = 2572.76 
R2 = 74.72%  R2(pred) = 33.94%  R2(adj) = 62.68% 
 
The most significant interactions based on the P and F-values (Table 5.8) by decreasing order 
are: the interactions X2X4 (P=0.001, F=15.79), X1X3 (P=0.001, F=13.46), X2X5 (P=0.004), the 
linear effect of X2 (P=0.007) and the quadratic effect of 
2
5X  (P=0.033). 
 
Table 5.8: Estimated regression coefficients for uncoded values. 
Term 
Coefficient 
Estimate 
F P 
Intercept 26.7532 - 0.000 
X1-CTAB -152.070 0.16 0.689 
X2-Tween 80 1788.44 8.98 0.007 
X3-Contact 
Time 
-78.6943 2.82 0.108 
X4-NaCl 22.6043 0.20 0.656 
X5-
Temperature 
5.33132 0.01 0.944 
2
5X  0.716580 5.24 0.033 
X1X3 196.111 13.46 0.001 
X2X3 1022.8 4.74 0.041 
X2X4 -245.077 15.79 0.001 
X2X5 -147.665 10.75 0.004 
 
The residual plots (Appendix 5.2c) indicate that the residuals are normally distributed and there 
is no evidence of skewness or outliers. 
 
Eq.13 
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5.3.1.2.2 Assessing Factor Effects with the Main Effects Plot 
Overall, the main effects plot for specific purity (Figure 5.16) showed similar trends with the 
respective plot for HA (Figure 5.15). Tween 80 appeared to exert the most significant main 
effect (Figure 5.16b) whereas the contact time with CTAB (Figure 5.16c) and NaCl 
concentration (Figure 5.16d) also affected the output. In particular, a reduction of specific purity 
was noted when the ionic strength was increased above 4.4 g/l, potentially suggesting co-
solubilisation of viral internal components. The splitting temperature had an important impact 
only at very high (2) or very low factor levels (-2). High CTAB concentration (2) led to an 
apparent increase in specific purity. As no replication of this experiment was conducted, the 
significance of this point needs to be investigated further.   
 
Figure 5.16: Main effects plot of (a) CTAB, (b) Tween 80, (c) contact time, (d) NaCl and  
(e) temperature on specific purity (SRID/TN). 
 
5.3.1.3 Purity (SDS-PAGE)  
For specific purity as measured by reduced SDS-PAGE only poor model fits were obtained and 
thus are not presented here in length. Specifically, SDS-PAGE results showed broadly similar 
band intensities for HA bands (HA1 and HA2) for all experimental splitting runs. Despite the 
conduction of splitting under various conditions distinct differences between the protein 
composition patterns were not seen in the SDS-PAGE profiles. Similar levels of the NP band 
(63 kDa) were observed in all gels. Following exposure to CTAB, the M1 band was rapidly 
cleaved and was clearly detected only in run 26 which corresponds to 0 CTAB contact time. 
Low MW proteins were also seen which possibly correspond to cleaved fragments of NP and 
M1 proteins. Fitting of a regression model to the specific purity results (HA1+HA2 %) as 
derived by densitometry was not possible due to low data variability (CV=4.7 %, mean=71%). 
With the exemption of the DoE runs 15 and 26 which yielded considerably higher HA content 
in the SRID assay, all runs showed lower specific purity (SRID/TN) than the relative 
percentages of HA bands according to SDS-PAGE. This relationship was anticipated as the 
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SRID assay detects only the active HA whilst SDS-PAGE does not detect all total protein 
present. The interval plot of Figure 5.17 also demonstrates the limited range of the densitometry 
data compared to the SRID/TN ratio. Hence, it is deduced that application of different splitting 
conditions has a greater impact on antigen activity (denaturation or sensitivity of the relative 
assays) whereas the total amount of solubilized HA (active and inactive) appears to be to some 
extent independent. 
 
 
 
 
 
 
 
 
 
Figure 5.17: Interval plot of SDS-PAGE, SRID/TN. 
 
5.3.1.4 Total Protein (TN Analyser)  
Taking into consideration that both the HA content and the specific purity are SRID dependent, 
independent analysis of the total post-splitting protein content was performed. The final model 
that was obtained after selection of the statistically important variables (Tables 5.9, 5.10) has 
poor predictive ability and it accounts only for 64.62% of the observed variability. In contrast 
to the previously described models for HA (Tables 5.5, 5.6) and specific purity (Tables 5.7, 
5.8), the impact of the interaction terms appears to be limited. 
 
Table 5.9: ANOVA in the regression model selected through variable selection for total protein (TN). 
Source DF Seq SS Adj SS Adj MS F P 
Regression 8 28091.0 28091.0 3511.38 5.48 0.001 
Linear 5 15833.4 15833.4 3166.68 4.94 0.005 
Square 2 8660.6 8660.6 4330.32 6.76 0.033 
Interaction 1 3597.0 3597.0 3597.00 5.61 0.026 
Residual Error 24 15379.9 15379.9 640.83 - - 
Lack-of-Fit 18 12939.4 12939.4 718.86 1.77 0.248 
Pure Error 6 2440.5 2440.5 406.75 - - 
Total 32 43471.0 - - - - 
S = 25.3146    PRESS = 30706.9 
R2= 64.62%  R2(pred)= 29.36%  R2(adj)= 52.83% 
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Table 5.10: Estimated regression coefficients for uncoded values. 
Term 
Coefficient 
Estimate 
F P 
Intercept -1287.28 - 0.000 
X1-CTAB 3372.74 0.00 0.975 
X2-Tween 80 532.675 3.84 0.062 
X3-Contact 
Time 
60.6162 2.16 0.155 
X4-NaCl 82.3362 10.05 0.004 
X5-
Temperature 
5.33132 8.67 0.007 
2
1X  -1790.29 5.79 0.024 
2
3X  -13.2572 8.36 0.008 
X1X5 -95.5016 5.61 0.026 
 
From Table 5.10, the total amount of solubilised protein is affected by the linear effect of X4 
(P=0.004) and X5 (P=0.007), the quadratic effect of  
2
3
X  (P=0.008) and 
2
1
X  (P=0.026) and only 
the interaction X1X5 (P=0.026). 
The main effects plot for total protein content (Figure 5.18) is distinctly different to those 
constructed for HA (Figure 5.15) and specific purity (Figure 5.16). Specifically, NaCl 
concentration or increase of ionic strength, splitting temperature and solubilisation duration 
appear to have the greatest effect on the amount of solubilised protein obtained whereas the 
concentration of detergents is less important. The following observations can be made:   
 
o Increase of the ionic strength possibly promotes to some degree solubilisation of the 
viral core proteins. 
o Contact time has a considerably less significant impact on the overall protein 
concentration compared to HA content (Figure 5.15c). Significant increase in protein 
recovery is noted when contact time increases from 0 to 1 h.  
o Higher protein concentrations are achieved with increasing temperature. However, in 
contrast to HA potency, at the highest temperature (10 oC) the protein concentration 
decreases. 
o The protein content increases with CTAB concentration when CTAB< 782 μg/ml. 
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Figure 5.18: Main effects plot of (a) CTAB, (b) Tween 80, (c) contact time, (d) NaCl and (e) temperature  
on total protein (TN). 
 
5.3.1.5 Optimisation of Splitting Parameters  
The values of the five factors that were shown to affect the solubilisation efficiency were 
optimised through the genetic algorithm calculation using the Excel Solver. Assuming an initial 
pre-splitting protein concentration of 2000 µg/ml, both the specific purity (Eq.13) and the HA 
yield (Eq.12) were maximised at a splitting condition of approximately 861 μg/ml CTAB, 131 
ml/l Tween 80, 5 g/l NaCl, with a 3 h CTAB contact time at a splitting temperature of 2.5 oC.  
Predicted value at these settings is 487.6 ug/ml HA and maximum specific purity. Taking into 
consideration that HA accounts for approximately 25% of the viral protein, viz. 500 µg/ml, the 
result of the optimization is regarded as reasonable and satisfactory. The splitting conditions 
determined as optimum by the current “Split Test” for the splitting of B/Hubei-
Wujiagang/158/2009 were 783 μg/ml CTAB concentration 94 ml/l Tween 80 concentration, 
contact time 2 h, at a temperature range of 2-8 oC.  
 
5.3.1.6 Summary of Initial Findings  
The selective solubilisation of HA from influenza virus membranes through CTAB detergent 
treatment is a complicated multi-step and multi-variable process. Using B/Hubei-
Wujiagang/158/2009 (BX-39) as a model virus, the impact of CTAB concentration, Tween 80 
concentration, NaCl concentration, solubilisation time and temperature on HA yield and 
specific purity across splitting was evaluated through a 5-factor, 5-level half fraction factorial 
study. The post-split material total protein recovery was also considered as an output. The final 
model fit in terms of HA yield and specific purity (SRID/TN) were R2=85.92% and 74.72% 
respectively. According to the analysis of specific purity and HA yield, the recommendation 
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for optimum parameters for the CTAB splitting of the B/Hubei-Wujiagang strain are 
summarised below (Table 5.11). 
 
Table 5.11: Influence factors and optimum parameters determined from the screening DoE. 
Factor 
Current 
Setting 
Optimal 
setting 
Impact Comments 
CTAB 
concentration 
738 
µg/ml 
861 
µg/ml 
Small 
Weak influence on both responses. 
Optimal results for higher concentrations 
Tween 
concentration 
94  
ml/L 
131 
ml/L 
Large 
Strong influence on all responses. Improved 
HA yield and recovery with higher 
concentrations 
Contact time 2 h 3 h Large 
Strong influence on both responses. Best 
responses 
obtained for 2-3 h contact time 
NaCl 
concentration 
- 5 g/l Small 
Small influence on both responses. A small 
decrease in 
specific purity is observed at higher NaCl 
concentrations 
Temperature 2-8 oC 2.5 oC Medium 
Strong influence on both HA content and 
specific purity at 
low or high temperatures 
  
 
With the exception of CTAB concentration, none of the recommended conditions are currently 
considered during optimisation of the solubilisation conditions. Particularly, no additional NaCl 
is used during splitting. This preliminary investigative study demonstrated that an increased 
NaCl concentration in combination with higher Tween 80 could lead to improved HA recovery 
and specific purity at least as far as the BX-39 strain is concerned. However, it is recognised 
that altering the ionic strength would require the introduction of a downstream ultrafiltration 
stage to maintain isotonicity of the final product. 
Although CTAB concentration did not have a very significant impact within the examined 
range, for optimal conditions a concentration around 860 µg/ml would be preferred.  
Tween 80 concentration was shown to have the most significant influence on both HA purity 
and yield of the HA protein post-splitting. Since Tween 80 is a mild detergent with well-
established stabilising properties it is not expected to directly co-induce solubilisation of the 
surface antigens and/or delipidation of influenza membranes. The role of Tween 80 was 
investigated further throughout the experiments described in 5.3.3.2 and 5.3.3.3.  
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5.3.2 Real-Time Monitoring of Antigen Solubilisation with DCS 
The DCS analyser was successfully employed for at-line monitoring of the solubilisation 
process for various strain subtypes. In theory, an efficient solubilisation procedure is predicted 
to lead to complete disappearance of the viral peak in the respective PSD. Representative results 
for two strains over a standard 2 hour solubilisation procedure are presented in Figure 5.19. It 
is noted that the reaction time points correspond to the time the sample was injected for analysis. 
CTAB appears to rapidly solubilise whole virus particles as indicated by the reduction of peak 
height directly after its addition. Approximately 90% of the virus is solubilised in the first 15 
minutes. Simultaneously, large aggregates that are not fully separated from the non-solubilised 
viral particles are instantly formed and increase significantly in size between 0-1 hours.  As 
shown in Figure 5.19a, ultracentrifugation after CTAB treatment and subsequent analysis of 
the supernatant led to complete depletion of aggregates, thus potentially suggesting that the 
solubilised viral cores are removed (pelleted out) after clustering together.  
 
 
 
 
 
 
  
 
Figure 5.19: PSDs of a) B/Massachusetts/2/2012 and b) A/California/07/2009 (X-181) throughout 
a typical antigen solubilisation procedure. 
 
Conducting solubilisation of B/Massachusetts/2/2012 viruses over an extended period of 10 
hours revealed that the population or size of aggregates is not substantially altered after the first 
three hours of incubation with CTAB (Figure 5.20). Figure 5.20a compares the amount of non-
solubilised viruses expressed by the viral peak height with the integrated area of particles>130 
nm as derived from analysis of the PSDs using OriginPro 8.0. Although it is readily 
hypothesised that these aggregated complexes are primarily composed of core proteins (NP, 
M1, etc.) and their formation eases separation from solubilised material, it was deemed essential 
to confirm or characterise their composition to determine if significant antigen loses are 
observed at this stage due to potential entrapment of unsplit virus in the aggregated cores 
(5.33.1, 5.3.3.2). As also demonstrated in Figure 5.20a, after approximately 3 hours of contact 
time with CTAB, no additional solubilisation of virus occurred. However, a peak of constant 
height corresponding to 2% of the initial virus amount is detected (~96 nm) between 5-10 hours 
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which possibly indicates the existence of a smaller virus population resistant to solubilisation 
by CTAB (Figure 5.20b).  This phenomenon is analysed in 5.3.4.1.   
 
 
 
 
 
 
 
 
 
Figure 5.20: a) Aggregates>130 nm and viral peak height during 10 hours of 
solubilisation of B/Massachusetts/2/2012 and b) selected PSDs.  
  
5.3.3 Antigen Solubilisation at Various Detergent Ratios: Impact on Aggregation and 
Antigen Yields 
5.3.3.1 Variation of CTAB/Protein Ratio  
Isolation of aggregates and subsequent determination of their composition was achieved 
through fractionation of post-solubilised preparations via continuous-step density gradient 
centrifugation as detailed in 5.2.7. This step facilitated further analysis of the sucrose-
containing “pellet” fractions through bioassays which typically is challenging as full 
resuspension of the pellet in PBS solution is not possible due to strong hydrophobic associations 
between the viral core proteins. Furthermore, the impact of different CTAB-to-protein ratios on 
aggregate generation and antigen recoveries was evaluated. Solubilisation experiments were 
performed as described in 5.2.5.1 using A/Texas/50/2012 virus at three CTAB-to-protein ratios, 
namely 1/2, 1/1.17 (current) and 1/0.67. The lipid bilayer as well as the surface antigens were 
specifically labelled with fluorescent dyes (5.2.4) in order to allow fast tracking of different 
virion components after disruption. All fractions collected were analysed for total protein 
content by BCA (Figure 5.21), fluorescence intensity of the DiD (lipids) and Alexa Fluor 546 
(membrane proteins) dyes (Figures 5.22 and 5.23) and protein composition by reduced SDS-
PAGE. As depicted in Figures 5.21-5.23, BCA and fluorescence measurements showed similar 
patterns. At least two distinct populations were detected at all three ratios: a denser and/or of 
bigger size at 30-50% w/w sucrose and a less dense population on the top layers of the gradient 
(0-5% w/w sucrose). The former is expected to correspond to the viral-related aggregates 
whereas the latter is composed predominantly of solubilised proteins and lipids.   
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Figure 5.21: Protein content (BCA) in sucrose gradient (5-60% w/w) after solubilisation of A/Texas/50/2012 at 
CTAB:Protein of 1/1.17, 1/2, 1/0.67. 
 
Based on protein analysis by BCA (Figure 5.21) approximately 31% of the total viral protein 
was solubilised at the currently used CTAB-to-protein ratio of 1/1.17 (fractions 31-35) whereas 
43% was concentrated at the 30-40% w/w sucrose layer (fractions 9-15). Conduction of 
solubilisation at a lower CTAB-to-protein ratio of 1/2 led to decreased protein recovery in the 
supernatant (17% in fractions 29-35) and a substantial increase in the amount of protein that 
sedimented through the gradient (50% in fractions 9-14) thus suggesting incomplete extraction 
of the membrane glycoproteins. Application of a higher CTAB-to-protein ratio of 1/0.67 failed 
to increase significantly the relative amount of solubilised proteins (33% in fractions 30-34) 
while it also resulted in formation of two separate aggregated species isolated at 40-50% (15% 
protein in fractions 6-8) and 30-40% w/w sucrose (21% protein in fractions 9-12).  
 
Figure 5.22: Fluorescence intensity at 570 nm in sucrose gradient (5-60% w/w) after solubilisation of A/Texas/50/2012 at 
CTAB:Protein of 1/1.17, 1/2, 1/0.67. 
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Measurements of fluorescence emission of the amine reactive dye (Figure 5.22) were generally 
in alignment with the respective protein results. It is noted that the emission intensity of whole 
virus before solubilisation was 11,767 FIU while PBS, sucrose and detergent solutions were 
not shown to interfere with the measurements (≤60 FIU). Nevertheless, significant spread of 
fluorescence and limited resolution of different species was observed.  High amounts of surface 
antigens were detected at sucrose levels 30-50% w/w therefore potentially suggesting co-
aggregation of unsplit or partially split whole virus particles with the solubilised viral cores. A 
relative yet probably insignificant increase in the concentration of proteins concentrated in the 
supernatant was achieved when higher CTAB-to-protein ratios were applied. It should be noted 
that although the Alexa Fluor 546 dye labelled mainly the membrane proteins of the enveloped 
influenza virus it is likely that during virus dissociation labelling of other viral components 
could have been favoured.  
 
Figure 5.23: Fluorescence intensity at 665 nm in sucrose gradient (5-60% w/w) after solubilisation of A/Texas/50/2012 at 
CTAB:Protein of 1/1.17, 1/2, 1/0.67. 
 
Analysis of fluorescence emission of the lipophilic DiD dye is presented in Figure 5.23. The 
emission of DID-labelled whole virus was 5.4 FIU while PBS, sucrose and detergents were not 
shown to interfere with the measurements (<0.01 FIU). Relative lipid recoveries in the 
supernatant were 38, 51 and 63% for CTAB-to-protein ratios of 1/2, 1/1.17 and 1/0.67 
respectively therefore indicating higher or enhanced delipidation at higher CTAB 
concentrations. Conversely, the amount of lipids found in the aggregated complexes of the 30-
50% w/w sucrose layer was inversely proportional to the CTAB-to-protein ratio used. 
Specifically, 39, 29 and 15% of lipids co-aggregated at CTAB-to-protein ratios of 1/2, 1/1.17 
and 1/0.67 respectively. These findings also suggest that a considerable level of unsplit whole 
virus is entrapped in the aggregated “stripped” viral cores.  
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The composition of all fractions was characterised by reduced SDS-PAGE analysis. In Figure 
5.24, profiles of notable high protein fractions (see also Figure 5.21) are provided. As 
demonstrated in Figure 5.24a the high density fractions 11 for CTAB-to-protein ratios of 1/2, 
1/1.17 and fraction 10 for CTAB-to-protein ratio of 1/0.67 contained non-solubilised membrane 
glycoproteins alongside the viral internal proteins M1 and NP.  Based on relative densitometric 
quantitation of the above-mentioned fractions (Figure 5.24b), the relative content of HA and 
NA reduced as the CTAB-to-protein ratio increased whereas the opposite was observed for the 
other viral proteins. At the current splitting ratio of 1/1.17, fraction 11, which is expected to 
closely represent the composition of the pellet after ultracentrifugation, was comprised of 31% 
surface antigens and 40% of core proteins. Increase of this ratio to 1/0.67 resulted in a 
composition of 51% core proteins and 21% surface antigens. As anticipated, SDS-PAGE 
analysis of fractions of the top of the gradient (Figure 5.24c) showed that primarily surface 
antigens were concentrated in the supernatant at all three examined ratios. Several unidentified 
high MW weight protein bands (>80 kDa) indicative of protein aggregation are also detected. 
Additionally, an apparent increase of low MW protein fragments was noted when solubilisation 
was performed at higher CTAB concentration or increased CTAB-to-protein ratio (1/0.67). 
These cleaved fragments could correspond to either core proteins (NP or M1) and/or surface 
antigens (HA or NA). Taking into consideration the distinctly different wide spread of viral 
protein content (Figure 5.21) at a CTAB-to-protein ratio of 1/0.67 as well as the respective 
SDS-PAGE profile, disruption of viral cores and CTAB-induced protein denaturation are 
plausible.  
 
 
 
 
 
 
 
 
 
 
Figure 5.24: a) Reduced SDS-PAGE gels of 1: fraction 11 (CTAB/Protein=1/1.17), 2: fraction 11 (CTAB/Protein=1/2) and 3: 
fraction 10 (CTAB/Protein=1/0.67). b) Densitometric analysis of a and c) 1: fraction 34 (CTAB/Protein=1/1.17), 2: fraction 34 
(CTAB/Protein=1/2) and 3: fraction 33 (CTAB/Protein=1/0.67). 
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DCS was used to obtain the particle size distribution of a limited number of fractions. As 
discussed in Chapter 2, DCS has proven to be accurate for measurement of influenza viral 
particles and can detect aggregated populations but has obvious shortcomings in regard to 
analysis of subunit vaccines due to the inherent inability to accurately predict the sample 
parameters of a mixture of non-spherical proteins. The PSDs of the high density fractions 11 
for CTAB-to-protein ratios of 1/2, 1/1.17 and fraction 10 for CTAB-to-protein ratio of 1/0.67 
are displayed in Figure 5.25. Comparison of these PSDs with those recorded during the 
solubilisation process of different strains in Figure 5.19 confirms that the viral cores sediment 
during centrifugation in an aggregated form. The increased degree of aggregation observed at 
a CTAB-to-protein ratio of 1/2 is possibly due the higher protein content in this fraction which 
in turn relates to higher levels of unsplit whole virus particles. Conversely, the depletion of 
aggregates at a CTAB-to-protein ratio of 1/0.67 potentially suggests complete destruction of 
the viral cores.     
 
 
 
 
 
 
 
 
 
 
Figure 5.25: PSDs of high density fractions at varying CTAB-to-protein ratios as determined by DCS. 
 
Finally, HA activity was quantified via SRID in fractions with protein content greater than 100 
μg/ml (fractions 10-11, 30-35). Due to sensitivity limitations of the SRID assay, accurate and 
complete determination of HA activity throughout the entire gradient was not feasible. Results 
are graphically shown in Figure 5.26. As predicted, higher losses of HA in the high density 
fractions (70% of all HA measured) were noted at the lowest CTAB-to-protein ratio. At ratios 
1/1.17 and 1/0.67 similar HA quantities were attained: almost 30% of HA was entrapped within 
the core-related aggregates while 70% of HA was recovered in the supernatant. Taking into 
account the PAGE analysis at a CTAB-to-protein ration of 1/0.67 (Figure 5.24) that had shown 
reduced levels of HA in the pellet fraction(s) as well as evidence of protein fragmentation, it 
can be deduced that at such high CTAB concentrations though most of the HA protein is 
solubilised extensive loss of protein functionality occurs.  
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Figure 5.26: HA recoveries (SRID) in supernatant and pellet fractions at varying CTAB-to-protein ratios. 
 
5.3.3.2 Variation of Tween 80/Protein Ratio  
Since Tween 80 was proven to be a critical factor in the initial screening DoE (5.3.1) and as it 
is typically added at specific concentrations depending on the viral subtype (Table 5.2), its role 
and mechanism of action was further investigated.  
DCS was employed for the at-line monitoring of the solubilisation rate of A/California/07/2009 
(H1N1) at increasing levels of Tween 80. Two sets of experiments were performed using this 
strain: solubilisation with CTAB in presence of 376-1880 µg/ml Tween 80 for 3 hours 
(Appendix 5.4) and solubilisation involving 376-3760 µg/ml Tween 80 for up to 72 hours. The 
PSDs obtained after 2 hours of incubation with CTAB at 376 (current), 1253, 1880 and 3760 
µg/ml Tween 80 are displayed in Figure 5.27.  
 
 
Figure 5.27: PSDs during solubilisation of A/California/07/2009 (X-181) at increasing concentrations of  
Tween 80 after 2 hours of CTAB treatment. 
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weakly binding to the aggregation-susceptible hydrophobic sites of the protein surface and thus 
minimising intermolecular hydrophobic interactions [37, 38]. Nonetheless, higher levels of 
Tween 80 also induced a distinct rise of non-solubilised particles, as suggested by the increased 
viral peak height (Figure 5.27). In particular, the population of un-split virus population was 
shown to increase linearly with increasing Tween 80 concentrations whereas aggregation 
exhibited the opposite trend (Figure 5.28).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.28: Aggregate formation and amount of non-solubilised virus present at increasing concentrations of Tween 80 
based on DCS data.     
 
Comparison of the PSD as recorded after 72 hours of solubilisation in presence of 3760 µg/ml 
Tween 80 with the one obtained after 2 hours of solubilisation at the standard Tween 80 
concentration of 376 µg/ml (Figure 5.29) noticeably demonstrates that Tween 80 substantially 
reduces the CTAB reaction rate. Hence, it can be tentatively hypothesised that high Tween 80 
levels might interfere with viral solubilisation possibly through competition with CTAB.  
 
 
Figure 5.29: Comparison of PSDs during viral solubilisation of A/California/07/2009 (X-181) at  
3760 and 376 μg/ml Tween 80. 
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It is emphasised that due to the complexity of this type of protein purification processes and 
also taking into account the limited understanding of the interactions between the two 
surfactants, definite conclusions cannot be drawn.  Although the Tween 80-CTAB mixed 
system has not been studied in the literature, Sidim et al. [67] showed that binary mixtures of 
CTAB with polysorbates (20, 40 and 60) in aqueous solutions exhibit synergism or cooperative 
interaction in their effects on the physicochemical properties of the system as an outcome of 
non-ideal mixing effects in the aggregates (micelles). Introduction of non-ionic polysorbates 
into the cationic CTAB micelles decreases the electrostatic repulsions between the charged 
detergent heads and therefore enables generation of mixed micelles [67]. This also results in 
considerably lower detergent CMCs compared to the CMCs of each individual detergent.  
Based on the above, addition of Tween 80 at higher levels could have theoretically promoted 
antigen solubilisation by reducing the CMC of CTAB. Since, the results presented here 
demonstrated an almost antagonistic effect between the two detergents; it can be assumed that 
detergent interactions and dynamics are more complex when biological membranes are 
involved.  
In order to assess whether the significant positive impact of Tween 80 on solubilisation of 
surface antigens in terms of both HA potency and specific purity (5.3.1) could be due to its 
ability to prevent aggregation of viral cores and consequently co-aggregation of non-solubilised 
virions, isolation of aggregates generated at varying Tween 80 levels was attempted as 
described in 5.2.5.2. Solubilisation experiments were performed on DiD-labelled 
B/Massachusetts/02/2012 at 188, 376 (current) and 472 μg/ml Tween 80 which correspond to 
Tween 80-to-protein weight ratios of 1/10.64, 1/5.32 and 1/4.24 respectively. The Tween 80 
concentrations chosen are comparable to those examined in the preliminary screening 
experiments on B/Hubei Wujiagang/158/2009 (5.3.1) and are substantially lower than those 
used above in order to minimise any potential inhibitory effect of Tween 80 on viral 
solubilisation. Isolation of aggregates and subsequent characterisation was conducted as in 
5.3.3.1. Detailed results are provided in Appendix 5.5 and are only briefly discussed here.  
According to protein analysis (BCA) of the collected fractions, increase of Tween 80 levels 
from 188 to 376 μg/ml resulted in 10% less viral protein in aggregated form. However, no 
further decrease was observed at 472 μg/ml Tween 80. DCS results showed that higher levels 
of Tween 80 reduced considerably the amount of aggregates forming the “pellet” fractions. 
Furthermore, virus peaks at 104 nm corresponding to 2-3% of the initial virus amount were 
detected in the supernatant regardless of Tween 80 levels. This occurrence which was also 
observed in 5.3.2 is considered to be strain specific and could suggest the presence of a virus 
population that is resistant to CTAB solubilisation. Finally, SDS-PAGE and SRID analysis also 
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showed that approximately 10% more HA was in the supernatant when Tween 80 was increased 
from 188 to 376 μg/ml. The minor increase of Tween 80 to 472 μg/ml had no additional 
influence on antigen recoveries.  
Thus, further optimisation of Tween 80 concentrations is required in order to achieve an 
intricate balance between two aspects, i.e. reduction of aggregation of un-split whole virus 
particles with the solubilised viral cores without concurrently inhibiting viral solubilisation. 
According to the findings presented here, Tween 80 concentrations at a range 376-625 μg/ml 
are recommended. It is worth noting that different strains could have different sensitivities to 
this effect. All experiments could not be performed on the same strain due to annual changes 
of influenza viruses included in the vaccine formulation and/or frequent limitations in sample 
volumes available for the technical studies. 
 
5.3.3.3 Variation of CTAB/Protein Ratio and Addition of Tween 80 Post-centrifugation  
The primary purpose of this study was to identify any potential advantages of introducing 
additional Tween 80 following centrifugation and prior to addition of Amberlite beads on 
product quality. Although Amberlite XAD-4 resins bind preferably to the hydrophobic region of 
CTAB (MW=364.5 Da) removal of polysorbate species included in Tween 80 (MW=1310 Da) 
also occurs [68]. Moreover, the effect of varying CTAB concentrations on HA and protein 
recoveries was evaluated. Five solubilisation experiments were performed using 
B/Brisbane/60/2008 whole virus concentrate at conditions detailed in the experimental section 
5.2.5.3. Protein (BCA) and HA activity (SRID) results are graphically depicted in Figure 5.30.  
 
 
  
 
 
 
 
Figure 5.30: Protein (BCA) and HA (SRID) recoveries during solubilisation of B/Brisbane/60/2008 at a) increasing CTAB-to-
protein ratios and b) after addition of Tween 80 post-centrifugation. 
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purity (HA/Protein) was noted at a CTAB-to-protein of 1/1.46 which suggests sub-
optimal or partial solubilisation. Application of CTAB-to-protein ratios of 1/3.57 or 
1/2.98 led to similar HA recoveries (≈65%). Since no increase in protein or HA content 
was noted at higher CTAB concentrations it can be presumed that the concentration 
currently used is appropriate and/or adequate for the extraction of membrane proteins. 
As demonstrated earlier, undesired co-aggregation of non-solubilised viruses and CTAB-
induced denaturation could account for the observed antigen loses. It is worth noting that 
all the CTAB-to-protein ratios examined here for solubilisation of B/Brisbane/60/2008 
are considerably lower than 1/2, which was originally determined as ideal by Bachmayer 
[25, 29, 30].  
o Addition of Tween 80 after ultracentrifugation at concentrations of 500 or 2500 µg/ml 
exerted no direct impact on HA activity (Figure 5.30b). It was postulated that higher 
levels of Tween 80 could further stabilise and protect HA from CTAB-induced damage 
during Amberlite mixing. Although an immediate stabilising effect of Tween 80 was not 
demonstrated, enhanced antigen stability at higher levels of Tween 80 over time is 
possible.  
o SDS-PAGE analysis of the solubilised preparations containing additional varying levels 
of Tween 80 showed broadly similar band profiles. Similar protein compositions were 
obtained at CTAB-to-protein ratios of 1/3.57 and 1/2.98 whereas noticeably higher M1 
traces were detected at a CTAB-to-protein ratio of 1/4.46 thus confirming incomplete 
solubilisation (data not shown).  
o Tween 80 had no impact/interference with SRID measurements though it resulted in 
higher presence of HA trimers. As mentioned in Chapter 6 (6.2.1.3), HA trimers are 
primarily responsible for the precipitin ring formation in the SRID assay. As part of the 
assay, subunit vaccine samples which are mainly composed of HA oligomers (rosettes) 
are pre-treated with the zwitterionic detergent Zwittergent 3-14 which converts the 
oligomers into trimers (Figure 6.8) [69]. Typically, HA monomers and oligomers not 
disrupted by Zwittergent 3-14 do not form precipitation zones and/or are inactive in SRID 
[70]. The monobulk Tween 80-containing samples generated in this study gave a signal 
(precipitin formation) on the SRID assay without incubation with Zwittergent 3-14 
(Appendix 5.6a). Specifically, increasing concentrations of Tween 80 led to larger 
precipitation zones. Native PAGE results (Appendix 5.6b) verified that higher Tween 80 
levels had led to increased stability of trimeric HA. Nonetheless, treatment of the samples 
with Zwittergent 3-14 resulted in significantly larger zones irrespective of Tween 80 
concentrations thus suggesting that Zwittergent 3-14, at least at the concentration of 1% 
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w/v commonly utilised in the SRID assay, is comparably more effective at disrupting 
HA oligomers. Consequently, the effects of Tween 80 on routine SRID measurements 
can be regarded as negligible.  
 
5.3.4 Antigen Solubilisation with Alternative Detergents  
5.3.4.1 Nonoxynol 9 (NP9 or Triton-N101) 
NP9 is exclusively employed by NV in the manufacture of the BPL-inactivated subunit vaccine 
Fluvirin which is expected to be soon replaced by Agrippal. Initial solubilisation experiments 
were performed by addition of 0.2% v/v NP9 -the standard NP9 concentration used in Fluvirin 
manufacture regardless of strain subtype and protein content- and the reactions were monitored 
over time via DCS. It is noted that antigen solubilisation in Fluvirin lasts approximately 10 
minutes. Figure 5.31a displays the PSDs obtained throughout approximately 4 hours of 
solubilisation of HCHO-inactivated B/Massachusetts/02/2012 virus of a protein content of 
2284.7 µg/ml.  
 
 
 
 
 
 
 
 
 
 
Figure 5.31: Solubilisation of B/Massachusetts/02/2012 with 0.2% v/v NP9 for ≈ 4 hours. a) PSD profiles according to DCS 
and b) SDS-PAGE analysis after 4 hours of solubilisation. 
 
In contrast to CTAB, NP9 solubilised only half of the viral amount in 10 minutes without any 
concomitant generation of aggregates (< 2 µm). A secondary sub-viral peak was detected at 
approximately 90 nm which could correspond to intact non-associated viral cores. No further 
solubilisation occurred after 1 hour while ultracentrifugation appeared to remove significant 
amounts of non-solubilised particles and/or viral cores. SDS-PAGE analysis of the collected 
supernatant (Figure 5.31b) showed high levels of M1 and NP proteins, equivalent to those 
present in whole virus particles, despite 4 hours of incubation with NP9. The inability of NP9 
to effectively solubilise HA and NA from HCHO-inactivated viruses was also evident when 
solubilisation of A/Texas/50/2012 whole virus concentrate of significantly higher protein 
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content was attempted (5306.3 µg/ml). Based on DCS results that are provided in Appendix 
5.7, the virions remained intact after 2 hours of interaction with 0.2% v/v NP9. The considerable 
impact of the inactivation method on the solubilisation efficiency with NP9 was confirmed by 
monitoring of the reaction of both BPL and HCHO-inactivated viruses with 0.2% v/v NP9 for 
10 minutes as per Fluvirin procedures (Figure 5.32). As anticipated, NP9 rapidly solubilised 
BPL-inactivated virus (Figure 5.32a) whereas it only partially solubilised virus inactivated with 
HCHO (Figure 5.32b). The resulting solubilised suspensions were subsequently fractionated 
via sucrose gradient centrifugation and individual fractions were analysed for protein 
concentration by BCA, composition by SDS-PAGE and particle size by DCS (Appendix 5.8). 
For the BPL-inactivated virus SDS-PAGE results showed complete separation of the viral cores 
from the solubilised antigens (subunit vaccine). Conversely, unsplit whole virus particles were 
detected throughout the entire sucrose gradient of the HCHO-inactivated preparation. 
 
 
 
 
Figure 5.32: Solubilisation PSDs of a) BPL-inactivated virus (B/Brisbane/9/2014) and b) HCHO-inactivated 
(B/Brisbane/60/2008) with 0.2% v/v NP9 for 10 minutes.  
 
A possible explanation for the observed resistance of HCHO-inactivated viruses to NP9 
solubilisation is the chemical cross-linking of surface antigens induced by HCHO. As also 
stated in Chapter 3 (3.3.1.8.1), HCHO readily reacts with the primary amines in proteins and 
forms strong, covalent bonds (cross-links) between two or more protein molecules [71, 72]. 
The outcome of this chemical modification is highly stable protein–protein interactions. 
Although there is some evidence that BPL is also capable of structurally altering surface 
proteins and affecting their function [73, 74], its effects are not well-characterised. As NP9 is a 
mild, non-ionic surfactant it should preferably solubilise HA and NA not significantly modified 
and/or stabilised through HCHO cross-links. This potentially explains why only a limited 
amount of viral particles are solubilised during the first 10 minutes of interaction with NP9 
(Figure 5.31, 5.32b). On the contrary, CTAB as a strong cationic denaturating detergent rapidly 
and effectively solubilises the majority of whole virus though small proportions of resistant 
populations persist (Figure 5.19, 5.20). Taking into account the pleomorphic nature of influenza 
virions, it can be hypothesised that the formaldehyde cross-linking effects are more extensive 
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in smaller particles. It is noteworthy that the influence of formalin as an inactivation reagent on 
solubilisation efficiency of influenza viruses has not been reported elsewhere. 
 
5.3.4.2 Sodium Deoxycholate (DOC) 
Solubilisation of membrane proteins from the surface of HCHO-inactivated virus with the 
anionic bile salt DOC was briefly evaluated. DOC is commonly used for the production of both 
BPL and HCHO-inactivated split virion vaccines (Table 5.1) and has been shown to have 
limited impact on HA and NA activities (average recoveries ≈70% [22]). Due to its relatively 
high CMC (2-8 mM) DOC can be easily removed from protein solutions by dialysis. DOC 
successfully disrupted B/Brisbane/60/2008 viruses following the methodology described in 
5.2.6.2. Nonetheless, the released internal viral components could not be fully separated 
through simple ultracentrifugation procedures without simultaneous losses of surface antigens 
(data not shown). Overall, HA activity and specific purity were lower compared to those 
typically obtained through CTAB solubilisation.  
 
5.3.4.3 Octaethylene Glycol Monododecyl Ether (C12E8) 
Finally, reconstitution of influenza virus envelopes (virosomes) was attempted with C12E8. 
Influenza virosomes are virus-like particles consisting of viral membrane phospholipids and 
integrated glycoproteins but are devoid of viral genetic material, i.e. their composition is similar 
to subunit vaccines [75, 76]. They are produced through detergent solubilisation followed by a 
membrane reconstitution process [54, 55]. Functionally reconstituted virosomes preserve the 
receptor-binding and membrane fusion properties of the viral envelope HA [75]. Although a 
number of influenza virosomal vaccines were approved in Europe (Inflexal, Nasalflu, Invivac) 
no licensed virosomal vaccines have been marketed since 2014.  
Generation of virosomes was performed via solubilisation of the viral membrane of DiD-
labelled B/Brisbane/60/2008 with the non-ionic detergent C12E8 at experimental conditions 
detailed in 5.2.6.3. The preparation was subsequently centrifuged on a continuous-step density 
gradient to remove viral nucleocapsids and enable biophysical separation of the derived 
virosomes. C12E8 was extracted from the supernatant (upper fractions) with hydrophobic 
resins.  All fractions collected were analysed for viral protein content by BCA (Figure 5.33) 
and fluorescence intensity of the DiD bound lipids (Figure 5.34, Appendix 5.9a). The generated 
virosomes contained approximately 38% of the total viral protein and 90% of the membrane 
lipids (fractions 24-27). These values are in good agreement with those reported in previous 
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pertinent studies [54, 55]. As indicated by the protein measurements (Figure 5.33), two 
additional species are distinguished in fractions 3-6 and in fractions 7-21.   
 
 
Figure 5.33: Protein content (BCA) in sucrose gradient (5-60% w/w) during reconstitution  
of B/Brisbane/60/2008 with C12E8.  
 
Figure 5.34: Fluorescence intensity at 665 nm in sucrose gradient (5-60% w/w) during reconstitution  
of B/Brisbane/60/2008 with C12E8.  
 
According to SDS-PAGE profiles (Figure 5.35a), the denser fractions 2-6 contain primarily 
nucleocapsids while fractions 7-21 correspond to whole virus particles. Analysis of 
representative fractions via DCS also verified this composition (Figure 5.35b). The purified 
virosomes (Figure 5.35a) consisted predominantly of membrane glycoproteins (80% HA, 10% 
NA).  Determination of HA activity by SRID revealed that approximately 60% of the initial 
functional HA was incorporated in the produced virosomes (fractions 24-27).  
Further characterisation of the purified virosomes by negative stain electron microscopy was 
attempted but only poor quality images were obtained (Appendix 5.9b). 
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Figure 5.35: a) SDS-PAGE analysis of fractions 4 (lane 1), 13 (lane 2) and 26 (lane 3).  b) PSDs of fraction 13 (up) and 4 
(down) as determined by DCS.  
 
Overall, the virosomal formulation generated utilising C12E8 as a solubilising agent was of 
superior purity compared to the current subunit vaccine produced with CTAB.  Nevertheless, 
lower HA recoveries were attained as significant amounts of virus remained non-solubilised 
despite the use of a detergent-to-protein ratio of 13:1 identified as optimum in published studies 
[53, 54]. Similarly to NP9, it is hypothesised that the non-ionic detergent C12E8 cannot 
effectively solubilise extensively formalin cross-linked HA molecules. Further optimisation of 
the solubilisation conditions could potentially enhance yield recoveries.   
 
5.3.5 Impact of Protease Inhibitors and Characterisation of Protease Activity 
5.3.5.1 Identification of Protease Target 
Analysis of reduced gels before and after antigen solubilisation of B/Massachusetts/02/2012 
viruses revealed the consistent generation of a low MW fragment (~17 kDa) which was early 
identified as a matrix protein M1 breakdown product (lane 1 in Figure 5.36) by mass 
spectrometry fingerprint analysis (data not shown). This was considered as a potential indication 
of proteolytic activity and therefore solubilisation experiments were executed in presence of a 
mixture (cocktail) of protease inhibitors. As shown in lane 2 of Figure 5.36, no M1 breakdown 
occurred when the mixture of inhibitors was introduced. These initial results suggest that a 
protease that preferentially degrades viral M1 matrix protein is possibly active in the Agrippal 
manufacturing process following viral solubilisation.  
Determination of the protease type and target was performed through conduction of 
solubilisation experiments in presence of individual specific protease inhibitors included in the 
mixture (AEBSF, Aprotinin, Bestatin, E-64, Leupeptin, Pepstatin and EDTA). The resulting 
preparations were compared in terms of protein composition (reduced SDS-PAGE); HA activity 
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(SRID) and protein content (BCA) with control experiments that included solubilisation in 
absence of inhibitors (“positive control”) and solubilisation with the cocktail of inhibitors 
(“negative control”). A “Pepstatin control” that involved solubilisation in presence of 
MeOH/AcOH (9:1) was also performed to assess any potential impact of the pepstatin diluent.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.36: SDS-PAGE analysis of 1: a typical solubilised sample of B/Massachusetts/02/2012and 2: in presence of a 
mixture of protease inhibitors. 3: whole virus.   
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 5.37: Screening of protease inhibitors based on SDS-PAGE patterns. 1: B/Massachusetts/02/2012 whole virus, 2: 
“positive control”, 3: “negative control”, 4: Aprotinin, 5: E-64, 6: Bestatin, 7: Pepstatin, 8: “Pepstatin control”, 9: EDTA, 10: 
AEBSF, 11: Leupeptin.  
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According to gel electrophoresis results (Figure 5.37) the following conclusions are deduced: 
o Addition of E-64, Bestatin and EDTA (lanes 5, 6 and 9) resulted in protein compositions 
identical to those obtained from a typical solubilisation or “positive control” (lane 2), 
i.e. absence of M1 protein and formation of the 17 kDa M1 fragment instead. This 
potentially suggests these inhibitors had no effect on any protease enzyme present. 
o Addition of Aprotinin and Leupeptin (lanes 4 and 11) led to preparations containing 
significant levels of M1 matrix protein. Nonetheless, the 17 kDa matrix M1 breakdown 
band was also detected.  Thus, these inhibitors possibly exhibited a partial inhibitory 
effect. 
o Addition of Pepstatin (lane 7) seemingly inhibited proteolysis as suggested by the M1 
protein detected. This was investigated further by performing a “Pepstatin control” as 
mentioned previously. As shown in lane 8, the Pepstatin diluent alone prevented 
fragmentation of M1, i.e. same effects were observed in presence or absence of 
Pepstatin. Taking into account that the diluent reduced the pH of the solubilisation 
mixture to 5, it is postulated that any protease could have been degraded due to the low 
pH applied.  
o Addition of AEBSF resulted in complete inhibition of proteolytic activity (lane 10). 
Protein compositions attained were identical to those after solubilisation in presence of 
the mixture of inhibitors (lane 3). Hence, AEBSF is the protease inhibitor of interest.  
 
The impact of the various inhibitors examined on the basis of M1 matrix protein presence is 
summarised in Table 5.12. The stronger inhibitory effect exerted by AEBSF compared to the 
serine protease inhibitors Aprotinin and Leupeptin could be associated with the irreversible 
mechanism of action of AEBSF and/or its much broader specificity. Notably, the solubilisation 
samples derived after addition of AEBSF or the mixture of inhibitors differ from the whole 
virus preparation (lane 1 in Figure 5.37) only with regards to NP relative amounts.  
 
Table 5.12: Protease inhibitor response summary. 
Inhibitor Protease family targeted Inhibitor type Protease inhibition observed 
AEBSF Serine protease Irreversible Complete 
Aprotinin Serine protease Reversible Partial 
Bestatin Amino-peptidase Reversible None 
E-64 Cysteine protease Irreversible None 
Leupeptin Serine and cysteine protease Reversible Partial 
Pepstatin Aspartic acid protease Reversible Inconclusive 
EDTA Metalloprotease Irreversible None 
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Protease activity in samples typically obtained after solubilisation as well as its inhibition by 
AEBSF was also confirmed through gelatin zymography (Figure 5.38a) as well as the qualitative 
H-RBBR test (Figure 5.38b). In absence of inhibitors, mainly five clear proteolytic bands were 
visualised in the zymogram (lane 1 in Figure 5.38a) approximately at 97, 72, 46 and 31 kDa. No 
proteolytic activity was detected when AEBSF was used (lane 2 in Figure 5.39b). The 
chromogenic substrate H-RBBR (Figure 5.38b) also verified the presence of protease enzymes 
in standard post-solubilised samples (blue colour) and their suppression by AEBSF (colourless). 
 
 
  
 
 
 
 
 
 
 
 
Figure 5.38: Detection of proteolytic activity by a) zymography (1: standard split and 2: in presence of AEBSF)  
and b) the H-RBBR method. 
 
Determination of HA activity via the SRID was performed in all the samples derived in 
presence or absence of protease inhibitors in order to evaluate whether prevention of proteolysis 
could enhance the efficiency of the solubilisation process with regards to HA recoveries. 
Results are provided in Appendix 5.10 and are not presented here in length. The significant 
variability observed between the three positive and negative control replicates (one required for 
each day of this study), does not allow any conclusions to be drawn regarding the impact of 
each individual protease inhibitor on HA potency. It is noted that the Pepstatin and the 
“Pepstatin control” samples gave no response on the SRID assay therefore confirming HA 
conformational change due to low pH. Further characterisation of the influence of the serine 
protease present on HA activity and stability is required.  
 
5.3.5.2 Correlation of Protease Action with the Mechanism of CTAB Solubilisation  
Based on the findings presented in 5.3.5.1, the serine endopeptidase activity detected performs 
a critical role in the Agrippal manufacturing process. Addition of a mixture of protease 
inhibitors or AEBSF revealed that the M1 matrix protein is retained at levels equivalent to those 
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present in whole virus formulations despite the selective surface antigen solubilisation using 
CTAB. Hence, the protease protein facilitates purity specifications for subunit vaccines to be 
met by degrading the M1 matrix.  
The form by which the M1 protein persists through the solubilisation process was briefly 
examined. Two hypotheses were formulated: 
 Antigen solubilisation is selective but centrifugation conditions are suboptimal: CTAB 
may selectively remove the HA and NA membrane proteins from the virus envelope 
leaving the solubilised viral cores intact. Non-ideal ultracentrifugation could result in 
presence of viral cores in the supernatant which are then exposed to the protease 
enzyme. AEBSF could inhibit the protease enzyme thus allowing the nucleocapsids to 
carry through the process. This mechanism is illustrated in Figure 5.39. 
 Antigen solubilisation is suboptimal and non-selective: CTAB may disrupt whole virus 
particles therefore liberating the internal proteins of the nucleocapsid including the M1 
protein. This is shown graphically in Figure 5.40. 
 
 
Figure 5.39: Schematic representation of hypothesised CTAB solubilisation mechanism in relation to protease presence: 
antigen solubilisation is selective but centrifugation conditions are suboptimal. 
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Figure 5.40: Schematic representation of hypothesised CTAB solubilisation mechanism in relation to protease presence: 
antigen solubilisation is suboptimal and non-selective. 
 
In order to investigate the plausibility of the afore-mentioned hypotheses, solubilisation 
experiments of B/Massachusetts/02/2012 viruses were conducted in presence of AEBSF 
followed by centrifugation at equivalent to current production conditions (89,712 g for 13 
minutes) and at increased centrifugation speed (120,000 g for 13 minutes). If the first hypothesis 
is valid (Figure 5.39), i.e. the solubilisation is selective, centrifugation at higher g force is 
expected to completely remove or diminish the amount of intact core particles present and 
consequently the levels of M1 protein detected. According to SDS-PAGE results (lanes 4 and 
5 in Figure 5.41), increased centrifugation speed failed to remove any additional M1 matrix 
protein. Therefore, as far as this strain is concerned, it can be tentatively deduced that CTAB 
under the current solubilisation conditions induces extensive disruption of the whole virus 
structure (Figure 5.40). The exposed hydrophobic contents of the nucleocapsid subsequently 
aggregate and are removed during ultracentrifugation whereas non-associated M1 protein, NA, 
HA and free or antigen associated serine protease are retained in the supernatant. This 
mechanism contradicts the intended and theoretical purpose of solubilisation, viz. selective 
removal/separation of surface antigens that leaves the viral cores intact for subsequent removal 
during centrifugation. It is noted that the CTAB-to-protein weight ratio applied for the 
solubilisation of B/Massachusetts/02/2012 (1:2.64) is substantially lower than the ratio at which 
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Bachmayer et al. observed virion dissociation (1:1) [25, 29, 30], i.e. disruption of virus can 
occur at lower CTAB concentrations.    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.41: Determination of M1 form in solubilised preparations via SDS-PAGE analysis. 1: B/Massachusetts/02/2012 
whole virus, 2: standard split, 3: addition of AESBF and ultracentrifugation at 89,712 g and 4:  addition of AESBF and 
ultracentrifugation at 120,000 g. 
 
5.3.5.3 Origin of Protease Activity during Solubilisation 
Allantoic fluid in embryonated eggs contains numerous endogenous trypsin-like serine proteases 
that can cleave HA thus allowing efficient propagation of influenza viruses [77, 78]. The 
majority of these proteolytic enzymes are theoretically removed during vaccine manufacture at 
the virus purification stage through sucrose gradient ultracentrifugation.  
As demonstrated here, proteinases are present during the antigen solubilisation process. This 
suggests that they are either externally bound to the surface of the viral particles and/or are 
included in the virion core. Comparison of the reduced SDS-PAGE profile of a production 
sucrose density gradient of A/Switzerland/9715293/2013 (H3N2) viruses with zymograms (non-
reduced) obtained from analysis of the same fractions confirmed that the observed proteolytic 
activity is virus associated (Figure 5.42). A potential mechanism by which proteases remain 
strongly bound to the virus could relate to the formaldehyde cross-linking effect.  
 
1 2 3 4 
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Figure 5.42: Comparison of proteolytic activity (up) with protein composition (down) throughout sucrose gradient 
purification of A/Switzerland/9715293/2013. 
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5.4 CONCLUSIONS AND FUTURE PROSPECTS 
The intricate, multi-step, multi-variable and poorly characterised solubilisation process of the 
membrane glycoproteins HA and NA from the surface of influenza virus by the detergent 
CTAB as applied in the Agrippal manufacture platform was comprehensively examined.   
Preliminary screening experiments investigating the impact of several factors (CTAB and 
Tween 80 concentrations, ionic strength, solubilisation duration and temperature) and 
interactions thereof on solubilisation efficiency (HA yield, specific purity, protein recovery) 
demonstrated that the stabiliser Tween 80 and the incubation time with CTAB exerted the most 
significant effects.  
In subsequent studies the DCS analyser was uniquely employed for the real-time monitoring of 
solubilisation procedures. It was shown that upon addition of the solubilising agent CTAB, 
whole virus particles are rapidly solubilised (90% of virus in 15 minutes) whilst large 
aggregates (>0.2 µm) are concurrently formed. Complete depletion of aggregates after 
ultracentrifugation suggested that the solubilised viral cores are removed (pelleted out) after 
clustering together. Conduction of solubilisation processes at increasing Tween 80 
concentrations revealed that Tween 80 reduces formation of virus-related aggregates. 
Nonetheless, increased levels of Tween 80 also induced a distinct rise of non-solubilised 
particles thus suggesting inhibition of viral solubilisation possibly through a competing 
mechanism with CTAB.  
Analysis of aggregate composition after fractionation of post-split preparations in sucrose 
gradients showed that under current solubilisation conditions approximately 30% of 
functionally active HA is entrapped within the core-related aggregates. Solubilisation at higher 
CTAB concentrations reduced the relative amount of HA found in the pellet but failed to 
increase recoveries of biologically active HA in the supernatant therefore indicating possible 
CTAB-induced protein denaturation. Conduction of solubilisation at slightly higher Tween 80 
levels (1.3-fold) also had no influence on antigen recoveries despite the evident decrease in 
aggregate formation. It is postulated that further optimisation of Tween 80 concentrations could 
strike an intricate balance between two aspects: reduction of aggregation of un-split whole virus 
particles with the solubilised viral cores without concomitantly inhibiting viral solubilisation. 
Additionally, the extraction of HA and NA glycoproteins from the membrane of formaldehyde-
inactivated influenza viruses with alternative detergents was evaluated. Extensive treatment 
with the non-ionic surfactant NP9 resulted in only partial virus solubilisation and high levels of 
core proteins present in the final collected supernatant. The observed resistance of HCHO-
inactivated viruses to NP9 solubilisation compared to BPL-inactivated viruses potentially 
relates to the formaldehyde-induced protein cross-linking effect. Reconstitution of influenza 
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virus envelopes with C12E8 was also attempted. Similarly to NP9, significant amounts of virus 
remained non-solubilised. Nevertheless, purified virosomes of superior purity (80% HA, 10% 
NA) compared to the current subunit vaccine were obtained. Further optimisation of the 
solubilisation conditions with C12E8 could improve HA yield recoveries.  
The last phase of this project explored the apparent proteolysis phenomenon observed in post-
solubilised CTAB preparations. A serine endopeptidase that preferentially degrades the viral 
M1 matrix protein was identified. Further investigations suggested that M1 is possibly retained 
through the solubilisation process in free non-virus associated form which consequently 
indicates disruption of whole virus particles and release of internal components.  
The next phase of this project could entail further elucidation of the role of Tween 80 as a 
stabiliser/inhibitor of aggregation, optimisation of solubilisation conditions to minimise the 
amount of non-solubilised antigens lost during centrifugation, characterisation of the influence 
of inactivation conditions with formaldehyde on solubilisation efficiency and further 
investigations of the observed proteolytic activity.  
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6. DEVELOPMENT OF A NOVEL GNA-BASED 
ENZYME-LINKED IMMUNOSORBENT ASSAY 
FOR THE QUANTIFICATION OF INFLUENZA 
HAEMAGGLUTININ 
 
6.1 INTRODUCTION  
6.1.1 The Single Radial Immunodiffusion (SRID) Assay 
The potency of influenza vaccines is defined by the content of haemagglutinin (HA) 
glycoprotein, which is the most significant immunogenic viral antigen eliciting antibody 
responses [1].   
To date, the only validated potency release assay used to quantify HA in trivalent influenza 
vaccines is an immunochemical method, the Single Radial Immunodiffusion (SRID or SRD) 
[2-4] which was recommended by the World Health Organisation (WHO) in 1978 to replace 
tests based on agglutination of erythrocytes [4-6]. The SRID test (Figure 6.1) relies upon the 
supply of reference whole-virus standards with known HA antigen content from regulatory 
agencies and it provides an estimation of antigenicity by measuring the radial diffusion of HA 
in an agarose gel that contains strain-specific polyclonal antibodies [7]. In further detail, in 
single radial diffusion, circular wells are cut into solidified agarose gel incorporated with a 
specific dilution of monospecific antisera. Vaccine virus preparations and reference antigen 
calibration standards that have been disrupted with a zwitterionic detergent (Zwittergent 3–
14) and dilutions thereof are subsequently added to the wells and are allowed to diffuse in all 
directions. As the HA antigen diffuses through the gel and interacts with the antibody, rings of 
antigen-antibody precipitation complexes are formed around the wells which are visualized 
after staining [8, 9]. The diameter of the immunoprecipitation ring obtained from the dilution 
series of the reference antigen with known HA concentration are statistically compared with 
those obtained from the dilution series of an unknown sample. The size of the diffusion area 
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has been historically considered to be linearly proportional to the concentration of antigen [2, 
10, 11]. The vaccine potency determined by this method is expressed as µg of HA per ml and 
the limit of detection is approximately 3–5 μg/ml [12]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: a) Principle of SRID and b) typical layout of an SRID plate. 
 
SRID is considered as the “gold standard” for the quantification of HA content in inactivated 
influenza vaccines and has been employed for vaccine release by most regulatory authorities 
worldwide for decades [2, 13]. It measures a biologically active (antigenic) form of HA, it is 
stability indicating, it has the ability to detect individual strains in trivalent vaccine 
formulations [4, 14, 15] and data from several clinical trials confirm that SRID values are 
related to vaccine effectiveness and seroconversion [16-18].  
However, despite these features, this assay has major well-described inherent limitations. 
SRID is laborious, time consuming, low throughput [13], has poor tolerance of high levels of 
contaminating proteins [19], poor dynamic range and low sensitivity [20]. These 
characteristics make it poorly suited for in-process yield monitoring [19]. Furthermore, it 
requires annual generation of strain specific reagents (homologous antigens and their 
corresponding antisera) [2, 21]. This process is complex, time-consuming and expensive [4] 
and in case of a pandemic might lead to significant delays of timely vaccine release as 
observed during the H1N1 pandemic in 2009 [13, 14, 21]. Additionally, any non-aqueous 
vaccine constituents as well as the susceptibility of HA to aggregate formation can result in 
improper diffusion in the agarose gel and erroneous readings [22, 23]. Thus, the WHO has 
been encouraging research organisations as well as pharmaceutical industries to develop 
b a 
Polyclonal antibodies 
incorporated in agar   
Precipitate 
forms ring 
Antigen 
diffusion 
HA 
189 
 
alternative physicochemical or immunological assays for HA quantification to complement or 
replace SRID [24].  
 
6.1.2 Desirable Features of an Improved Potency Assay  
In 2011, several meetings, which focused on the ideal properties that a new potency assay for 
inactivated influenza vaccines should have, took place between regulators (WHO CCS, 
ERLS, IFPMA, and EVM) and influenza vaccine manufacturers. Following these discussions, 
a document enlisting the most significant features was composed and presented to ECBS in 
October 2011. Notable characteristics in this list include [25, 26]:  
 
 Measurement of functional, biologically active HA: 
Correlation with clinical efficacy, stability indicating, bridging to SRID 
 Robustness:  
Precision, accuracy and reproducibility 
 Sub-type specificity 
 Flexibility and practicability: 
Global applicability, acceleration of batch release, applicability in in-process control, 
flexibility and suitability in QC environment 
 Applicability to existing and novel vaccines 
 Increased robustness of reference calibration reagents:  
Strain specific independent reagents, robustness and speed of supply  
 
Recently, IVMI, an HHS collaborative initiative between CDC, FDA and NIAID, classified 
the newly developed technologies that have been proposed to substitute SRID into three 
categories, based on their potential to meet this outline of requirements [27]. Enzyme-linked 
Immunosorbent Assays (ELISAs) and Isotope Dilution Mass Spectrometry (IDMS) were 
recognised as methods with high potential whereas Surface Plasmon Resonance (SPR) and 
Antibody Independent Label-Free Mass Spectrometry were considered of moderate potential. 
Conversely, High Performance Liquid Chromatography (HPLC) and variations thereof were 
characterised as techniques of low potential. Table 6.1 summarises the screening of these 
methods for a number of essential criteria.  
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Table 6.1: Screening of potential potency assays [15].  
Green: high potential, Amber: medium potential and Red: low potential.  
Desired Quality ELISA 
MS-based  
Methods 
HPLC-based  
Methods 
SPR 
HA specific     
Detects functional antigens     
Stability indicating     
Subtype specific     
Applicable worldwide     
Not depending on reagents     
Improved Sensitivity     
 
6.1.3 Alternative Methods for Determination of HA Content 
6.1.3.1 Physicochemical Approaches 
Various physicochemical techniques have been considered as alternate assays for HA 
quantification. Several research groups have developed reversed-phase high performance 
liquid chromatography (RP-HPLC) methods suitable for measuring HA content in both cell 
culture and egg-based monovalent whole virus vaccine preparations [23, 28, 29] and in final 
trivalent influenza formulations [28-33]. All these assays are based on quantification of the 
peak of the hydrophilic HA1 subunit of HA which is proportional to the total amount of HA, 
via UV [28, 29] or fluorescence detection [31, 33]. Prior to the analysis, solubilisation of the 
viral surface proteins with a detergent (Zwittergent 3–14) and cleavage of HA into HA1 and 
HA2 subunits with a reducing agent (dithiothreitol, DTT) is subsequently applied [23]. 
Application of size exclusion chromatography following RP-HPLC analysis has also been 
reported [31, 33]. RP-HPLC based methods have demonstrated significant advantages such as 
fast analysis time, ability to differentiate HA derived from different viral subtypes (Figure 
6.2) based on the retention time [23, 28, 32] for seasonal as well as pandemic strains [29] and 
applicability in both egg and cell culture-derived samples [23]. During the 2009 H1N1 
pandemic, RP-HPLC was permitted for clinical trials and was considered by regulatory 
authorities as an alternative method for pre-qualification and faster release of vaccine lots 
whilst the SRID reference calibration reagents were still being produced [34]. Nonetheless, 
this technique is principally unable to evaluate antigenic activity or vaccine stability and 
therefore SRID or other antibody depending methodologies will still be required for thorough 
clinical assessment and release of influenza batches [7, 15, 35].   
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Figure 6.2: RP-HPLC chromatogram of a trivalent vaccine (Influvac®). Elution of HA1 subunit derived from the strains, 
B/Malaysia/2506/2004, A/Hiroshima/52/2005 (H3N2), and A/NewCaledonia/20/99 (H1N1) at 3.2, 3.7, and 4.8 min, 
respectively [23]. 
 
Mass spectrometry (MS) based approaches have also been examined for determination of HA 
in influenza vaccines [36-42]. Liquid chromatography–tandem mass spectrometry (LC-
MS⁄MS) methods involving isotope dilution mass spectrometry (IDMS) in conjunction with 
multiple reaction monitoring (MRM) have been applied in the simultaneous quantification of 
different HA subtypes in purified virus samples and in monovalent or trivalent matrices [37, 
39, 41, 42]. The principle of this technique relies upon the selection of specific peptides that 
are stoichiometric representatives of the protein of interest that are subsequently cleaved via 
proteolytic digestion (trypsinisation). An isotopically labelled reference peptide is 
subsequently spiked into the sample as an internal standard. Quantification of HA is 
performed by comparing the signal peak area of the isotopically labelled reference peptide 
with that of the target peptide isolated from the target protein [37, 38, 40, 42]. LC-MS/MS 
presents a number of distinct advantages over other methods such as high selectivity and 
sensitivity, fast analysis time, potential for characterisation of all protein constituents in the 
vaccine product and it does not depend on specific antibodies or standard antigens [39]. 
However, similarly to HPLC methods, it is only measuring the total antigen quantity (mass) 
and it does not provide information regarding HA antigenicity. Moreover, it requires high 
technical expertise and expensive equipment [40]. 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) has also been 
proposed as potential replacement of SRID. Although SDS-PAGE has shown 88–120% 
comparability with SRID data [43], protein denaturation or/and deglycosylation is necessary 
for sample analysis and therefore no assessment of clinical potency can be made.  
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6.1.3.2 Immunoassays 
Besides the aforementioned physicochemical methods, several immunological assay formats 
have also been investigated.  
Production of universal polyclonal antibodies against HA (anti-HA) that target the most 
broadly conserved fusion peptide in all subtypes of HA of influenza A and B viruses (Figure 
6.3) has been extensively reported [44-46]. These antibodies have subsequently been used in 
various immunoassay platforms including a competitive ELISA [44] and a dot blot (or slot 
blot) method [47, 48]. Although dot blot was described as a straightforward and inexpensive 
technique [47, 48], comparisons with SRID were not presented and no further progress has 
been noted since the original publications. 
 
 
Figure 6.3: Crystal structure of the HA molecule. The HA1 subunit is shown in blue, the HA2 subunit is shown in red, and 
the residues of the N-terminal of HA2 that correspond to the highly conserved fusion peptide are shown in yellow [49]. 
 
The competitive ELISA method described by Chun et al. demonstrated no cross-reactivity 
with any egg proteins of the allantoic fluid whilst relative good correlation with SRID values 
was observed [44]. In a more recent publication [50], a sandwich ELISA variant involving 
two avian glycan IgM monoclonal antibodies is detailed. Both these universal antibody-based 
assays [44, 50] have shown potential as characterisation tools for future vaccine development 
and manufacturing. Nevertheless, they lack strain discrimination, thus they cannot be applied 
in HA quantification in trivalent vaccines.  
A solid-phase enzyme linked receptor-binding assay, similar to a sandwich ELISA, entailing 
adsorption of virus in 96-well microtitre plates coated with fetuin and binding of horseradish 
peroxidise (HRP)-labelled sialylglycoproteins to the solid phase-immobilised virions has also 
been developed [51]. This method was primarily examined for receptor-binding properties 
and has not been assessed for potency determination of influenza vaccines. 
HA1 
HA2 
Fusion 
peptide 
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In 2013, two noteworthy ELISA methodologies were published [34, 35]. Hashem et al. [34] 
described an ELISA that utilises synthetic sialic acid receptors for HA antigen capture and 
strain-specific antibodies for detection. It was shown that the receptor–based ELISA has 
higher sensitivity than SRID and faster turnaround time. The authors also suggest that the 
assay is potentially stability indicating as only properly folded trimeric HA should bind to the 
receptor. However, it is noted that the availability and synthesis of the receptors could be 
challenging. Similarly, the enzyme immunoassay developed by Bodle et al. [35] demonstrated 
enhanced sensitivity and reasonable comparability to the SRID assay. The ELISA employs 
strain specific monoclonal antibodies (mAbs) for both capture and detection (coupled with 
HRP) which is assumed to limit the detection only to the functional form of HA [35].  
Surface plasmon resonance (SPR) has also been recommended as a potential replacement of 
the SRID assay [21, 52, 53]. The principle of SPR involves competitive binding of specific 
anti-HA antibodies between the HA antigen in the tested sample and recombinant HA 
immobilised on a biosensor. The detected signal is inversely proportional to the amount of 
HA in the sample [21]. Research has focused on identifying appropriate ligands that could 
lead to higher sensitivity [52, 53]. 
Finally, the commercial kit VaxArray (formerly known as Flu-ToC or Titer on Chip) became 
available in 2014. Similarly to an ELISA, Flu-ToC utilises a series of subtype strain specific 
and broadly reactive mAbs that are “printed” in microarrays while detection is performed 
using a universal fluor-linked antibody [54, 55]. Hence, this method eliminates the need for 
reference antisera reagents. Additionally, acceptable correlation with SRID, ELISA and 
protein assays has been reported when recombinant HA samples were analysed [54]. 
Nonetheless, VaxArray relies on SRID reference antigen standards for assay calibration and 
HA quantification.  
 
6.1.4 Novartis Vaccines’ Proposal for a Potential Alternative Potency Assay 
6.1.4.1 Overview  
Within Novartis Vaccines (NV), research and development activities have been pursuing a 
number of options for an alternative assay to the SRID. The overall NV vision is composed of 
three interrelated steps that aim to replace specific SRID functions and is summarised in 
Figure 6.4.  
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Figure 6.4: NV recommendation for an alternative potency assay. 
  
The first step involves separation of immunologically active HA from inactive HA through 
biochemical/biophysical pre-treatment. Previous work by NV has shown that a pre-sieving 
step can efficiently separate heat denatured or low pH-treated monobulk antigen, which are 
not detected by SRID, from native, well-folded HA, which is detected by SRID. This finding 
suggests that one possible measure of HA quality in SRID is the separation of zwittergent 
soluble material from non-zwittergent soluble aggregates on the basis of ability to diffuse 
through the agarose gel.   
In the second stage, HA derived from the previous preparative step is quantified via RP-
HPLC. This assay can serve two purposes: generation of homologous HA protein standards to 
be used in immunoassays for polyvalent vaccine release and measurement of HA in 
monovalent bulks for pandemic release (SRID independent standards). 
The last step consists of a monoclonal antibody-based serological assay, and specifically a 
lectin-capture ELISA, preceded by sieving to assure measurement of immunologically active 
HA. The ELISA assay may be used for monovalent and trivalent bulks and for both pandemic 
and seasonal vaccines and is further explained in the next section.  
 
6.1.4.2 Prior Work: GNA lectin-based Sandwich ELISA    
Preliminary studies led to the development of an ELISA which has shown promise and was 
therefore selected as the best alternative approach. The novelty of this assay (Figure 6.5) is 
based on capture of HA by a mannose-binding lectin derived from Galanthus nivalis 
agglutinin (GNA). Although mannose is a common carbohydrate residue in glycoproteins 
including HA and NA, previous research in NV revealed that mannose binding lectins (Table 
6.2) can efficiently capture HA with high specificity regardless of the glycosylation levels of 
HA [56]. GNA, which generally recognises mannose (α 1-3) residues [56, 57], was shown to 
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capture the HA from a wide variety of influenza strains with much higher avidity compared to 
other viral components and host-derived proteins [56]. Captured HA may then be detected by 
strain-specific affinity purified polyclonal sheep immunoglobulins (IgGs) conjugated to biotin 
in an ELISA platform (Figure 6.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5: GNA capture ELISA format.  
GNA structure adapted from [58] using UCSF Chimera [59].  
 
Table 6.2: Examples of common mannose-binding plant lectins.  
Symbol Name Origin Ligand-binding motif 
GNA Snowdrop lectin Galanthus nivalis (α 1–3)-linked terminal mannose residues [57] 
NPA/NPL Daffodil lectin 
Narcissus 
pseudonarcissis 
alpha linked mannose with preference towards 
polymannose structures containing (α 1-6) 
 linkages [60] 
ASA Garlic lectin Allium sativum α 1–2-linked mannose residues [61] 
LCH Lentil lectin Lens culinaris 
fucosylated residue attached to asparagine-linked N-
acetylglucosamine residues [62] 
ConA Concanavalin A 
Canavella 
ensiformis 
α-D-mannosyl and α-D-glucosyl residues [63] 
 
 
Although affinity purified polyclonal IgGs are relatively inexpensive and easy to produce they 
are generally not the first choice for development of immunoassays aimed to be used in 
manufacturing of biotherapeutics. Polyclonal antibodies exert high potential for cross 
reactivity as they contain numerous individual clones of antibodies that recognise multiple 
ALKP 
Strain 
Specific 
IgGs 
 
Biotin 
HA 
pNPP 
Coloured 
Product 
GNA 
Streptavidin 
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epitopes on the antigen with varying affinities [64-66]. Furthermore, IgGs commonly include 
significant quantities of non-specific antibodies and they are characterised by batch-to-batch 
variability due to expected variation in the animals used for antibody generation as well as 
differences in recognising epitopes and number of clones produced [64, 66].  
Consequently, mAbs are typically selected when higher specificity, sensitivity, reproducibility 
and eventually standardisation is intended [65].  
 
6.1.4.3 Monoclonal Antibody Generation (Potency Panel)    
In contrast to IgGs, mAbs are derived from a single B lymphocyte clone and they bind to only 
one epitope on an antigenic target with high specificity and therefore limited or no cross-
reactivity [64-66]. MAbs can consistently and continuously be produced from cultures of 
hybridoma clones, i.e. the same antibody can be produced by different manufacturers [66]. 
Additionally, use of mAbs for detection in immunoassays may be indicative of changes in 
native antigen conformation since denaturation may diminish binding affinity [67].   
The rationale for utilising mAbs for HA detection also relates to the limited seasonal 
modifications in influenza HA sequence. Seasonal changes in HA result from drifting regions 
of immunodominance and change in existing epitopes. Generally, very few surface mutations 
lead to this change and since many surface regions do not change seasonally (Figure 6.6a) 
monoclonal antibodies that bind those regions should still bind well. Conversely, pandemic 
viruses change the HA surface significantly (Figure 6.6b). As pandemic vaccines are typically 
monovalent, release via other methods, e.g. RP-HPLC following sieving, is possible.  
 
 
 
 
 
 
 
 
 
 
Figure 6.6: Comparison of HA structures of a) the seasonal H1N1 strains A/Solomon Islands/3/2006 (left) [68] and 
A/Brisbane/59/2007 (right) and b) the seasonal H1N1 strain A/Brisbane/59/2007 (left) with the pandemic swine origin H1N1 
A/California/7/2009 (right) [69]. Yellow regions denote differences in sequences from A/Brisbane. The 3D model of 
A/Brisbane/59/2007 was produced through the IntFOLD server [70]. 
 
a b 
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In order to achieve redundancy, an updatable panel of multiple non-competing monoclonal 
antibodies needs to be generated (Figure 6.7). This could potentially prevent individual 
surface mutations from rendering the panel non-functional, i.e. loss of one of the mAbs is not 
loss of the whole. 
 
 
 
 
 
 
 
 
 
Figure 6.7: Appearance of potency panel. Squares represent different antibodies. Row A antibodies are chosen from 
antibodies that bind H1N1 monobulk, row B antibodies are selected from antibodies that bind H3N2 etc [71]. As strains 
evolve some mAbs may no longer bind well to the HA. These are removed and replaced by new. Nonetheless, a basal level 
of 3-4 mAbs is always expected to bind. 
 
6.1.5 Aims and Objectives 
The primary aim of this study was the development and optimisation of a novel GNA lectin-
based ELISA assay using strain specific purified monoclonal antibodies for the rapid 
detection and quantification of the HA antigen of different viral types and subtypes in egg-
based inactivated influenza vaccine samples.  
The first stage of this project focused on optimisation of a previously developed ELISA based 
method using the monoclonal antibody CR6268 against H1N1 A/California/07/2009 (swine 
influenza pandemic strain) as a model.  
Additionally, screening of hybridomas, raised against four subtypes of influenza strains, was 
performed through an indirect ELISA assay. The selected antibodies were subsequently 
purified and produced in larger quantities to form the basis of the initial antibody panel and 
were re-evaluated and re-screened using the trial lectin-based ELISA platform.   
Based on the outcome of the second screening process, main objectives in the final phase 
included modification of the original immunoassay and investigation of alternative ELISA 
formats suitable for the generated antibodies.  
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6.2 MATERIALS AND METHODS 
6.2.1 Optimisation of the Original GNA-Based Sandwich ELISA: Use of mAbs as 
Primary Antibodies 
6.2.1.1 Preparation of Biotinylated mAb Conjugate 
Purified CR6268 mAb was concentrated to 1 mg/ml by centrifugation at 3000 rpm using an 
AMICON ULTRA-15 Ultracel-10k column and was incubated 1 hour at room temperature in 
a 20 times molar excess of NHS-PEG4-Biotin (Pierce #21329) dissolved in PBS at a 
concentration of 20 mM. After incubation, the mixture was separated on a PD-10 column (GE 
Healthcare Life Sciences #17-0851-01) equilibrated in PBS-2 mM EDTA, pH=7.3. Five 
fractions of 1 ml were collected, and the concentration of biotinylated mAb was determined 
by UV absorbance at 280 nm, assuming that an absorbance of 1.4 OD indicates a 1 mg/ml 
mAb-biotin concentration [72]. 
 
6.2.1.2 GNA Coating and Blocking 
The coating or adsorption was performed on EIA/RIA 1x8 Stripwell plates (Costar #2582) by 
adding 200 µl/well of GNA lectin (Sigma #L8775) at the experimentally determined optimum 
concentration of 50 µg/ml in PBS Ca2+/Mg2+ free (Appendix 6.1). Plates were incubated 
overnight at +20°C. The next day wells were aspirated and washed 4 times with 350 µl/well 
of post-coating wash buffer (PBS Ca2+/Mg2+ free, 0.05% v/v Tween 20, pH=7.4) to remove 
any unbound GNA. The plates were subsequently incubated with 350 µl/well of blocking 
buffer (10 mM Tris-HCl, 150 mM NaCl, 3% sucrose, 1% BSA, pH 7.68) for 1 hour at room 
temperature to prevent non-specific adsorption of the antigen/antibodies to the wells. After 
incubation, blocking buffer was aspirated and the plates were either immediately used for the 
assay or dried overnight at room temperature and then stored at +4°C. 
 
6.2.1.3 Sample Pre-treatment 
Whole virus and monobulk samples were diluted in PBS Ca2+/Mg2+ free to a starting 
estimated HA concentration of 30 μg/ml and then they were treated with zwittergent 3-14 at a 
final concentration of 1% w/v for 1 hour at room temperature as in the SRID assay. The 
purpose of this step (Figure 6.8) is a) to effectively solubilise HA from the virion and b) to 
convert the highly immunogenic HA oligomers/rosettes - the predominant component of a 
subunit vaccine-to HA trimers, which are considered primarily responsible for the precipitin 
ring formation in the SRID assay [73]. 
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Figure 6.8: Impact of zwittergent 3-14 treatment on HA conformation. EM images from [74].  
Mechanism scheme adapted from [75].  
 
6.2.1.4 Sandwich ELISA  
Seven two-fold serial dilutions of the samples were made in PBS, Ca2+/Mg2+ free. Each 
dilution was loaded in duplicate onto a GNA-coated 96 well plate (100 µl/well) and incubated 
30 minutes at 37 °C. After incubation, biotinylated-mAbs, diluted to the experimentally 
predetermined concentration of 8 µg/ml (Appendix 6.1) in wash buffer (50 mM Tris, 150 mM 
NaCl, 0.05% v/v Tween 20, pH 7.5) were added (100 µl/well) to the antigen without washing 
and incubated for a further 30 minutes at 37 °C. Wells were then aspirated and washed 4 
times with 350 µl/well of wash buffer to remove excess antibody and unbound reagents. 
Antigen-mAb was then detected by adding 200 µl/well of 1 µg/ml streptavidin-conjugated 
alkaline phosphatase (Streptomyces avidini-derived, Sigma #S2980) in wash buffer and 
incubating for 30 minutes at 37 °C. The plates were washed as described previously, and 200 
µl/well of pNPP (p-Nitrophenyl Phosphate, Alkaline Phosphatase Yellow Liquid Substrate, 
Sigma #N7653) were added to the wells and incubated for 30 minutes at room temperature. 
The absorbance of the yellow end product p-nitrophenol was measured at 405 nm in a 
microplate reader (Figure 6.9). 
Whole Virus 
(SRID Reference Antigen) 
Vaccine 
(HA rosettes/oligomers) HA Trimer 
Zwittergent 3-14 
(non-ionic detergent) 
Zwittergent 3-14 
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Dominant form of egg-based 
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Main form  
measured in SRID 
200 
 
 
 
Figure 6.9: ALKP-catalyzed hydrolysis of pNPP. 
 
6.2.1.5 Data Analysis  
OD values were reported on an Excel worksheet. Mean and standard deviations were 
calculated for each replicate. The reference curve was constructed by plotting the OD values 
in the y-axis and the HA concentration (as measured by SRID) on the x-axis. Four Parameter 
Logistic (4PL) nonlinear regression of the OD data from unknown samples on the reference 
equation allowed HA quantification (Appendix 6.2). The data were processed using SoftMax 
Pro 5.4 software (Molecular Devices) or in Origin 9. The accepted value was the average of at 
least five different dilutions with a coefficient of variation (CV)≤15%. Furthermore, the 
parallelism between different serial dilution curves was assessed. OD values were evaluated 
through regression analysis after logistic transformation through the equation: 
Logit (OD) = 





OD1
OD
 log  
Multiple comparisons among slopes were conducted using Tukey's HSD test [76]. The 
statistical analysis was performed using Minitab 16.  
 
6.2.2 Screening of Hybridoma Supernatants and Characterisation of Monoclonal 
Antibodies  
6.2.2.1 Screening of Hybridoma Clones by Indirect ELISA 
Mice were immunized with purified HA from four influenza virus strains, namely 
A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (B1: 
B/Victoria lineage) and B/Florida/4/2006 (B2: B/Yamagata lineage). The production method 
of the monoclonal antibodies was carried out by a third party and is out of the scope of this 
thesis. Eighty hybridoma clones were generated (20 per viral subtype) and sent to NV to be 
characterised for activity/cross-reactivity using an indirect ELISA assay (immobilised 
antigen, Figure 6.10) adapted from [72, 77, 78]. Plates were coated with 50 µl/well viral 
antigen (1 µg/ml in PBS) from each strain or neat allantoic fluid (NAF) as negative control 
pNPP p-nitrophenol 
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and incubated overnight at 4 °C. Plates were washed three times with PBS, 0.05 % v/v Tween 
20, pH=7.3 (PBS-T) and then blocked with 50 µl/well 1% w/v BSA in PBS for 1 h at room 
temperature. After washing with PBS-T, 50 µl/well of hybridoma supernatants were added, 
and the plates were incubated for 1 h at 37 °C.  Plates were washed again as previously and 50 
µl/well of horse radish peroxidise (HRP)-conjugated anti-mouse IgG (Sigma #A4416) diluted 
1:9000 in blocking buffer was added and the mixture was incubated for 1 h at 37 °C.  After 
washing, 100 µl/well of 3,3',5,5'-tetramethylbenzidine substrate (TMB) was added. The 
reaction was stopped after 15 min by adding 50 μl/well of 1 M H2SO4 and the absorbance was 
measured at 450 nm using a microtitre plate reader. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10: Indirect ELISA assay used for the initial screening of hybridoma cells. 
 
6.2.2.2 Haemagglutination Inhibition (HAI) 
6.2.2.2.1 Assay Principle 
According to the initial screening results, selected antibodies were subsequently purified and 
re-screened for binding affinity and strain cross-reactivity on the basis of a positive 
haemagglutination inhibition (HAI) test. The purification process of the monoclonal 
antibodies was carried out by a third party and is out of the scope of this thesis. 
As described in section 3.2.7, influenza viruses are able to agglutinate erythrocytes (red blood 
cells, RBCs) through binding of the surface HA to the receptors on the surface of the 
erythrocyte thus forming a lattice structure (haemagglutination) (Figure 6.11a). The RBCs 
that are not bound by influenza particles will typically precipitate out as a red pellet to the 
bottom of a round bottom microplate (Figure 6.11b). In the presence of subtype-specific 
neutralising antibodies, the antibodies bind to the surface antigens resulting in inhibition of 
haemagglutination as schematically illustrated in Figure 6.11c. The extent of inhibition 
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Antibody 
(IgG) 
HA 
TMB 
Coloured 
Product 
202 
 
depends on the concentration and binding affinity of the antibodies. This inhibition of the 
agglutination reaction of HA by antibodies/antisera is the basis of the HAI test [79].  
 
  
           
+                                                                                                        
 
 
   
 
 
 
                                      +                                
                                            
                                          +   
 
 
Figure 6.11: a) Viral particles bind to red blood cells and form a lattice structure (haemagglutination). b) In the absence of 
influenza virus, RBCs sink to the bottom of a microtitre plate and appear as a red dot. c) Neutralising antibodies bind to the 
virus and prevent haemagglutination (haemagglutination inhibition). Image adapted from [80].  
 
6.2.2.2.2  Determination of 4 Haemagglutination Units (HAUs) 
All antigen samples were diluted to 4 haemagglutination units (HAUs) prior to the HAI test. 
Determination of 4 HAUs was conducted as follows: test samples from four different strains 
(A/California/7/2009, A/Victoria/210/2009, B/Brisbane/60/2008 and B/Florida/4/2006) were 
pre-diluted 1/10 with PBS, pH=7.3. 25μl/well of PBS was dispensed to all wells of a U-
bottom microtitre plate whereupon 50μl/well of PBS were added to all wells in a row assigned 
as a negative control. 25 μl/well of the pre-diluted samples (1/10) were subsequently 
inoculated to the first two wells of each row and a series of 11 double dilutions were 
performed across the plate by carrying over 25 μl of solution. 25 μl/well of PBS, pH=7.3 was 
pipetted into all wells arriving at a final volume of 50 μl/well. Finally, 50μl/well of 0.5% 
turkey RBC suspension was dispensed to all wells. The plates were incubated at room 
temperature for 60 minutes and read after tilting. 4HAUs were allocated to the last well in a 
row where 100% haemagglutination was observed (see Table 3.1 in 3.2.6.2).  
Virus RBCs Haemagglutination 
No Reaction 
Haemagglutination 
Inhibition 
a 
b 
c 
= 
= 
= 
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6.2.2.2.3 Assay Execution 
The HAI assay was performed according to NV internal Standard Operating Procedure (SOP) 
using 2-fold antibody dilutions. All antigen test material was diluted to 4 HAUs as described 
in 6.2.2.2.2. Each monoclonal antibody solution was diluted 1/10 using PBS, pH=7.3. PBS 
buffer was dispensed to all wells of a U-bottom microtitre plate. 50 μl/well of PBS were 
subsequently added to all wells in a row assigned as a negative control. 25 μl/well of the pre-
diluted mAbs (1/10) were then inoculated to the first two wells of the appropriate rows and a 
series of 11 double dilutions was performed across the plate by carrying over 25 μl of mAb 
solution. 25 μl/well of test antigen set at 4 HAUs was pipetted into all wells containing mAb 
titrations reaching a final volume of 50 μl/well. The plate was incubated for 60 minutes at 
room temperature to allow contact between antibody and test sample. After the 60 minutes 
incubation period, 50 μl/well of 0.5% RBC suspension was dispensed to all wells containing 
test samples and controls. Finally, the plates were incubated for 60 minutes at room 
temperature and read after tilting. The HI titre, was determined by examining the last well in 
each row where 100% settling of RBCs was seen, i.e.  the value of the highest dilution of 
mAb leading to complete inhibition of the 4 HAUs.  
 
6.2.3 Determination of Degree of Biotinylation  
The efficiency of the degree of labelling for a representative number of biotinylated mAbs, 
that exerted low signal when used in the GNA-based ELISA, was measured using the 
commercial kit FluoReporter® (Molecular Probes, #F30751) following the supplier’s 
instructions [81]. The principle of this assay is graphically presented in Figure 6.12.  
 
 
 
 
 
 
 
 
 
 
Figure 6.12: Principle of Biotective Green reagent-based assay, where D: Alexa Fluor® 488 fluorescent dye, Q: HABA 
quencher dye ligands and B: Biotin. Adapted from [81]. 
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This method involves fluorescence resonance energy transfer (FRET) quenching and 
dequenching of a reagent known as Biotective Green. Biotective Green is a complex of avidin 
labelled with a fluorescent dye (Alexa Fluor® 488) with quencher dye ligands (HABA, Q) 
bound to the biotin binding sites. In the absence of biotin or biotin labelled substances, the 
fluorescence of the Alexa Fluor 488 dye is quenched via FRET to HABA. If biotin is present, 
it binds to the Biotective Green thus dislocating HABA from the avidin resulting in 
dequenching of the Alexa Fluor 488 dye and increase in fluorescence [82]. 
 
6.2.4 A Modified ELISA for Detection of Antibody Responses  
6.2.4.1 GNA Coating and Blocking  
EIA/RIA 1x8 Stripwell plates (Costar #2582) were coated with 200 µl/well of GNA lectin 
(Sigma #L8775) at a concentration between 25-100 µg/ml as experimentally determined for 
each mAb through a full factorial DoE approach in PBS Ca2+/Mg2+ free, pH=7.7 (Appendix 
6.3) and incubated overnight at +4°C. The next day wells were aspirated and washed 3 times 
with 350 µl/well of post-coating wash buffer (PBS Ca2+/Mg2+ free, 0.05% v/v Tween 20, 
pH=7.7) and were subsequently blocked for non-specific binding with 350 µl/well of blocking 
buffer (PBS, 3% w/v sucrose, 1% w/v BSA,  pH=7.7) for 1 hour at room temperature. After 
incubation, blocking buffer was aspirated and the plates were immediately used for the assay. 
 
6.2.4.2 Sample Pretreatment  
Preparation of whole virus and monobulk antigen samples was performed as detailed in 
6.2.1.3.  
 
6.2.4.3 Sandwich ELISA 
Serial two-fold dilutions of the samples were made in PBS, Ca2+/Mg2+ free. Each dilution was 
loaded in duplicates on the GNA-coated wells (100 µl/well) and incubated for 1 hour at 37 
°C. Plates were washed three times with 350 µl/well PBS 0.05 % v/v Tween 20 and incubated 
for 30 minutes at 37 °C with mAbs (100 µl/well) pre-diluted at an experimentally defined 
concentration (Appendix 6.3) in blocking buffer PBS, 3% w/v sucrose, 1% w/v BSA, pH=7.7. 
Wells were then washed as described previously. 100 µl/well of alkaline phosphatase 
(ALKP)-conjugated anti-mouse IgG (Sigma #A5153) diluted 1:7000 in blocking buffer were 
added and the mixture was incubated for 30 minutes at 37 oC. After washing, 200 µl/well of 
pNPP (SIGMA #N7653) were added to the wells and incubated for 30 minutes at room 
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temperature. Plates were read by measuring absorption at 405 nm in a microplate reader. The 
assay set-up is depicted in Figure 6.13. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13: Modified GNA-based ELISA platform.  
 
6.2.4.4 Data Analysis  
Data were recorded and analysed in a similar manner as described in section 6.2.1.5. All 
statistical analysis was performed in Minitab 16.  
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6.3 RESULTS AND DISCUSSION 
6.3.1 Optimisation of the Original GNA-Based Sandwich ELISA: Use of mAbs as 
Primary Antibodies 
6.3.1.1 Application in Monobulk Samples 
Initial studies, which are not described here, included optimisation of the basic ELISA method 
in order to achieve the highest sensitivity based on the highest signal-to-noise ratio. Factors 
that were investigated were the concentrations of the biotinylated CR6268 mAb and GNA as 
well as the antigen dilution range (data available in Appendix 6.1). 
Three monobulk samples of A/California/07/2009 were tested with the sandwich ELISA as 
detailed in the experimental procedure. The reproducibility was tested by comparison of the 
three independent assays in terms of standard curve parameters and quantification of HA 
content of each sample using the other two as calibrators (SRID-calibrated). The serial 
dilution curves of the three batches are displayed in Figure 6.14 and the characteristics of the 
4PL models fitted to each curve are summarised in Table 6.3. For all curves adjusted R2 was 
found>0.99 thus indicating that the system is adequately characterised by the non-linear 
regression model.  
 
Table 6.3: Description of 4PL models (Appendix 6.2).  
Parameter Batch 1 Batch 2 Batch 3 
Reduced Chi-Sqr 5.25E-05 1.50E-05 2.13E-05 
Adj. R-Square 0.999 1.000 1.000 
A1 0.002 0.006 -0.004 
A2 1.591 1.073 3.644 
x0 568 313 1886 
p 1.253 1.454 1.014 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.14: Concentration curves of the three examined monobulk samples. 
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To evaluate whether monobulk samples can be potentially used as reference, the reverse 
calculation using each SRID-calibrated monobulk as reference and the other two unknown 
batches was performed. In Table 6.4 the results obtained for all three samples are shown. 
Overall, the CV values calculated for the mean concentrations derived from the different 
concentrations can be considered acceptable (<10%).  Additionally, the HA content measured 
by the HA-ELISA is comparable to the SRID values with a maximum difference of 
approximately 6%.  
 
Table 6.4: Quantification of HA in monobulk samples. 
Sample Calibration 
HA 
(μg/ml) 
CV (%) 
HA 
(μg/ml)-
SRID 
Difference 
with 
SRID (%) 
Batch 1 
Batch 2 221.8 4.5  
220.0 
0.8 
Batch 3 215.0 9.4 2.3 
Batch 2 
Batch 1 146.4 5.8  
138.0 
6.1 
Batch 3 136.5 6.8 1.1 
Batch 3 
Batch 1 45.6 5.2  
44.0 
3.6 
Batch 2 44.0 8.1 0.0 
 
The parallelism between the serial dilution curves of the three batches was further assessed 
through Tukey’s HSD statistical test. After logistic transformation of the OD values, linear 
regression was performed with R2 > 0.98 for all curves with the slopes between − 0.888 and − 
0.907 (Figure 6.15). A Tukey's HSD test demonstrated that the slopes of the serial dilution 
curves did not differ significantly from each other (P-value=0.92> 0.05=significance level).  
 
 
Figure 6.15: Linear regression on logistically transformed OD data. 
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6.3.1.2 Application in Whole Virus Samples 
Similar analysis was conducted for the evaluation of the HA-ELISA assay in determining HA 
content in whole virus samples. Two A/California/07/2009 SRID whole virus reference 
standards were analysed (NIBSC, lots 11/202, 08/294) alongside a monobulk (subunit 
vaccine) sample. The dilution curves and the 4PL regression equations are shown in Figure 
6.16 and Table 6.5 respectively. Satisfactory model fits were achieved.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.16: Concentration curves of the whole virus and monobulk samples.  
 
Furthermore, it was assessed whether whole virus can be used as a calibration standard for 
measurement of HA levels in monobulk material and vice versa. Based on the HA estimations 
in Table 6.6, both sample matrices are suitable for the calibration of the assay (CV<15%). 
Good correlations with the SRID values are also noted. 
 
Table 6.5: Description of 4PL models (Appendix 6.2).  
Parameter 
Whole Virus 
11/202 
Whole Virus 
08/294 
Monobulk 
Reduced Chi-Sqr 0.002 0.002 5.03E-04 
Adj. R-Square 0.991 0.990 0.998 
A1 -0.040 -0.030 -0.015 
A2 714.092 13.099 4.164 
x0 3686540 10152 1019 
P 0.696 0.731 0.895 
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Table 6.6: Quantification of HA in monobulk samples. 
Sample Calibration HA (μg/ml) CV (%) HA (ug/ml)-SRID 
Difference with  
SRID (%) 
Whole Virus 11/202 
Whole Virus 08/294 77.1 8.6 
74.0 
4.2 
Monobulk 69.1 3.8 6.7 
Whole Virus 08/294 
Whole Virus 11/202 26.8 5.8 
29.0 
7.4 
Monobulk 25.6 7.7 11.6 
Monobulk 
Whole Virus 11/202 146.6 5.3 
138.0 
6.2 
Whole Virus 08/294 142.0 14.9 2.9 
 
 
6.3.2 Screening of Hybridoma Supernatants and Characterisation of Monoclonal 
Antibodies  
6.3.2.1 Screening of Hybridoma Clones by Indirect ELISA 
The specificity and activity of the produced mAbs against each strain were investigated 
through indirect ELISAs. Indirect ELISAs (Figure 6.10) are generally used for the primary 
hybridoma screening of potential antibody candidates since they utilise unlabelled primary 
antibodies in combination with labelled secondary antibodies, i.e. they are suitable for a wide 
variety of primary antibodies. Results are graphically illustrated in Figures 6.17-6.20. Cross-
reactivity was observed with all strains for a significant number of mAbs that were tested. 
Specifically, 12 out of the 20 mAbs raised against the H1 subtype showed the highest activity 
but only 4 of them did not cross-react with other influenza subtypes and other components of 
AF (Figure 6.17). All the anti-H3 mAbs demonstrated high reactivity (Figure 6.18) and 15 of 
them reacted exclusively with the H3 subtype. Conversely, only one of the tested mAbs was 
shown to specifically bind to the B1 subtype (Figure 6.19). Nevertheless, 9 mAbs exhibited 
strong reactivity with both B strains. Similarly, only 4 mAbs specifically reacted with the B2 
isolates while 16 also reacted with B1 (Figure 6.20) and were therefore unable to differentiate 
between the two antigenically distinct B lineages.  
 
210 
 
 
Figure 6.17: Evaluation of reactivity and specificity of anti-H1N1mAbs against influenza A & B viruses (mAbs annotated as 
VP1-1, VP1-2…VP1-20). Antibodies that exhibited OD>1 are considered of higher avidity whereas antibodies that gave 
similar responses when tested with NAF or HA isolated from other viral subtypes (H3N2, B1, B2) are deemed as cross-
reactive. Cross-reactivity is represented by overlapping points in the graph. Four antibodies were identified as H1N1 specific, 
namely VP1-7, VP1-8, VP1-9 and VP1-13 (circled in red).  
 
 
Figure 6.18: Evaluation of reactivity and specificity of anti-H3N2 mAbs against influenza A & B viruses (mAbs annotated 
as VP2-1, VP2-2…VP2-20). Antibodies that exhibited OD>1 are considered of higher avidity whereas antibodies that gave 
similar responses when tested with NAF or HA isolated from other viral subtypes (H1N1, B1, B2) are deemed as cross-
reactive. Cross-reactivity is represented by overlapping points in the graph. Fifteen antibodies were identified as H3N2 
specific, namely VP2:1-6, VP2: 9-13 and VP2:16-19 (circled in red). 
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Figure 6.19: Evaluation of reactivity and specificity of anti-B1 mAbs against influenza A & B viruses (mAbs annotated as 
VP3-1, VP3-2 …VP3-20). Antibodies that exhibited OD>1 are considered of higher avidity whereas antibodies that gave 
similar responses when tested with NAF or HA isolated from other viral subtypes (H1N1, H3N2, B2) are deemed as cross-
reactive. Cross-reactivity is represented by overlapping points in the graph. VP3-20 was the only antibody identified as B1 
specific (circled in red). 
 
 
Figure 6.20: Evaluation of reactivity and specificity of anti-B2 mAbs against influenza A & B viruses (mAbs annotated as 
VP4-1, VP4-2 …VP4-20). Antibodies that exhibited OD>1 are considered of higher avidity whereas antibodies that gave 
similar responses when tested with NAF or HA isolated from other viral subtypes (H1N1, H3N2, B1) are deemed as cross-
reactive. Cross-reactivity is represented by overlapping points in the graph. Four antibodies were identified as B2 specific, 
namely VP4-10, VP4-11, VP4-19 and VP4-20 (circled in red). 
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The list of hybridoma clones chosen for further purification is presented in Table 6.7. All the 
clones that reacted exclusively with the influenza B types are also included as different 
antigen concentration range in the assay could potentially allow differentiation between the 
two lineages. 
 
Table 6.7: Summary of findings: mAb screening. 
H1 
Subtype 
H3 
Subtype 
B1 
Subtype 
B2 
Subtype 
Strong Reactions with 
both B1 and B2 Subtypes 
VP1-7 
VP1-8 
VP1-9 
VP1-13 
VP2-1 
VP2-2 
VP2-3 
VP2-4 
VP2-5 
VP2-6 
VP2-9 
VP2-10 
VP2-11 
VP2-12 
VP2-13 
VP3-20 
VP4-10 
VP4-11 
VP4-19 
VP4-20 
VP3-1 
VP3-2 
VP3-6 
VP3-7 
VP3-8 
VP3-9 
VP3-10 
VP3-18 
VP3-19 
VP4-1 
VP4-2 
VP4-3 
VP4-4 
VP4-5 
VP4-6 
VP4-7 
VP4-8 
VP4-9 
VP4-12 
VP4-13 
VP4-14 
VP4-15 
VP4-16 
VP4-17 
VP4-18 
 
6.3.2.2 Haemagglutination Inhibition (HAI) 
According to the results of the initial screening, selected mAbs were purified and further 
characterised for specificity and cross-reactivity by the HAI assay. Prior to the test, 
determination of 4HAUs or the 100% haemagglutination endpoint was achieved, as described 
in 6.2.2.2.2, for four HA antigen subtypes (Table 6.8).  
 
Table 6.8: Determination of 4HAUs. Green: 100% haemagglutination and Red: No haemagglutination. 
 
 
All virus subtypes were examined with a series of mAbs to assess the minimum antibody 
concentration (HI titre) that causes complete inhibition of the 4 HAUs. Results are 
summarised in Table 6.9. No inhibition of HA activity was observed for the two anti-H1 
antibodies that were evaluated. All mAbs raised against the H2 subtype blocked 
haemagglutination at low concentrations (high dilutions) whilst none of them were shown to 
1/5 1/10 1/20 1/40 1/80 1/160 1/320 1/640 1/1280 1/2560 1/5120 1/10240
A/California /07/2009 (H1N1) 1/2560
A/Victoria /210/2009 (H3N2) 1/5120
B/Brisbane /60/2008 (B1) 1/2560
B/Florida /4/2006 (B2) 1/280
Sample Dilution Factor 4HAUs 
Dilution
Sample
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react with the other HA isolate preparations. These low HAI endpoins are indicative of high 
antigenic relatedness or antigenic similarity, which subsequently suggests that vaccination, 
would potentially induce an immune response capable of neutralising virus infectivity [83]. 
Specifically, as HI titres have historically been shown to correlate well with protective 
immunity, antibodies that interfere with receptor binding are possibly adequately 
immunorelevant and can be utilised to assess vaccine potency. The mAb raised against the B1 
subtype also exhibited a neutralising effect at a low concentration whereas none of the anti-B2 
antibodies demonstrated considerable and specific inhibition of HA activity.  
 
Table 6.9: Reactivity of monoclonal antibodies (mAbs).  
Note: Antibodies VP1-7,8 were depleted in experiments described at 6.3.3.  
mAb Code HA origin 
HAI Endpoint 
(µg/ml) 
Cross-reactivities 
VP2-1 H3N2 3.13 NONE 
VP2-2 H3N2 3.13 NONE 
VP2-3 H3N2 3.13 NONE 
VP2-4 H3N2 0.39 NONE 
VP2-5 H3N2 0.39 NONE 
VP2-6 H3N2 0.39 NONE 
VP2-9 H3N2 0.78 NONE 
VP2-10 H3N2 12.50 NONE 
VP2-11 H3N2 0.78 NONE 
VP2-12 H3N2 1.56 NONE 
VP2-13 H3N2 0.39 NONE 
VP1-9 H1N1 NONE or >60 H3 (>30 μg/ml) 
VP1-13 H1N1 NONE or >100 H3 (>50 μg/ml) 
VP3-20 B1 1.56 H3(>50 μg/ml) 
VP4-10 B2 NONE or >100 
H3 and B1  
(>100 μg/ml) 
VP4-11 B2 50 
H3 (>100 μg/ml) and 
B1 (>50 μg/ml) 
VP4-19 B2 NONE or >100 
H3 and B1  
(>100 μg/ml) 
VP4-20 B2 NONE or >100 
H3 and B1  
(>100 μg/ml) 
 
6.3.3 Evaluation of the Trial GNA-Based ELISA 
Following purification and generation of the enlisted mAbs (Table 6.7), next steps included 
application in the lectin-based ELISA and optimisation of assay factors (concentration of 
GNA and mAb, HA assay range) similarly to the CR6268 mAb prototype. Repeated 
experiments for 6 antibodies (VP1-7, VP1-8, VP1-9, VP1-13, VP2-1, VP2-2) that involved 
broad GNA, mAb and HA titrations resulted in considerably low signal response (max 
OD≤0.1). Additionally, no dose-response relationship was observed. Representative data are 
provided in Appendix 6.4a. 
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Generally, low absorbance values in ELISA assays are due to the following [84-88]: 
 
o Insufficient amount of antibody 
o Insufficient amount of target protein 
o Short incubation time or inappropriate incubation conditions 
o Use of contaminated or expired reagents 
o Low antibody binding/activity 
o Sodium azide in wash buffers inhibits mAb activity 
o Ineffective mAb biotinylation 
o Biotinylation/labelling interferes with antibody binding ability  
 
Taking into account that wide range titrations of all critical assay components had been 
performed, new reagents were used and that incubation parameters were adequately optimised 
through previous experimental studies, it was deemed essential to assess the efficiency of 
biotinylation or possible elimination of mAb activity post-purification/concentration.   
The degree of biotinylation was determined through the Fluoreporter commercial kit (see 
section 6.2.3). The degree of labelling (DOL) was calculated for 6 antibodies and is shown in 
Table 6.10.  
 
Table 6.10: Determination of DOL via Fluoreporter.  
mAb (Code) Origin DOL 
VP1-7 H1N1 0.85 
VP1-8 H1N1 0.44 
VP1-9 H1N1 1.17 
VP1-13 H1N1 0.62 
VP2-1 H3N2 1.23 
VP2-2 H3N2 0.82 
 
Based on the results in Table 6.10, it was found that on average the DOL was less than 2. 
Typically, the recommended protein/biotin molecular ratios theoretically lead to optimal DOL 
between 3 and 8 per intact mAb molecule [89]. It is noted, that DOL in this range does not 
normally affect the antigen binding properties of the antibody [89, 90]. Alternative 
biotinylation kits/methods were not examined. The biotinylation reagent previously used was 
NHS-PEG4-Biotin which is presented in Figure 6.21.    
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Figure 6.21: Chemical structure of NHS-PEG4-Biotin. 
 
NHS-PEG4-Biotin labels antibodies and proteins that contain primary amines through 
formation of amide bonds between lysine or N-terminal amino groups with the NHS ester 
group [91]. Generally, amines are the primary target moiety for antibody biotinylation due to 
the abundance of lysine side chain ε-amines and N-terminal α-amines, as indicated in the 
antibody structural diagram in Figure 6.22. Hence, it was deduced that biotinylation reagents 
that target other less common functional groups are unlikely to result in more efficient mAb 
biotinylation.  
  
 
Figure 6.22: Antibody structure and NHS-PEG4-Biotin labelling sites (shown in red). Image adapted from [92]. 
 
Finally, in order to evaluate if the current biotinylation method had an adverse effect on the 
affinity of the antibodies as well as whether the purification process of the hybridoma clones 
or the subsequent storage of the antibodies in 0.03% azide solution had a considerable impact 
on biological activity, four purified mAbs were re-screened before and after biotin labelling 
with the indirect ELISA assay (Figure 6.10) used for characterisation of the hybridoma 
supernatants. As indicated in Figure 6.23, the reduction of signal magnitude after biotinylation 
is not significant (<5%). Additionally, the examined antibodies showed overall high affinity 
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to HA as suggested by OD values>2. Therefore, alternative ELISA formats or other types of 
labelling (e.g. non covalent), more appropriate for the produced mAbs had to be explored. 
 
 
Figure 6.23: Response before and after biotinylation (5 μg/ml antigen, 10 µg/ml mAb) as measured with the indirect 
screening assay. 
 
6.3.4 A Modified ELISA for Detection of Antibody Responses 
6.3.4.1 Overview of Different ELISA Approaches 
Several assay types that did not require biotinylation of the primary strain-specific antibody 
were examined for HA quantification. In brief, the following ELISA formats were evaluated: 
 
1) An indirect ELISA with the HA antigen immobilised onto the plate and secondary 
HRP-conjugated IgG for detection (Figure 6.10). 
2) A modified version of (1) by incorporating GNA as capture. 
3) A direct ELISA involving GNA for capture and noncovalent labelling of the primary 
mAb with fluorescently labelled Fab fragments (Zenon labelled Alexa Fluor 488). 
4) A sandwich ELISA employing GNA or ConA for capture and secondary ALKP-
conjugated IgG for detection (Figure 6.13). 
  
The ELISA of (1), which is essentially the method employed for the screening process, 
resulted in an antigen dependent response for 4 antibodies (Figure 6.24). However, as 
typically observed in indirect immunoassay types [85, 93. 94], the signal to noise ratio (S/N) 
was relatively low, i.e. there was significant background noise (S/N<20, data not shown). 
Furthermore, indirect ELISA formats are not generally preferred for routine potency 
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determinations due to the potential impact on antigen stability from immobilisation onto a 
plate.  
 
 
Figure 6.24: Concentration curves of monobulk vaccine using the indirect ELISA.  
 
Consequently, GNA was introduced as capture in ELISA (1) to increase sensitivity and 
specificity of antigen binding (ELISA (2)). Titrations at different levels of GNA (Appendix 
6.4b) readily suggested the potential cross-reactivity between GNA and the secondary non-
specific detecting HRP-linked IgG (high absorbance values for blanks/negative controls, 
indistinguishable signal at different antigen concentrations). Thus, this approach was early 
abandoned.  
A direct ELISA was tested next (3). This method entailed quick labelling of the antibodies 
with a novel reagent (Appendix 6.4c) and minimal number of washes between steps. Despite 
the initial promising results, no reproducibility was noted.  
Finally, a lectin based sandwich ELISA (4), which is detailed in 6.2.4, was considered the 
most desirable methodology and was therefore taken forward for further optimisation and 
development. 
 
6.3.4.2 Assay Development and Optimisation 
Initial assay optimisation was performed through full factorial experiments consisting of 3 
factors, namely GNA concentration, starting antigen concentration (monobulk samples) and 
concentration of the primary mAb, at different levels (Appendix 6.3). The aim was to achieve 
an OD ~ 1, minimise use of precious reagents and identify an antigen dilution range that 
would allow satisfactory 4PL fitting.  This procedure was applied for all the influenza 
subtype-specific antibodies of Table 6.7 with the exception of the anti-H1N1 mAbs as they 
had been depleted in previous experiments. A representative ANOVA analysis with the 
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corresponding main effects plot is presented in Table 6.11 and in Figure 6.25 respectively. As 
suggested by both Table 6.11 and Figure 6.25, the amounts of antigen and antibody exert the 
most significant effect on signal response whereas GNA levels are less critical across the 
range evaluated. 
 
Table 6.11: ANOVA for OD from optimisation grid for VP2-2 (R-Sq = 98.13%). 
Source DF Seq SS Adj SS Adj MS F P 
[mAb] 3 2.98275 2.98275 0.99425 776.47 0.000 
[GNA] 2 0.03624 0.03624 0.01812 14.15 0.000 
[HA] 2 0.27047 0.27047 0.13523 105.61 0.000 
[mAb]*[GNA] 6 0.06854 0.06854 0.01142 8.92 0.000 
[mAb]*[HA] 6 0.12841 0.12841 0.0214 16.71 0.000 
Error 52 0.06658 0.06658 0.00128   
Total 71 3.55299     
 
 
 
 
Figure 6.25: Main effects plot for OD from optimisation grid for VP2-2. 
 
The respective, individual recommended values of GNA and antibody concentrations for all 
the mAbs that were tested are summarised in Table 6.12. An HA protein range 23.4-3000 
ng/ml was found suitable for all mAbs used.  
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Table 6.12: Optimised ELISA components as determined by Full Factorial screening DoE. 
mAb Code HA origin 
GNA 
(µg/ml) 
mAb 
(µg/ml) 
VP2-1 H3N2 25 4 
VP2-2 H3N2 50 4 
VP2-3 H3N2 100 4 
VP2-4 H3N2 100 8 
VP2-5 H3N2 50 4 
VP2-6 H3N2 25 4 
VP2-9 H3N2 100 4 
VP2-10 H3N2 100 4 
VP2-11 H3N2 25 2 
VP2-12 H3N2 50 2 
VP2-13 H3N2 100 4 
VP3-20 B1 50 2 
VP4-10 B2 25 8 
VP4-11 B2 100 4 
VP4-19 B2 50 2 
VP4-20 B2 25 4 
 
 
6.3.4.3 Application in Monobulk Samples 
6.3.4.3.1 Assessment of Parallelism  
Monobulk preparations of A/Victoria/210/2009 and B/Brisbane/60/2008 were tested with the 
sandwich ELISA according to the experimental procedure. Indicative HA concentration 
curves for mAb VP2-6 are displayed in Figure 6.26 and the characteristics of the 4PL models 
fitted to each curve are summarised in Table 6.13. Overall, curves adjusted R2 was 
found≥0.99 for all mAbs which suggests that though the system is adequately defined by the 
4PL model further assay improvement is possible.  
 
Table 6.13: Description of 4PL models for VP2-6 (Appendix 6.2).  
Parameter Batch 1 Batch 2 Batch 3 
Reduced Chi-Sqr 9.31E-05 1.09E-04 2.13E-05 
Adj. R-Square 0.997 0.997 0.994 
A1 -0.102 -0.106 -0.188 
A2 6.136 5.371 8.359 
x0 2.46E-06 1.05E-06 3.41E-07 
p 0.314 0.323 0.246 
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Figure 6.26: Typical 4PL concentration curves for three H3N2 vaccine monobulk formulations using VP2-6. 
 
The parallelism between different serial dilution curves for each antibody was also 
investigated through Tukey’s HSD test as previously described (see 6.3.1.1). Following 
logistic transformation of the OD values, linear regression was performed on all the 
constructed antigen curves for each mAb used (Figure 6.27).  
 
 
Figure 6.27: Linear regression on logistically transformed OD data for VP2-6. 
 
Multiple comparisons among the calculated slopes were conducted using Tukey's HSD test 
(Table 6.14). In summary, this test demonstrated that the slopes of the serial dilution curves 
did not differ significantly from each other (P-value>0.05=significance level) for all mAbs 
utilised.  
y = -0.424x + 0.274
R² = 0.995
y = -0.423x + 0.395
R² = 0.989
y = -0.444x + 0.416
R² = 0.994
-3.0
-2.5
-2.0
-1.5
-1.0
-0.5
0.0
0.5
1.0
0 2 4 6 8
A
. 
U
. 
Power of two-fold dilutions (2X)
221 
 
Table 6.14: Comparison of concentration curves through Tukey’s test. 
Test mAb  
No of Curves  
Analysed 
P-value 
VP2-1 3 0.997 
VP2-2 3 0.938 
VP2-3 3 0.751 
VP2-4 3 0.930 
VP2-5 3 0.639 
VP2-6 3 0.720 
VP2-9 3 0.973 
VP2-10 2 0.713 
VP2-11 2 0.879 
VP2-12 2 0.950 
VP2-13 3 0.948 
VP3-20 3 0.894 
 
 
6.3.4.3.2 Comparability with SRID  
Quantification of HA content of vaccine samples was achieved by using two other samples as 
calibrators (SRID-calibrated) in independent assays. Fifty-six measurements were recorded, 
employing twelve antibodies (Appendix 6.5). In general, the intra-assay variation calculated 
for the mean concentrations derived from at least four concentrations/dilutions can be 
regarded acceptable (CV<15%). The results are graphically illustrated in Figure 6.28.  
 
Figure 6.28: Quantification of HA with the ELISA using 12 mAbs. The black line represents the target SRID value whereas 
the upper and lower limits denote the typical SRID standard deviation. 
 
Relatively good correlations with the SRID target value of 3000 ng/ml are observed (all 
comparisons made for the upper range of the ELISA assay) with an average difference of 
approximately -3%. Nevertheless, several random, non-antibody related unusual observations 
were noted that showed more than ±15% difference from the SRID. Adequate explanation 
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cannot be provided for this phenomenon and repetition of the measurement is required. 
However, it needs to be mentioned that these discrepancies could also have arisen from SRID 
measurements and therefore they might not necessarily represent ELISA defects.  
Furthermore, comparability with the SRID assay was characterised through a 1-Sample t-Test 
procedure (Figure 6.29). Analysis suggested that ELISA results do not differ significantly 
from the respective SRID values (P-value=0.323>0.05), i.e. ELISA exhibited equivalent 
precision to detect HA antigen in virus samples as SRID. 
 
 
Figure 6.29: Comparison of HA values calculated via ELISA with SRID. The average estimated concentration value (X) is 
likely to be equal to the SRID reference value specified in H0 (3000), since this value is within the confidence interval.  
 
 
6.3.4.4 Application in Whole Virus Samples 
Similar analysis was conducted for the evaluation of the HA-ELISA assay in determining HA 
content in whole virus samples. Purified whole virus SRID reference standard of 
A/Victoria/210/2009 was analysed (NIBSC, lot 12/112) alongside monobulk antigen 
preparations. Sigmoidal dose-response relationships were obtained, thus indicating that the 
assay is able to detect HA in zwittergent solubilised (split) viral formulations. However, a 
two-fold reduction in signal response was observed when the whole virus curves were 
compared to the respective monobulk curves regardless of the detecting antibody used (Figure 
6.30). This potentially demonstrates that solubilised whole virus is not suitable as a calibration 
standard for measurement of HA levels in monobulk material and vice versa, i.e. different 
sample matrices do not react similarly in the ELISA assay.  
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Figure 6.30: Concentration curves of whole virus and monobulk samples using VP2-1. A 2-fold decrease in absorbance is 
noted.  
 
6.3.4.5 Reactivity of ELISA mAbs with Evolved Strain Subtypes  
One of the advantages of the development of a panel of non-competing mAbs is the potential 
of extended use of antibodies due to limited mutations in HA sequence. To confirm this 
assumption, viral subtypes from subsequent annual vaccine formulations were analysed in the 
ELISA with the set of antibodies raised against A/Victoria/210/2009 (H3N2), lastly used in 
the 2011-2012 influenza campaign. The current H3N2 strain included in the 2013-2014 
seasonal vaccine is A/Texas/50/2012 which shows 91.2% overlap in HA sequences with 
A/Victoria/210/2009. As displayed in Figure 6.31a, some antibodies were able to bind to the 
evolved strain with similar or equal affinity, therefore suggesting that the specific epitope of 
HA that is recognised has not been modified. Conversely, other mAbs demonstrated 
significantly reduced avidity for the A/Texas strain which is indicative of complete loss of the 
binding epitope (Figure 6.31b). 
 
 
  
 
 
 
 
 
 
 
Figure 6.31: Use of mAbs to detect different H3N2 subtypes. a) VP2-3 and b) VP2-11. 
a b 
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6.4 CONCLUSIONS AND FUTURE PROSPECTS 
An ELISA method was developed for HA detection and quantification in influenza vaccine 
formulations as an alternative to the currently used SRID assay. The method involves capture 
of HA based on GNA lectin binding of mannose residues and subsequent detection of the 
bound HA by strain specific monoclonal antibodies. Preliminary findings using an anti-H1N1 
monoclonal antibody suggested that the assay can be employed for HA determination in 
whole virus as well as monobulk (post-split) samples. Both sample matrices can be potentially 
used as antigen standards for assay calibration.  
Furthermore, eighty hybridoma culture supernatants, raised against the viral strains H1N1, 
H3N2, B1 and B2, were screened for activity/cross-reactivity through an indirect ELISA 
platform. Half of those exerting the strongest binding ability to the antigen were chosen and 
were further purified. The purified antibodies were subsequently characterised for their ability 
to inhibit receptor binding on the basis of a positive haemagglutination inhibition test. 
Application of the original GNA-based assay protocol proved unsuccessful due to inefficient 
biotinylation of the antibodies.  
Consequently, a modified immunoassay was developed, suitable for the generated antibodies. 
This method also utilises GNA for universal capture of HA but detection is performed 
through an enzyme-conjugated secondary antibody that binds to the strain-specific antibody, 
thus eliminating the need for biotinylation. Overall, the ELISA is less time consuming than 
SRID and relatively easy to perform and it has higher sensitivity. Furthermore, it was 
demonstrated that quantification of HA by ELISA correlates satisfactorily with corresponding 
SRID assays and that immunorelevant material is detected. Calibration of the assay can be 
performed with antigen HA for vaccine release. Finally, the ELISA is high-throughput, 
readily automated and has a potential for extended life of reagents. 
The next phase of this project could entail demonstration that the assay is stability indicating 
(e.g. by forced degradation studies), application in trivalent and quadrivalent vaccine mixtures 
and identification of the antibody-binding epitopes on HA.   
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7.THESIS CONCLUSION 
 
This multidisciplinary thesis focused on the Agrippal base product, an egg-based inactivated 
subunit TIV influenza vaccine produced by Novartis Vaccines in a semi-automated 
manufacturing site in Liverpool. Egg-based influenza vaccine production is characterised by 
notable challenges such as lack of real time viral growth monitoring during virus propagation, 
use of non-specific offline analytical methods for product characterisation for upstream, 
“crude” operations (e.g. SDS-PAGE, protein assays), limitations of offline assays and long 
analysis times for determination of main quality attributes throughout the downstream 
processing (e.g. SRID, HA assay), egg variability and annual changes of influenza strains 
included in the TIV preparation, extreme biological product complexity and limited process 
understanding. Main objectives of this project included optimisation of assays and introduction 
of analytical technologies that could potentially facilitate characterisation of viral 
concentration, particle size and aggregation interactions with a view to promote understanding 
of product stability and identify opportunities for process optimisation and yield improvements 
in the Agrippal platform.    
The first phase of this project (Chapter 2) explored methods of nanoparticle analysis that could 
enable efficient monitoring of viral content from the early stages of product development and 
throughout the downstream operations. A comparative evaluation between commonly used 
particle analysers (DLS, NTA, DCS, LD) indicated that DCS is the most suitable method for 
the analysis of in-process influenza vaccine samples. Following the evaluation, NV recognised 
the potential value of DCS and purchased one instrument for further studies.  
Optimisation of DCS measurements and applications of the technique throughout the 
manufacturing of Agrippal were subsequently investigated (Chapter 3). DCS was proven to be 
a valuable analytical tool by demonstrating high potential for process investigation and 
monitoring. Key applications include direct real time determination of viral content in allantoic 
fluid quantification of viral titres and estimation of viral recoveries between whole virus process 
stages (upstream and downstream), characterisation of unit operations on a particle based 
approach/PSD fingerprinting (e.g. Amberlite mixing, determination of filtration losses, 
monitoring of inactivation etc.) and detection and monitoring of the kinetics of aggregate 
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formation that could cause manufacturability issues before and after viral solubilisation.  Future 
work could involve routine use of the DCS for early phase or seed optimisation studies (e.g. 
determination of optimum incubation conditions and input dose) as an orthogonal method to 
current off-line analytical methods that require viral purification (SDS-PAGE, protein 
concentration, SRID) as well as implementation of the technique for at-line analysis during 
manufacturing. Typical PSD batch profiles for different strains belonging to the three influenza 
types (H1N1, H3N2 and B) could be established for all production stages and subsequently 
DCS could be used for rapid identification of deviations in real time (~15-20 minutes). This 
could possibly enable prediction of filter blockages, e.g. when significant/unusual aggregation 
phenomena are observed, and thus enable improved monitoring of process performance.  
DCS was also specifically employed in a novel application entailing determination of viral 
growth in allantoic fluid upon addition of glucocorticoids and other compounds 
(hydrocortisone, dexamethasone, corticosterone, AFZ077 and BYF589) into the seed inoculum 
subsequent inoculation through the allantoic cavity of fertilised chicken eggs (Chapter 4). It 
was shown that co-administration of hydrocortisone with B type viruses at a dose range of 0.5-
5 µg/egg resulted in viral yields greater than 50% compared to typical control values 
irrespective of virus provenance. The more potent synthetic glycocorticoid dexamethasone 
yielded comparable results at the lower dose of 0.1 µg/egg though it also had a noticeable 
impact on the quality of harvested allantoic fluid as demonstrated by increase of turbidity and 
elevated blood diffusion. The avian glycocorticoid corticosterone as well as the NV research 
compounds AFZ077 and BYF589 had no influence on viral growth of influenza B strains. In 
contract to B viruses, addition of hydrocortisone at 1 and 10 µg/egg halted virus multiplication 
in A strains by approximately 20 and 40% respectively based on DCS data. The mechanism by 
which hydrocortisone inhibits growth of influenza A viruses is unknown as this phenomenon 
had not been established prior to conduction of the studies reported here. It is tentatively 
postulated that the observed inhibitory impact of HC on multiplication of A viruses in eggs is 
associated with differences in interferon expression, activity and infection dynamics compared 
to B strains. Administration of corticosterone appeared to have limited or insignificant influence 
on viral recoveries of A type viruses. Furthermore, it was demonstrated that injection of 
hydrocortisone at increasing concentrations modified the composition of the generated virions 
of B virus types by increasing the relative mass percentage of NA on the viral surface, viz. the 
higher the hydrocortisone dose injected, the higher the percentage of NA. This effect was also 
accompanied by a decline of the ratio of membrane glycoproteins (HA/NA). Moreover, it was 
shown that administration of hydrocortisone at doses greater than 0.1-1 μg/egg induced 
production of viral particles containing disproportionally high amounts of inactive or impaired 
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NA thus suggesting a possible mismatch between NA physical mass and activity. These 
findings are novel and potentially explain why viral multiplication of B strains was not favoured 
at high hydrocortisone concentrations. Although the impact of hydrocortisone on viral 
morphology needs to be fully investigated it needs to be emphasised that as Agrippal is a subunit 
vaccine -there is no requirement for in-process whole virus influenza protein purity profile and 
relative quantification of proteins- and only presence/detection of NA through the NA fetuin 
activity assay is required for vaccine release, the CQAs of the final product are expected to 
remain unaffected. Depletion of the residual hydrocortisone throughout processing and no 
interference with assays should be proven nonetheless. The next phase of this project could 
involve further characterisation of the mechanism of action of hydrocortisone and other 
structurally related glycocorticoids on viral growth of B strains in terms of interferon responses, 
elucidation of the antagonistic function of hydrocortisone in A strains and identification of a 
non-steroidal compound that could promote replication of A type viruses. It is noted that 
although the NV candidates AFZ077 and BYF589 had no influence on the growth of B viruses, 
they could exert a different effect when used with A viruses. The hydrocortisone-induced 
modification of viral composition of influenza B virus types and/or morphology needs to be 
investigated further (e.g. TEM analysis, alternative methods of quantification of NA activity, 
NA sequencing etc.). Finally, the impact of hydrocortisone on viral yields of B strains needs to 
be confirmed at pilot and production scale through engineering batches.        
The intricate, multi-step, multi-variable and poorly characterised solubilisation process of the 
membrane glycoproteins HA and NA from the surface of influenza virus by the detergent 
CTAB as applied in the Agrippal manufacture platform was comprehensively examined with 
the aim of enhancing process understanding by identifying the key parameters potentially 
affecting solubilisation efficiency and product quality (Chapter 5). Preliminary screening 
experiments investigating the impact of several factors (CTAB and Tween 80 concentrations, 
ionic strength, solubilisation duration and temperature) and interactions thereof on 
solubilisation efficiency (HA yield, specific purity, protein recovery) demonstrated that the 
stabiliser Tween 80 and the incubation time with CTAB exerted the most significant effects. In 
subsequent studies the DCS analyser was uniquely employed for the real-time monitoring of 
solubilisation procedures. It was shown that upon addition of the solubilising agent CTAB, 
whole virus particles are rapidly solubilised (90% of virus in 15 minutes) whilst large 
aggregates (>0.2 µm) are concurrently formed. Complete depletion of aggregates after 
ultracentrifugation suggested that the solubilised viral cores are removed (pelleted out) after 
clustering together. Conduction of solubilisation processes at increasing Tween 80 
concentrations revealed that Tween 80 reduces formation of virus-related aggregates. 
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Nonetheless, increased levels of Tween 80 also induced a distinct rise of non-solubilised 
particles thus suggesting inhibition of viral solubilisation possibly through a competing 
mechanism with CTAB. Analysis of aggregate composition after fractionation of post-split 
preparations in sucrose gradients showed that under current solubilisation conditions 
approximately 30% of functionally active HA is entrapped within the core-related aggregates. 
Solubilisation at higher CTAB concentrations reduced the relative amount of HA found in the 
pellet but failed to increase recoveries of biologically active HA in the supernatant therefore 
indicating possible CTAB-induced protein denaturation. Conduction of solubilisation at 
slightly higher Tween 80 levels (1.3-fold) also had no influence on antigen recoveries despite 
the evident decrease in aggregate formation. It is postulated that further optimisation of Tween 
80 concentrations could strike an intricate balance between two aspects: reduction of 
aggregation of un-split whole virus particles with the solubilised viral cores without 
concomitantly inhibiting viral solubilisation. Additionally, the extraction of HA and NA 
glycoproteins from the membrane of formaldehyde-inactivated influenza viruses with 
alternative detergents was evaluated. Extensive treatment with the non-ionic surfactant NP9 
resulted in only partial virus solubilisation and high levels of core proteins present in the final 
collected supernatant. The observed resistance of HCHO-inactivated viruses to NP9 
solubilisation compared to BPL-inactivated viruses potentially relates to the formaldehyde-
induced protein cross-linking effect. Reconstitution of influenza virus envelopes with C12E8 
was also attempted. Similarly to NP9, significant amounts of virus remained non-solubilised. 
Nevertheless, purified virosomes of superior purity (80% HA, 10% NA) compared to the 
current subunit vaccine were obtained. Further optimisation of the solubilisation conditions 
with C12E8 could improve HA yield recoveries. The last phase of this project explored the 
apparent proteolysis phenomenon observed in post-solubilised CTAB preparations. A serine 
endopeptidase that preferentially degrades the viral M1 matrix protein was identified. Further 
investigations suggested that M1 is possibly retained through the solubilisation process in free 
non-virus associated form which consequently indicates disruption of whole virus particles and 
release of internal components. The next phase of this project could entail further elucidation 
of the role of Tween 80 as a stabiliser/inhibitor of aggregation, optimisation of solubilisation 
conditions to minimise the amount of non-solubilised antigens lost during centrifugation, 
characterisation of the influence of inactivation conditions with formaldehyde on solubilisation 
efficiency and further investigations of the observed proteolytic activity. Overall, the work 
performed as part of this thesis lead to enhanced process understanding and highlighted the 
need for subsequent characterisation studies.  
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Finally, the development and optimisation of a novel GNA-binding ELISA as an alternative 
replacement to the SRID potency assay for detection and quantification of HA in vaccine 
samples (Chapter 6). The method involves capture of HA based on GNA lectin binding of 
mannose residues and subsequent detection of the bound HA by strain specific monoclonal 
antibodies. Preliminary findings using an anti-H1N1 monoclonal antibody suggested that the 
assay can be employed for HA determination in whole virus as well as monobulk (post-split) 
samples. Both sample matrices can be potentially used as antigen standards for assay 
calibration. Furthermore, eighty hybridoma culture supernatants, raised against the viral strains 
H1N1, H3N2, B1 and B2, were screened for activity/cross-reactivity through an indirect ELISA 
platform. Half of those exerting the strongest binding ability to the antigen were chosen and 
were further purified. The purified antibodies were subsequently characterised for their ability 
to inhibit receptor binding on the basis of a positive haemagglutination inhibition test. 
Application of the original GNA-based assay protocol proved unsuccessful due to inefficient 
biotinylation of the antibodies. Consequently, a modified immunoassay was developed, suitable 
for the generated antibodies. This method also utilises GNA for universal capture of HA but 
detection is performed through an enzyme-conjugated secondary antibody that binds to the 
strain-specific antibody, thus eliminating the need for biotinylation. Overall, the ELISA is less 
time consuming than SRID and relatively easy to perform and it has higher sensitivity. 
Moreover, it was demonstrated that quantification of HA by ELISA correlates satisfactorily 
with corresponding SRID assays and that immunorelevant material is detected. Calibration of 
the assay can be performed with antigen HA for vaccine release. Finally, the ELISA is high-
throughput, readily automated and has a potential for extended life of reagents. It needs to be 
noted that even though this ELISA might not be able to fully replace the SRID assay, primarily 
due to lack of clinical data correlating to potency as well difficulties relating to the supply of 
common HA standards for influenza vaccine manufacturers, it can be used in a complementary 
manner. The next phase of this project could entail demonstration that the assay is stability 
indicating (e.g. by forced degradation studies), application in trivalent and quadrivalent vaccine 
mixtures and identification of the antibody-binding epitopes on HA.   
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APPENDIX 
 
APPENDIX 1  
1.1 Summary of Unit Operations 
Process Step Goal 
Critical Control 
Parameters 
Analytical Test  
Egg Delivery 
Delivery of pre-
incubated fertile hens 
eggs, from accredited 
suppliers to Novartis 
manufacturing facilities. 
- Pre -Incubation 
temperature of 
transportation 
-Temperature and 
duration of nebulization 
-Temperature of pre-
incubation 
-Percentage of candling 
eggs 
None 
Egg Inoculation 
Inoculation of influenza 
virus into the allantoic 
cavity of embryonated 
chicken eggs in order to 
allow 
virus replication and 
growth. 
Volume of 
inoculum into 
eggs 
Sterility  
(European Ph.) 
Virus Propagation 
and 
Egg Chilling 
Virus growth by 
incubation at chilling of 
eggs at the end of 
incubation in order to 
stop virus replication 
and allow the 
subsequent allantoic 
fluid 
harvesting 
-Temperature of 
incubation 
-Relative Humidity 
-Duration of incubation 
-Temperature of chilling 
-Duration of chilling 
None 
AF Harvesting 
Selective recovery of 
AF containing virus 
from eggs and egg 
discard 
- Flow rate of peristaltic 
pump 
- Flow rate of AF going 
to the clarifying 
centrifuge 
- AF volume at the end 
of ultrafiltration 
-HA Titre 
(Haemagglutination) 
Virus Inactivation 
Inactivation of the virus 
using formaldehyde to 
enable viral replication 
-Temperature 
-Duration 
-Initial and operating 
mixing speed 
-End pH 
-Free HCHO 
-HATitre 
(Haemagglutination) 
-Free HCHO  
(European Ph.) 
- Bioburden  
(Filtration by 
Membrane) 
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Process Step Goal 
Critical Control 
Parameters 
Analytical Test  
 
 
AF Purification by 
Zonal 
Ultracentrifugation 
(Sucrose Gradient) 
 
 
 
 
 
Purification of the virus 
from the egg protein 
-Operating speed 
-Banding speed 
-Flow rate 
-Volume of 
AF/centrifuge 
-Volume of peak 
Fraction 
-Volume of shoulder 
fraction 
-HATitre 
(Haemagglutination) 
-Bioburden (Filtration 
by 
Membrane) 
-Endotoxins (European 
Ph.) 
NaOH Addition 
pH adjustment between 
9.0 and 10.0 in order to 
create an unfavorable 
environment 
for bacterial growth 
pH None 
Barium Sulphate 
Treatment of 
Shoulder Fractions 
Endotoxin removal 
from shoulder fractions 
-Addition of WFI 
-BaSO4 suspension 
-Magnetic Stirring 
-Duration 
-Storage at 2-8°C 
-Centrifugation time 
-Centrifugation speed 
-Sodium citrate addition 
-HA 
Titre 
(Haemagglutination) 
-Bioburden (Filtration 
by 
Membrane) 
-Endotoxins (European 
Ph.) 
Purification by 
Diafiltration and 
Clarifying filtration 
Elimination of residual 
sucrose, BaSO4 and 
sodium citrate and 
exchange with 
PBS pH7.3 via 
diafiltration 
-Concentration volume 
-Volume of PBS to use 
for the diafiltration 
-Pressure during 
diafiltration 
-HA 
Titre 
(Haemagglutination) 
-Bioburden (Filtration 
by 
Membrane) 
-Endotoxins (European 
Ph.) 
-HAContent and 
Identity 
(SRID) 
-Protein content 
(Kjeldhal) 
-Split Test (SRID, NA, 
Proteins, SDS) 
Surface Antigen 
Solubilisation 
Separation of the 
surface antigens HA and 
NA from the virus 
membrane and selective 
recovery without 
destroying 
theimmunogenicity. 
-Mixing time for Tween 
and 
CTAB 
-Centrifugation speed 
-Temperature of the 
cold 
Room 
-Flow rate 
None 
Amberlite 
Treatment 
Reruction of CTAB 
present in the whole 
virus concentrate by 
Amberlite 
Stirring time 
CTAB 
(Spectrophotometric) 
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Process Step Goal 
Critical Control 
Parameters 
Analytical Test  
Final Filtration 
Filtration of product 
before shipment to 
Rosia 
Pump Speed to control 
pressure 
Bioburden (Filtration by 
Membrane) 
Monovalent Pool 
Harvest  
Final Product - 
- NA Identity (ELISA) 
- HA Identity (SRID) 
- pH (potentiometric) 
- Total Proteins/HA 
(Kjeldahl/HA) 
- Purity (SDS-PAGE) 
- CTAB (colorimetric) 
- Barium (Atomic 
Absorption) 
- Sodium Citrate 
Tribasic (HPLC) 
- Tween 80 (TLC) 
- Ovalbumin (ELISA)  
- Formol (colorimetric) 
- Sterility (European 
Ph.) 
- Viral Inactivation 
(European Ph.) 
-Aspect (European Ph.) 
- Endotoxins (European 
Ph.) 
- SRID  
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APPENDIX 2 
2.1 Blockade Magnitude Plots (SIOS) 
 
 
 
 
 
 
2.2 Previous Evaluation of CPS and Zetasizer 
a) Size distribution from DLS measurements of a mixture of four PVC standards: 1.1 μm, 
0.47 μm, 0.37 μm and 0.25 μm (Zetasizer, Novartis Vaccines & Diagnostics, Liverpool, UK, 
April 2012). 
 
 
b) Size distribution from disc centrifugation measurements of a mixture of four PVC 
standards: 1.1 μm, 0.47 μm, 0.37 μm and 0.25 μm (CPS, Novartis Vaccines, Marburg, 
Germany, April 2012). 
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APPENDIX 3 
3.1 Calculation of Haemagglutination Units (HAUs)  
 
Initial 
Dilution 
HA 
Assessment 
Well number 
1 2 3 4 5 6 7 8 9 10 11 12 
1/10 
+ 6 13 25 50 100 200 400 800 1600 3200 6400 12800 
++ 8 15 30 60 120 240 480 960 1920 3840 7680 15360 
+++ 9 18 35 70 140 280 560 1120 2240 4480 8960 17920 
++++ 10 20 40 80 160 320 640 1280 2560 5120 10240 20480 
1/100 
+ 63 125 250 500 1000 2000 4000 8000 16000 32000 64000 128000 
++ 75 150 300 600 1200 2400 4800 9600 19200 38400 76800 153600 
+++ 88 175 350 700 1400 2800 5600 11200 22400 44800 89600 896000 
++++ 100 200 400 800 1600 3200 6400 12800 25000 51200 102400 1024000 
1/1000 
+ 625 1250 2500 5000 10000 20000 40000 80000 160000 320000 640000 1280000 
++ 750 1500 3000 6000 12000 24000 48000 96000 192000 384000 768000 1536000 
+++ 875 1750 3500 7000 14000 28000 56000 112000 224000 448000 896000 8960000 
++++ 1000 2000 4000 8000 16000 32000 64000 128000 256000 512000 1024000 10240000 
 
 
3.2 Boltzmann Sigmoidal Models (Growth Curves) 
 
2/)(
21
1
A
e
AA
y
dxoxx





 
where A1: initial y value y(-∞), A2: final y value y(+∞), x0: centre, dx: width (slope)  
 
a) For B/Massachusetts/2/2012 (32 oC): 
6.12
1
5.12
62.1/)2.47(




xe
y , R2=0.988 
 
b) For A/Texas/50/2012 (34 oC): 
69.7
1
56.6
34.4/)43.37(




xe
y , R2=0.974 
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3.3 Growth Variability in Individual Eggs 
a) A/Texas/50/2012 
 
 
 
Egg No 
Peak 
Height 
1 6.20 
2 5.13 
3 5.85 
4 10.44 
5 6.05 
6 7.41 
7 5.00 
8 5.61 
9 6.16 
10 5.80 
11 5.84 
12 6.07 
13 4.99 
14 5.82 
15 6.17 
16 6.44 
17 7.83 
18 8.31 
19 5.81 
20 5.48 
21 8.16 
22 7.81 
23 6.65 
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Egg16 Egg 17 Egg 18
Egg 19 Egg 20 Egg 21
Egg 22 Egg 23
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b) A/Christchurch/16/2010 (NIB74) 
  
 
 
Egg No Peak Height 
1 9.25 
2 9.61 
3 8.43 
4 9.13 
5 9.36 
6 6.78 
7 8.47 
8 9.93 
9 9.23 
10 6.73 
11 14.31 
12 13.48 
13 12.71 
14 6.28 
15 7.90 
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3.4 Inactivation PSDs of B/Massachusetts/02/2012 
 
 
3.5 Barium Sulphate Absorption-Elution 
a) Example of sucrose density gradient profile based on total protein (Bio-Rad) and 
electrophoresis analysis (reduced SDS-PAGE). 
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b) Sampling plan for characterisation of BaSO4 treatment step. In red: routine testing and in 
green: additional analysis conducted as part of the study.   
Sample Description 
Protein Content  
(Bio-Rad) 
HA titre 
(HA assay) 
Viral Content  
(DCS) 
HA2 Density  
(SDS-PAGE) 
Peak Fraction (III)     
Shoulder Fractions (II+IV)     
Waste Worksteam A     
Waste Worksteam B     
Waste Worksteam C     
Eluate 1 (Workstream A)     
Eluate 2 (Workstream A)     
Eluate 3 (Workstream A)     
Eluate 1 (Workstream B)     
Eluate 2 (Workstream B)     
Eluate 3 (Workstream B)     
Eluate 1 (Workstream C)     
Eluate 2 (Workstream C)     
Eluate 3 (Workstream C)     
Workstream A BaSO4 waste     
Workstream B BaSO4 waste     
Workstream C BaSO4 waste     
Eluate Pool 1     
Eluate Pool 2     
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APPENDIX 4 
4.1 Run 1: Analytical Measurements 
a) DCS 
 
 
 
b) Protein (Bio-Rad) 
 
[HC]   
(µg/egg) 
Protein Concentration (µg/ml) 
A B Mean St. Dev. CV (%) 
0 123 134 128.5 7.8 6.1 
1 277 231 254.0 32.5 12.8 
5 265 254 259.5 7.8 3.0 
10 240 230 235.0 7.1 3.0 
20 246 232 239.0 9.9 4.1 
 
c) HA Potency (SRID) 
 
[HC]   
(μg/egg) 
HA (µg/ml) 
A B Mean  St. Dev. CV (%) 
0 28.4 40.3 34.4 8.4 24.4 
1 70.3 99.7 85.0 20.8 24.4 
5 95.3 105.4 100.3 7.2 7.1 
10 84.8 95.8 90.3 7.8 8.6 
20 106.5 98.7 102.6 5.5 5.4 
 
d) Purity (SDS-PAGE) 
 
[HC]   
(μg/egg) 
HA2 Relative Intensity 
A B Mean StDev CV (%) 
0 1 1.17 1.09 0.1 11.0 
1 1.98 1.83 1.91 0.1 5.6 
5 1.93 1.57 1.75 0.3 14.5 
10 1.80 1.76 1.78 0.0 1.6 
20 2.10 2.23 2.17 0.1 4.2 
[HC]  
(μg/egg) 
Peak Height (µg/µm) 
A B Mean St. Dev. CV (%) 
0 7.4 7.4 7.4 0.0 0.2 
1 20.4 12.1 16.3 5.9 36.1 
5 15.2 19.3 17.2 2.9 16.8 
10 13.8 13.6 13.7 0.2 1.2 
20 18.7 19.7 19.2 0.7 3.7 
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4.2 Run 2: Analytical Measurements 
a) DCS 
 
[HC or DEX] 
(µg/egg) 
Peak Height (µg/µm) 
DEX HC 
A B Mean 
St. 
Dev. 
CV 
(%) 
A B Mean 
St. 
Dev. 
CV 
(%) 
0 18.4 14.0 16.2 3.1 19.2 18.4 14 16.2 3.1 19.2 
0.02 18.7 18.7 18.7 0.0 0.0 17.0 17.8 17.4 0.6 3.3 
0.1 17.9 18.9 18.4 0.7 3.8 21.8 20.0 20.9 1.3 6.1 
0.5 20.1 20.9 20.5 0.6 2.8 22.8 24.5 23.7 1.2 5.1 
 
b) Protein (Bio-Rad) 
 
[HC or 
DEX] 
(µg/egg) 
Protein Concentration (μg/ml) 
DEX HC 
A B Mean 
St. 
Dev. 
CV 
(%) 
A B Mean 
St. 
Dev. 
CV 
(%) 
0 198.4 160.4 179.4 26.9 15.0 198.4 160.4 179.4 26.9 15.0 
0.02 238.5 194.0 216.2 31.5 14.6 209.0 211.4 210.2 1.7 0.8 
0.1 277.9 299.4 288.6 15.2 5.3 230.7 249.3 240.0 13.2 5.5 
0.5 237.1 256.6 246.8 13.8 5.6 259.7 278.5 269.1 13.3 4.9 
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c) HA Potency (SRID) 
 
[Steroid] 
(µg/egg) 
HA (µg/ml) 
A B Mean St. Dev. CV (%) 
0 80.7 61.9 71.3 13.3 18.6 
DEX 0.02 104.8 101.8 103.3 2.1 2.1 
DEX 0.1 165.6 124.5 145.1 29.1 20.0 
DEX 0.5 127.4 106.7 117.1 14.6 12.5 
HC 0.02 80.7 61.9 71.3 13.3 18.6 
HC 0.1 72.3 79.9 76.1 5.4 7.1 
HC 0.5 91.6 98.2 94.9 4.7 4.9 
  
 
4.3 Run 3: Analytical Measurements 
a) DCS 
 
[Compound]  
(μg/egg) 
Peak Height (µg/µm) 
A B Mean St. Dev. CV (%) 
CTRL 20.5 - 20.5 - - 
DMSO 0.87 v/v % 17.9 - 17.9 - - 
HC 1 29.3 27.8 28.6 1.1 3.7 
DEX 0.1 25.5 26 25.8 0.4 1.4 
AFZ 1.75 20.1 17.2 18.7 2.1 11.0 
AFZ 3.5 19.1 18.2 18.7 0.6 3.4 
AFZ 8.75 18.1 19.2 18.7 0.8 4.2 
BYF 1.75 13.2 13 13.1 0.1 1.1 
BYF 3.5 15.9 17.8 16.9 1.3 8.0 
BYF 8.75 14.9 13.6 14.3 0.9 6.5 
 
b) Protein (Bio-Rad) 
 
[Compound]  
(μg/egg) 
Protein Concentration (µg/ml) 
A B Mean St. Dev. CV (%) 
CTRL 208.4 - 208.4 - - 
DMSO  
0.87 v/v % 
198.5 - 198.5 - - 
HC 1 283.2 308.7 295.9 18.0 6.1 
DEX 0.1 295.2 332.7 314.0 26.5 8.5 
AFZ 1.75 238.1 203.9 221.0 24.2 11.0 
AFZ 3.5 226.7 204.2 215.5 15.9 7.4 
AFZ 8.75 206.3 203.0 204.7 2.3 1.1 
BYF 1.75 172.7 176.6 174.6 2.8 1.6 
BYF 3.5 227.0 204.2 215.6 16.1 7.5 
BYF 8.75 219.2 169.1 194.1 35.5 18.3 
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c) HA Potency (SRID) 
 
[Compound]  
(μg/egg) 
HA (µg/ml) 
A B Mean St. Dev. CV (%) 
CTRL 70.7 - 70.7 - - 
DMSO  
0.87 v/v % 
78.2 - 78.2 - - 
HC 1 134.0 129.9 132.0 2.9 2.2 
DEX 0.1 147.8 159.7 153.8 8.4 5.5 
AFZ 1.75 83.8 77.1 80.5 4.7 5.9 
AFZ 3.5 71.9 79.3 75.6 5.2 6.9 
AFZ 8.75 79.8 80.9 80.4 0.8 1.0 
BYF 1.75 70.9 71.8 71.4 0.6 0.9 
BYF 3.5 81.7 92.6 87.2 7.7 8.8 
BYF 8.75 95.0 90.1 92.6 3.5 3.7 
 
4.4 Run 5: Analytical Measurements 
a) DCS 
[Compound] 
(μg/egg) 
Peak Height (µg/µm) 
A B C Mean St. Dev. CV (%) 
CTRL 7.7 6.7 9.0 7.8 1.1 14.3 
DEX 0.1 7.0 5.9 6.0 6.3 0.7 10.3 
HC 1 5.9 5.7 6.8 6.1 0.6 9.4 
CC 0.01 7.8 9.4 7.9 8.4 0.9 10.5 
CC 0.1 8.7 8.5 8.9 8.7 0.2 2.7 
CC 1 8.4 9.5 7.8 8.6 0.9 10.1 
 
b) Protein (Bio-Rad) 
[Compound] 
(μg/egg) 
Protein Concentration (µg/ml) 
A B C Mean 
St. 
Dev. 
CV (%) 
CTRL 153.2 125.2 127.6 135.3 15.5 11.4 
DEX 0.1 125.7 121.3 112.3 119.8 6.8 5.7 
HC 1 116.2 128.2 115.9 120.1 7.0 5.8 
CC 0.01 154.1 136.6 129.4 140.0 12.7 9.0 
CC 0.1 179.6 130.9 133.9 148.1 27.3 18.4 
CC 1 151.1 146.2 116.5 137.9 18.7 13.6 
 
c) HA Potency (SRID) 
[Compound]  
(μg/egg) 
HA (µg/ml) 
A B C Mean St. Dev. CV (%) 
CTRL 69.0 67.9 58.0 65.0 6.1 9.3 
DEX 0.1 49.9 55.0 55.9 53.6 3.2 6.0 
HC 1 55.0 48.1 60.0 54.4 6.0 11.0 
CC 0.01 76.6 71.6 66.8 71.7 4.9 6.8 
CC 0.1 67.1 72.9 68.1 69.4 3.1 4.5 
CC 1 80.7 65.7 66.2 70.9 8.5 12.0 
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4.5 Run 6: Analytical Measurements 
a) DCS 
 
[Compound]  Peak Height (µg/μm) 
(μg/egg) A B C Mean St. Dev. CV (%) 
CTRL 10.2 7.6 10.0 9.3 1.4 15.6 
HC 0.1 7.9 9.7 9.6 9.1 1.0 11.2 
HC 10 4.0 6.5 6.2 5.6 1.4 24.5 
CC 0.001 10.5 8.4 9.4 9.4 1.1 11.1 
CC 1 9.8 10.0 7.8 9.2 1.2 13.2 
CC 10 8.0 7.9 7.7 7.9 0.2 1.9 
 
b) Protein (Bio-Rad) 
[Compound]  
(μg/egg) 
Protein Concentration (µg/ml) 
A B C Mean St. Dev. CV (%) 
CTRL 136.9 113.5 133.0 127.8 12.5 9.8 
HC 0.1 135.1 133.9 148.9 139.3 8.3 6.0 
HC 10 81.7 101.2 100.6 94.5 11.1 11.7 
CC 0.001 152.9 157.4 148.0 152.8 4.7 3.0 
CC 1 121.3 145.9 165.2 144.1 22.0 15.2 
CC 10 133.3 140.8 140.2 138.1 4.2 3.0 
 
c) HA Potency (SRID) 
[Compound] 
(μg/egg) 
HA (µg/ml) 
A B C Mean St. Dev. CV (%) 
CTRL 78.3 56.2 60.8 65.1 11.7 17.9 
HC 0.1 65.0 59.5 66.8 63.8 3.8 6.0 
HC 10 38.5 37.9 36.7 37.7 0.9 2.4 
CC 0.001 67.0 78.5 75.9 73.8 6.0 8.2 
CC 1 58.2 73.4 76.6 69.4 9.8 14.2 
CC 10 57.2 66.8 63.7 62.6 4.9 7.8 
 
 
 
 
 
 
 
 
 
 
 
 
 254 
 
4.6 Run 13 (Growth Kinetics): Analytical Measurements 
a) DCS 
 
Temperature  
(oC) 
Time  
(h) 
Peak Height (µg/μm) 
- HC + HC 
33 
12 0.0 0.0 
24 0.0 0.0 
36 0.9 0.0 
48 9.1 9.9 
60 12.8 21.5 
72 13.3 18.0 
34 
12 0.0 0.0 
24 0.0 0.0 
36 1.5 0.0 
48 12.2 23.3 
60 12.4 18.0 
72 10.3 26.0 
35 
12 0.0 0.0 
24 0.0 0.0 
36 1.6 0.0 
48 11.0 16.2 
60 11.4 15.7 
72 6.6 16.5 
 
b) Protein (Bio-Rad) 
 
Temperature  
(oC) 
Time  
(h) 
Protein Concentration (µg/ml) 
- HC + HC 
33 
12 0.0 0.0 
24 0.0 0.0 
36 0.0 0.0 
48 92.5 148.4 
60 141.0 240.6 
72 122.4 214.0 
34 
12 0.0 0.0 
24 0.0 0.0 
36 0.0 0.0 
48 121.0 175.6 
60 143.2 235.9 
72 119.2 207.6 
35 
12 0.0 0.0 
24 0.0 0.0 
36 0.0 0.0 
48 108.1 170.6 
60 151.9 214.8 
72 92.1 185.0 
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c) HA Potency (SRID) 
 
Temperature  
(oC) 
Time  
(h) 
HA (µg/ml) 
- HC + HC 
33 
12 0.0 0.0 
24 0.0 0.0 
36 0.0 0.0 
48 33.6 37.8 
60 40.3 83.5 
72 35.0 80 
34 
12 0.0 0.0 
24 0.0 0.0 
36 0.0 0.0 
48 41.5 67.5 
60 44.2 66.6 
72 34.5 77 
35 
12 0.0 0.0 
24 0.0 0.0 
36 0.0 0.0 
48 35.2 66.8 
60 43.0 99.9 
72 28.5 65.5 
 
d) Purity (SDS-PAGE) 
 
Temperature  
(oC) 
Time  
(h) 
HA1+HA2 (%) 
- HC + HC 
33 
12 0.0 0.0 
24 0.0 0.0 
36 0.0 0.0 
48 40.3 41.4 
60 52.3 45.6 
72 47.9 41.4 
34 
12 0.0 0.0 
24 0.0 0.0 
36 0.0 0.0 
48 53.1 45 
60 52.3 46.2 
72 48.8 45.2 
35 
12 0.0 0.0 
24 0.0 0.0 
36 0.0 0.0 
48 52.9 45.2 
60 49.2 47.2 
72 45.3 46.8 
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e) Infectivity (EID50) 
 
Temperature  
(oC) 
Time  
(h) 
EID50/ml 
- HC + HC 
33 
12 1.6E+02 2.5E+01 
24 2.0E+06 4.0E+05 
36 4.0E+08 6.3E+07 
48 1.0E+09 7.9E+09 
60 6.3E+09 1.0E+09 
72 - - 
34 
12 1.0E+02 6.3E+01 
24 2.5E+06 1.0E+05 
36 3.2E+08 1.0E+09 
48 6.3E+09 6.3E+09 
60 2.5E+09 1.6E+09 
72 - - 
35 
12 1.6E+02 1.0E+03 
24 2.5E+06 4.0E+05 
36 1.0E+09 2.5E+08 
48 4.0E+09 6.3E+08 
60 4.0E+09 1.3E+09 
72 - - 
 
4.7 on Composition of Influenza B Viruses 
Indicative densitometry analysis on SDS-PAGE gels (reduced) 
 
a) Run 10 (B/Massachusetts/2/2012) 
Replicate 
 
HC  
(μg/egg) 
NA  
(%) 
HA1+HA2  
(%) 
MP+NP  
(%) 
A 
0 3.2 44.6 39.0 
0.1 3.7 42.9 44.4 
0.5 5.6 41.2 43.7 
1 6.9 40.6 43.8 
5 8.7 38.8 43.5 
100 9.6 37.5 44.3 
B 
0 2.9 43.3 39.9 
0.1 3.8 39.1 41.7 
0.5 5.5 41.2 45.0 
1 6.4 41.2 44 
5 7.8 39.6 43.2 
100 10.0 36.4 45.6 
C 
0 2.6 43.1 40.3 
0.1 3.8 42.9 44.8 
0.5 5.3 40.8 45.2 
1 6.1 40.7 44.3 
5 7.7 38.4 44.5 
100 10 36.2 45 
 
 
NP 
HA1 
HA2 
MP 
NA 
0     0.1   0.5    1       5    100 
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b) Run 11 (B/Brisbane/60/2008) 
 
Replicate 
  
HC  
(μg/egg) 
NA  
(%) 
HA1+HA2 
(%) 
MP+NP 
(%) 
A 
0  3.1 40.4 40.5 
0.1 3.3 40.4 43.5 
0.5 4.7 40.4 45.2 
1 5.1 40.1 45.6 
5 4.5 39.8 45.6 
100 8.1 33.5 46.7 
B 
0 3.4 42.5 40.1 
0.1 3.4 41.6 44.6 
0.5 4.5 40.5 45.0 
1 4.6 41.1 45.0 
5 4.6 39.6 44.9 
100 7.0 35.0 47.6 
C 
0  2.9 41.6 42.3 
0.1 2.7 41.8 44.8 
0.5 4.3 40.9 45.8 
1 3.9 38.5 47.4 
5 4.1 39.7 45.3 
100 6 28.1 46.5 
 
c) Run 12 (BX-51B)  
 
Replicate 
  
HC  
(μg/egg) 
NA  
(%) 
HA1+HA2 
(%) 
MP+NP 
(%) 
A 
0  4.4 42.7 43.3 
0.1 5.0 41.9 43.3 
0.5 6.3 40.0 47.0 
1 6.0 40.2 46.9 
5 7.8 38.2 45.5 
100 9.8 36.6 46.2 
B 
0 4.0 41.6 42.0 
0.1 5.6 41.7 43.5 
0.5 6.9 38.9 45.8 
1 6.9 39.7 46.7 
5 7.6 40.2 45.5 
100 10.8 36.4 46.1 
C 
0  4.9 40.4 39.6 
0.1 4.9 40.9 43.7 
0.5 5.8 40.0 45.6 
1 6.5 39.2 45.9 
5 8 38.3 44.6 
100 10.5 36.1 44.5 
 
 
0     0.1   0.5    1     5    100 
HA1 
MP 
NA 
HA2 
NP 
0     0.1   0.5    1     5    100 
HA1 
MP 
NA 
HA2 
NP 
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APPENDIX 5 
5.1 The “Split Test” 
The purpose of this laboratory test is to establish the optimum concentration of CTAB both 
for new or little-known strains of the campaign of the current year and for strains that are 
known and have already been used in the campaigns of previous years and for which 
historical data is known. 
The “Split Test” is performed based on internal SOP as follows:  
1. Calculation of f and CF factors 
Historical data of the strain under examination are analysed, e.g. if the new strain is a 
H1N1 strain, the historical data of the H1N1 strain of the previous year(s) is collated 
and analysed. Data (for every batch produced) consists of: protein concentration (μg/ml) 
of whole virus sample as determined by Kjeldahl method, HA concentration of whole 
virus (μg/ml) as determined by SRID, dilution of whole virus performed in production 
prior to solubilisation and concentration of CTAB used. The values f (ratio between the 
concentrations of protein and HA) and CF (ratio between the concentrations of CTAB 
actually used and the theoretical HA concentration of the whole virus after dilution) are 
calculated for every batch of the strain in the previous year:  
 
 
A mean value for f and CF is recorded.  
 
2. Splitting of the first batch of a new strain 
The QC Analytical Laboratory determines the protein concentration of the whole virus 
sample according to the Kjeldahl method. The sample is subsequently diluted with 
PBS pH 7.3, to obtain a final working protein concentration between 1900 and 2100 
μg/ml. 2 ml of diluted virus are then mixed with 150 (H3N2 strains) or 185 (H1N1 and 
B strains) μl of 0.6% v/v Tween 80. The mixture is stirred at 5°C ±3°C for 1 hour.  
Based on the protein concentration (~2000 μg/ml) along with the f and CF values, the 
theoretical HA concentration (HAT) and the theoretical optimum concentration of 
CTAB (TOCC) are calculated: 
 
 
 
 
 
g/ml)HA(
g/ml)(Protein 
f


 xf
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
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
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


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
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TOCC is the concentration that should result in the best purification of the virus in 
terms of HA recovery based on historical data. A range of CTAB concentrations, 
normally covering a range of 50% to 150% of TOCC, are evaluated. These are 
estimated as follows:  
 
 
 
The volume of 1% w/v CTAB required to achieve each examined CTAB 
concentration is calculated for an initial sample volume of 2 ml (final volume = 3 ml) 
that is: 
Volume of 1% w/v CTAB (2 ml sample) = Required CTAB concentration (μg/ml) × 
0.3   
PBS, pH 7.3 is used to make a final volume of 3ml. The solutions are stirred at 5°C 
±3°C for 2 hours. The liquid of each sample is divided into two or more test tubes and 
centrifuged in a refrigerated centrifuge at 5°C ±3°C for 1 hour at 18,800 g. The 
supernatant is then collected and a pool of the aliquots of each sample is generated. The 
residual CTAB is reduced by addition of Amberlite XAD4 excess:   
A (ml) = S (ml) x 0.1 x CTAB concentration (μg/ml) 
where A is the Amberlite volume and S is the volume of the whole virus, Tween 80, 
CTAB and PBS.  
PBS is added to normalise the sample volume and therefore allow comparable results:  
Volume of PBS to add (ml) = Maximum volume of Amberlite in any sample in the 
split test (ml) – Volume of Amberlite added to sample (ml) 
The samples are stirred for 1 hour at ambient temperature. The Amberlite is allowed to 
sediment and the supernatants are removed and analysed for Verification of the 
presence of neuraminidase activity, SDS-PAGE for purity and SRID for HA 
quantification. The best conditions are selected and confirmed in three consecutive 
production batches. In subsequent lots, CTAB concentration is calculated only on the 
basis of total protein content.  
 
3. Splitting of a known strain 
This test is conducted to verify and confirm the CTAB concentration of a strain present 
in the influenza campaign of the previous year. CF and f factors are estimated from 
historical data as in section 1. In this case smaller ranges of CTAB concentrations are 
assessed such as 80%, 100% and 120% of TOCC. The procedure detailed in the 
100
ion concentrat % required x  TOCC
 g/ml)( CTAB 
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previous section is performed. The “Split Test” on a known strain is carried out on the 
first batch of the strain. If the optimum conditions are comparable to those determined 
in previous year’s campaign, then the conditions can be reported to production for use. 
If different conditions shown to be optimum the split test must be repeated until the 
analytical results are reproducible for three consecutive batches. 
 
5.2 Screening DoE  
a) CCD matrix. Central runs in yellow: 2,3,4, 9, 11, 19, 27 
 
Run 
Order 
CTAB 
(µg/ml) 
Tween 80 
(μg/ml) 
Contact 
Time (h) 
NaCl 
(g/l) 
Temperature 
(oC) 
1 860.2 300 1 5.844 8 
2 782 376 2 4.383 6 
3 782 376 2 4.383 6 
4 782 376 2 4.383 6 
5 860.2 300 3 2.922 8 
6 703.8 452 1 2.922 4 
7 860.2 452 1 2.922 8 
8 860.2 300 1 2.922 4 
9 782 376 2 4.383 6 
10 703.8 300 1 2.922 8 
11 782 376 2 4.383 6 
12 860.2 452 1 5.844 4 
13 703.8 300 1 5.844 4 
14 860.2 452 3 5.844 8 
15 860.2 452 3 2.922 4 
16 703.8 300 3 5.844 8 
17 703.8 300 3 2.922 4 
18 860.2 300 3 5.844 4 
19 782 376 2 4.383 6 
20 703.8 452 1 5.844 8 
21 703.8 452 3 5.844 4 
22 703.8 452 3 2.922 8 
23 782 224 2 4.383 6 
24 782 376 2 7.305 6 
25 782 376 2 1.461 6 
26 625.6 376 2 4.383 6 
27 782 376 2 4.383 6 
28 782 376 4 4.383 6 
29 938.4 376 2 4.383 6 
30 782 376 0 4.383 6 
31 782 376 2 4.383 2 
32 782 524 2 4.383 6 
33 782 376 2 4.383 10 
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b) Residual plots for HA (SRID). 
 
 
 
 
 
 
 
 
 
 
c) Residual plots for specific purity (SRID/TN). 
 
5.3 Sucrose Gradients for Fractionation of Detergent Treated Preparations 
a) A/Texas/50/2012 (variation of CTAB/Protein ratio) 
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b) B/Massachusetts/02/2012 (variation of Tween 80/Protein ratio) and B/Brisbane/60/2008 
(comparison of NP9 solubilisation efficiency in BPL and formalin inactivated viruses) 
Sucrose  
(% w/v) 
Volume  
(ml) 
60 2 
50 3 
40 3 
30 4 
20 4 
10 6 
5 8 
 
c) B/Brisbane/60/2008 (C12E8) 
Sucrose  
(% w/v) 
Volume  
(ml) 
60 2 
50 3 
40 5 
30 3 
20 2 
10 10 
5 5 
 
5.4 DCS: Solubilisation of B/Massachusetts/02/2012 with CTAB in presence of 376-
1880 µg/ml Tween 80 for 3 hours 
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5.5 Variation of Tween 80-to-protein Ratio: Analytical Results 
 
a) Protein (BCA)  
 
 
b) Fluorescence (DiD) 
 
c) DCS  
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d) SDS-PAGE 
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e) SRID 
 
 
 
5.6 Effect of Increasing Levels of Tween 80 on HA Trimer Formation  
a) Precipitation zones in the SRID assay at increasing concentrations of Tween 80 added post-
centrifugation (B/Brisbane/60/2008) with and without Zwittergent 3-14 treatment.  
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b) Native PAGE analysis of B/Brisbane/60/2008 after solubilisation containing increasing 
levels of Tween 80 added post-centrifugation with and without Zwittergent 3-14 treatment. 1: 
No additional Tween 80, 2: 500 μg/ml Tween 80 3: 2,500 μg/ml Tween 80.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.7 DCS: Solubilisation of A/Texas/50/2012 with NP9. 
Reaction of A/Texas/50/2012 whole virus concentrate (5306.3 µg/ml) with 0.2% v/v NP9 for 
2 hours. Whole virus is shown in blue. Post-solubilisation PSD is shown in red.  
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5.8 Solubilisation of BPL and HCHO-inactivated viruses with 0.2% v/v NP9 for 10 
minutes 
a) Protein (BCA)  
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b) SDS-PAGE  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B/Brisbane/60/2008 HCHO-inactivated 
B/Brisbane/60/2008 HCHO-inactivated 
HA1 
 
HA2 
 
HA2 
 
B/Brisbane/09/2014   BPL-inactivated 
HA1 
 
MP 
 
NP 
 
MP 
 
NP 
 
 269 
 
c) DCS  
 
 
 
 
5.9 Generation of Virosomes with C12E8 
a) Fluorescence intensity of DiD of individual sucrose fractions after reduced SDS-PAGE.  
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b) TEM images of virosomes contained in Fraction 27.  
 
 
 
 
 
 
 
 
5.10 Impact of Protease Inhibitors on HA Recovery (SRID Results) 
 
Sample 
No  
Description Day 
HA 
 (µg/ml) 
Assay CV 
from 3 
replicates  
(%) 
1 Control Split 1 216.5 7.4 
2 
Cocktail of 
Inhibitors 
1 202.1 
8.5 
3 Aprotinin 1 196.8 7.8 
4 E-64 1 212.8 8.4 
5 Control Split 2 197.9 5.4 
6 
Cocktail of 
Inhibitors 
2 241.6 
13.0 
7 Bestatin 2 266.8 8.7 
8 Pepstatin 2 Not detected - 
9 Control Split 3 178.4 3.9 
10 
Cocktail of 
Inhibitors 
3 119.5 6.4 
11 
Pepstatin 
Control 
3 Not detected - 
12 EDTA 3 119.8 11.9 
13 AEBSF 3 180.1 10.1 
14 Leupeptin 3 189 5.2 
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APPENDIX 6 
6.1 Grid Experiment for GNA Capture-monoclonal Detection Assay 
a) Grid (mAb:CR6268) 
 
 
 
 
 
 
 
 
 
 
b) Calculation of S/N ratio(mAb:CR6268) 
 
 
 
 
 
 
6.2 Four Parameter Logistic (4PL) Nonlinear Regression Model 
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Where:  
 A1 = Minimum asymptote 
 A2 = Maximum asymptote 
 p = Hill's slope 
 x0 = Inflection point  
2 μg/ml  detection 4 μg/ml  detection
1 2 3 4 5 6 7 8 9 10 11 12
25 μg/ml 
GNA
25 μg/ml 
GNA
50 μg/ml 
GNA
50 μg/ml 
GNA
100 
μg/ml 
GNA
100 
μg/ml 
GNA
25 μg/ml 
GNA
25 μg/ml 
GNA
50 μg/ml 
GNA
50 μg/ml 
GNA
100 
μg/ml 
GNA
100 
μg/ml 
GNA
A
0.75 
μg/ml  
mono
0.75 0.75 0.75 0.75 0.75
0.75 
μg/ml  
mono
0.75 0.75 0.75 0.75 0.75
B
0.5 μg/ml
mono
0.5 0.5 0.5 0.5 0.5
0.5 μg/ml
mono
0.5 0.5 0.5 0.5 0.5
C
0.25 
μg/ml  
mono
0.25 0.25 0.25 0.25 0.25
0.25 
μg/ml  
mono
0.25 0.25 0.25 0.25 0.25
D Blank 0 0 0 0 0 Blank 0 0 0 0 0
E
0.75 
μg/ml  
mono
0.75 0.75 0.75 0.75 0.75
0.75 
μg/ml  
mono
0.75 0.75 0.75 0.75 0.75
F
0.5 μg/ml
mono
0.5 0.5 0.5 0.5 0.5
0.5 μg/ml
mono
0.5 0.5 0.5 0.5 0.5
G
0.25 
μg/ml  
mono
0.25 0.25 0.25 0.25 0.25
0.25 
μg/ml  
mono
0.25 0.25 0.25 0.25 0.25
H Blank 0 0 0 0 0 Blank 0 0 0 0 0
8 μg/ml  detection 10 μg/ml  detection
2 μg/ml  detection 4 μg/ml  detection
1 2 3 4 5 6 7 8 9 10 11 12
25 μg/ml 
GNA
25 μg/ml 
GNA
50 μg/ml 
GNA
50 μg/ml 
GNA
100 
μg/ml 
GNA
100 
μg/ml 
GNA
25 μg/ml 
GNA
25 μg/ml 
GNA
50 μg/ml 
GNA
50 μg/ml 
GNA
100 
μg/ml 
GNA
100 
μg/ml 
GNA
A 6 52 43 44 39 39 50 57 90 70 68 74
B 5 40 33 35 30 32 41 43 67 59 55 63
C 3 29 27 26 23 23 32 31 50 38 42 49
D 1 1 1 1 1 1 1 1 1 1 1 1
E 69 245 640 621 289 226 717 139 501 62 183 73
F 67 223 627 567 260 216 631 124 455 56 163 65
G 56 177 495 509 205 165 433 97 395 51 134 55
H 1 1 1 1 1 1 1 1 1 1 1 1
8 μg/ml  detection 10 μg/ml  detection
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6.3 Optimisation Grids for Modified GNA Capture-monoclonal ELISA  
 
 
 
 
 
 
 
 
 
 
 
 
6.4 Other ELISA Approaches 
a) Detection Signal Using the Trial GNA-Based ELISA (mAb concentration: 20 µg/ml) 
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2 μg/ml  detection 4 μg/ml  detection
8 μg/ml  detection 10 μg/ml  detection
GNA 
(ug/ml)
110 100 90 80 70 60 50 40 30 20 10
5000 0.101 0.055 0.044 0.052 0.069 0.04 0.037 0.034 0.039 0.051 0.043
2500 0.043 0.06 0.039 0.04 0.029 0.026 0.034 0.043 0.035 0.029 0.029
1250 0.039 0.04 0.042 0.031 0.03 0.034 0.022 0.025 0.023 0.024 0.019
625 0.056 0.052 0.027 0.038 0.036 0.044 0.028 0.03 0.032 0.024 0.021
312.5 0.042 0.041 0.034 0.052 0.05 0.025 0.032 0.036 0.024 0.023 0.026
156.3 0.048 0.054 0.041 0.04 0.039 0.037 0.027 0.029 0.029 0.02 0.022
78.1 0.041 0.041 0.039 0.034 0.04 0.034 0.031 0.028 0.034 0.022 0.022
39.1 0.042 0.047 0.113 0.033 0.032 0.032 0.028 0.034 0.028 0.026 0.02
HA 
(ug/ml)
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b) GNA Titrations with HRP-conjugated secondary IgG 
 
 
c) Direct ELISA with Zenon labelling 
 
 
 
 
 
 
 
Concentration
1 10 100 1000 10000
454
464
474
484
494
504
Graph#1
4-P Fit: y = (A - D)/( 1 + (x/C)^B ) + D: A B C D R^2
Std (Standards: Concentration vs MeanValue) 456 1.25 179 504 0.975
__________
Weighting: Fixed
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6.5 ELISA Quantifications-Correlation with SRID 
 
Obs No mAb 
HA 
(ng/ml) 
Stdev CV (%) 
1 VP2-1 2982 373 13 
2 VP2-1 3102 105 3 
3 VP2-1 3054 340 11 
4 VP2-1 3066 293 10 
5 VP2-1 2925 270 9 
6 VP2-1 2983 195 7 
7 VP2-2 2913 439 15 
8 VP2-2 2831 159 6 
9 VP2-2 2629 400 15 
10 VP2-2 2993 260 9 
11 VP2-2 3306 338 10 
12 VP2-2 3220 200 6 
13 VP2-3 3163 406 13 
14 VP2-3 4872 644 13 
15 VP2-3 2537 265 10 
16 VP2-3 3755 420 11 
17 VP2-3 2839 144 5 
18 VP2-3 2907 186 6 
19 VP2-4 3255 182 6 
20 VP2-4 3081 331 11 
21 VP2-4 3131 179 6 
22 VP2-4 3736 117 3 
23 VP2-4 2887 251 9 
24 VP2-4 2356 88 4 
25 VP2-5 3237 292 9 
26 VP2-5 6172 714 12 
27 VP2-5 2636 229 9 
28 VP2-5 1442 145 10 
29 VP2-5 1572 171 11 
30 VP2-5 3119 275 9 
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Obs No mAb 
HA 
(ng/ml) 
Stdev CV (%) 
31 VP2-6 3280 230 7 
32 VP2-6 3529 276 8 
33 VP2-6 2765 217 8 
34 VP2-6 3280 388 12 
35 VP2-6 2480 147 6 
36 VP2-6 2779 164 6 
37 VP2-9 3203 288 9 
38 VP2-9 5547 387 7 
39 VP2-9 2923 258 9 
40 VP2-9 5186 276 5 
41 VP2-9 1715 107 6 
42 VP2-9 1735 72 4 
43 VP2-10 1889 93 5 
44 VP2-10 4769 384 8 
45 VP2-11 3402 114 3 
46 VP2-11 2766 247 9 
47 VP2-12 3060 283 9 
48 VP2-12 2553 245 10 
49 VP2-13 3815 205 5 
50 VP2-13 3857 434 11 
51 VP2-13 2379 254 11 
52 VP2-13 3094 362 12 
53 VP2-13 2561 124 5 
54 VP2-13 2962 91 3 
55 VP3-20 3459 383 11 
56 VP3-20 2842 173 6 
 
 
 
 
